SymbolNONOF
NameNOVO-NORDISK A/S
SectorHEALTH CARE
RegionEurope
Industry-
Address10179 United States NY 383 Madison Avenue Floor 11
Telephone4544448888
Fax
Email
Websitehttps://www.novonordisk.com/
IncorporationDK
Incorporated On
Employees
Fiscal Year12/31
Public Since
ExchangesOTC;NASDAQ
AuditorVictor Mokuolu, CPA PLLC;DeVisser Gray LLP, Chartered Accountants;Smythe LLP;Dale Matheson Carr-Hilton Labonte LLP;Grant Thornton - Halifax, NS (Canada);Interactive Edgar Corp.;Davidson & Company LLP;DeVisser Gray LLP, Chartered Accountants;Charlton & Co.;Deloitte Touche Tohmatsu;PKF OConnor Davies, LLP;RSM Partners;Grassi & Co., CPAs, P.C.;Main Street Consulting and Accounting;Haynie & Company, CPA;YHB;Patrick D. Heyn, CPA, P.A.;Mary B. George;Shim & Associates LLP - Vancouver, British Columbia (Canada);Grant Thornton UK LLP;WWC, Professional Corporation;Harish Belwal, CPA;Dylan Floyd Accounting & Consulting;BDO AG;Prager Metis CPAs LLC;RBSM LLP;Dale Matheson Carr-Hilton Labonte LLP;Sam S. Mah Inc.;Thomas Tran;Turner Stone & Co.;MNP LLP;Fruci & Associates II, PLLC;Jones & OConnell LLP.;Victor Mokuolu, CPA PLLC;KPMG LLP.;Grant Thornton LLP;Davidson & Company LLP;Rachel Boulds, CPA;KPMG LLP.;MNP LLP;Elliott Davis;Davidson & Company LLP;Whitley Penn;Hay & Watson;Weinberg & Company;Bolko & Associates, LLC;Integritat Audit, Accounting & Advisory, LLC;PricewaterhouseCoopers LLP;Salberg & Company, P.A.;Mayer Hoffman McCann P.C.;CohnReznick LLP;TPS THAYER, LLC;Deloitte & Touche LLP;KCCW Accountancy Corp;Kesselman & Kesselman C.P.A.s;Jackson & Company, Chartered Accountants;NoFire Technologies;Olayinka Oyebola & Co;Torres Obregon y Asociados, SC;Rotenberg Meril Solomon Bertiger & Guttilla, P.C.;DBB McKennon;KPMG LLP.;Marcum LLP;UHY LLP;WithumSmith+Brown;Whitley Penn - Fort Worth, Texas (USA);PricewaterhouseCoopers LLP;Dale Matheson Carr-Hilton Labonte LLP;SRCO Professional Corporation, Charted Accountant;Deloitte Touche Tohmatsu, LLC;Ronald R. Chadwick, P.C.;Manning Elliott LLP;Bulloch, Brown, DuPertuis, Seger & Company, PC;BDO;Baker Tilly US, LLP;KPMG LLP - New York, New York, (USA);Pipara & Co LLP;Pitcher Partners Queensland;Marcum LLP;MNP LLP;Fresh Notion Financial Services;HTL CPAs & Business Advisors;S.R. Snodgrass, P.C.;Dalby, Wendland & Co., PC;PricewaterhouseCoopers LLP;Baker Tilly US, LLP;Lynda R. Keeton CPA, LLC;Chuck Ragland CPA;KPMG LLP.;McGovern Hurley LLP;Davidson & Company LLP;PricewaterhouseCoopers LLP;Yount, Hyde & Barbour, P.C.;EY - Perth, WA (Australia);Ernst & Young LLP;MNP LLP;Deloitte & Touche LLP;Charlton & Co.;CBIZ CPAs P.C.;BDO Audit Pty Ltd;Dale Matheson Carr-Hilton Labonte LLP;MNP LLP;Deloitte & Touche LLP;Smith Elliott Kearns & Company, LLC;TPS THAYER, LLC;Bauer and Company;MNP LLP;Ernst & Young LLP;MNP LLP;Latiff Chagpar CPA;RBSM LLP;PricewaterhouseCoopers LLP;BF Borgers CPA PC;MaloneBailey, LLP;KPMG Accountants N.V.;Eide Bailly LLP;MNP LLP;D&H Group LLP;PricewaterhouseCoopers LLP;PricewaterhouseCoopers LLP;Baker Tilly WM LLP;Ernst & Young LLP;Yount, Hyde & Barbour, P.C.;Green & Company CPAs;Macias Gini & OConnell LLP;BDO USA, LLP;Hacker, Johnson & Smith PA;PricewaterhouseCoopers LLP;Deloitte LLP;DBB McKennon;Deloitte LLP;Ernst & Young LLP;Mercurius & Associates LLP;Baker Tilly US, LLP;Saturna Group Chartered Professional Accountants LLP;HTL CPAs & Business Advisors;MaloneBailey, LLP;Crowe MacKay LLP;PricewaterhouseCoopers LLP;Shibu Abraham Professional Corporation;Ernst & Young LLP;Baker Tilly US, LLP;Crowe MacKay LLP;GreenGrowth CPAs;Nanuk Warman, CPA Inc.;MoneyMinds Management LLC;UHY LLP;Manning Elliott LLP;Ernst & Young LLP;Cox CPA Services, Inc.;DMCL Chartered Accountants;Pitcher Partners Queensland;FORVIS, LLP;Deloitte LLP;Baker Tilly WM LLP;Manning Elliott LLP;MNP LLP;Carl Ford Associates;Canas, CPA LLC;Astra Audit & Advisory, LLC;Davidson & Company LLP;RSM US LLP;Lakeport Business Services;Q Accountancy Corporation;Fruci & Associates II, PLLC;Ernst & Young LLP;Davidson & Company LLP;Victor Mokuolu, CPA PLLC;WithumSmith + Brown PC;Astra Audit & Advisory, LLC;Mao & Ying LLP;Davidson & Company LLP;DeVisser Gray LLP, Chartered Accountants;TAAD LLP;Dale Matheson Carr-Hilton Labonte LLP;Harish Belwal, CPA;Davidson & Company LLP;PricewaterhouseCoopers LLP;Grant Thornton, LLP;Daszkal Bolton LLP;BDO Audit (WA) Pty Ltd - Subiaco, Western Australia (Australia);RBSM LLP;McGovern Hurley LLP;Baker Tilly US, LLP;Ernst & Young LLP;Wipfli LLP;Kronick Kalada Berdy & Co, PC;Deloitte LLP;Tanner LLC;B F Borgers CPA PC;Crowe MacKay LLP;Brightman Almagor & Co.;Zakai CPA;Weinberg & Company;YCM CPA INC.;D&H Group LLP;Kost Forer Gabbay & Kasierer;Crowe Horwath, LLP;Bluechip Accounting LLC;Grassi & Co., CPAs, P.C.;MNP LLP;PricewaterhouseCoopers LLP;Ernst & Young LLP;Baker Tilly US, LLP;Shandong Haoxin Certified Public Accountants Co., Ltd.;Patterson CPAs, LLC;Assure CPA, LLC;Dale Matheson Carr-Hilton Labonte LLP;BDO Espana;PricewaterhouseCoopers LLP;Clearline Chartered Accountants;Meyers Norris Penny, LLP;FRUCI & ASSOCIATES, P.S.;Hongxin CPA Ltd;Crowe MacKay LLP;Crowe MacKay LLP;Marcum LLP;Manning Elliott LLP;KCCW Accountancy Corp;PricewaterhouseCoopers LLP;Marcum LLP;PricewaterhouseCoopers LLP;Baks & Co;Morgan & Company, Chartered Accountants;Grant Thorton LLP;Hall Chadwick;DeVisser Gray LLP, Chartered Accountants;A Chan & Company LLP;Smythe LLP.;Marcum LLP;JDDA CPA, LLC;KPMG LLP - New York, New York, (USA);Davidson & Company LLP;Cross Davis & Co. LLP;Ziv Haft Certified Public Accountants (Isr.);PricewaterhouseCoopers LLP;Kingery & Crouse, P.A.;Audirevi S.P.A.;GBQ Partners LLC;Audacie;MaloneBailey, LLP;Grassi & Co., CPAs, P.C.;BDO USA, LLP;Fruci & Associates II, PLLC;Marcum LLP;RJI International CPAs;Centurion ZD CPA Limited;Deloitte & Touche LLP;Marcum LLP;Crowe, LLP;Warren Averett, LLC;Clearhouse LLP;Michael Gillespie & Associates, PLLC;FORVIS, LLP;Davidson & Company LLP;Friedman LLP;Yount, Hyde & Barbour, P.C.;BF Borgers CPA PC;K.K. Mehta CPA Associates PPLC;BDO Canada LLP;McGovern Hurley LLP;Baker Tilly WM LLP;RSM Australia Partners - Perth, WA (Australia);KPMG;RSM US LLP;Baker Tilly WM LLP;KPMG Accountants N.V.;LAO Professionals;Ernst & Young LLP;PricewaterhouseCoopers LLP;M&K CPAS, PLLC;Kauffman Kim LLP;BDO USA, LLP;Adeptus Partners, LLC;M&K CPAS, PLLC;Mr. Yusuke MORIKUBO;BDO Seidman, LLP;MNP LLP;James Stafford Chartered Accountants;William Buck Audit and Assurance;Brown, Edwards & Company L.L.P;Deloitte LLP;Keens Accounting LLC;Marcum LLP;Grant Thornton LLP;Marcum LLP;Manning Elliott LLP;GreenGrowth CPAs;M&K CPAS, PLLC;Ernst & Young LLP;KPMG LLP.;Grant Thornton UK LLP;PricewaterhouseCoopers LLP;Hudgens CPA, LLC;Turner, Stone & Company, L.L.P.;Victor Mokuolu, CPA PLLC;Davidson & Company LLP;Boulay Group P.L.L.P.;Dale Matheson Carr-Hilton Labonte LLP;M&K CPAS, PLLC;Ernst & Young LLP - Toronto, Ontario (Canada);PKF OConnor Davies, LLP;Synergia CPA, LLC;Goff Backa Alfera & Company, LLC;Manning Elliott LLP;L J Soldinger Associates, LLC;Slappey Financial & Tax Services, LLC;Deloitte Touche Tohmatsu;Dale Matheson Carr-Hilton Labonte LLP;Astra Audit & Advisory, LLC;Crowe MacKay LLP;Hall Chadwick;Grant Thornton LLP;Baker Tilly WM LLP;PKF Littlejohn;UHY McGovern Hurley LLP;BDO USA, LLP;RSM Norge AS - Oslo;Dale Matheson Carr-Hilton Labonte LLP;Saturna Group Chartered Professional Accountants LLP;Kreit & Chiu;RBSM LLP;MNP LLP;Davidson & Company LLP;BDO Audit Pty Ltd;PricewaterhouseCoopers LLP;PKF OConnor Davies, LLP;S.R. Snodgrass, P.C.;Elkana Amitai CPA;Quality Financial Services LLC;Aloba, Awomolo & Partners;BF Borgers CPA PC;UHY McGovern Hurley LLP;ND Design, Inc;Clark, Schaefer, Hackett & Co.;Weaver and Tidwell, L.L.P.;BPM LLP;MNP LLP;Saturna Group Chartered Professional Accountants LLP;Meyers Norris Penny, LLP;MNP LLP;Baker Tilly WM LLP;Marcum LLP;Fruci & Associates II, PLLC;Haskell & White LLP;Weinberg & Company;J&S Associate;MNP LLP;CFO Oncall, Inc.;Dale Matheson Carr-Hilton Labonte LLP;BF Borgers CPA PC;Kenway Mack Slusarchuk Stewart LLP Charted Accountants;CDA/CPA Group;Davidson & Company LLP;Eric Gurr CPA, LLC Accountants;Marincovich & Co.;Baker Tilly US, LLP;BDO USA, LLP;J&S Associate;Turner, Stone & Company, L.L.P.;Weinberg & Company;MNP LLP;De Joya Griffith & Company, LLC;Dale Matheson Carr-Hilton Labonte LLP;DMCL Chartered Accountants;Bush & Associates CPA;Victor Mokuolu, CPA PLLC;Marcum LLP;Onestop Assurance PAC - (Singapore);Dale Matheson Carr-Hilton Labonte LLP;UHY LLP;PricewaterhouseCoopers LLP;The Bonadio Group;Stovall, Grandey & Allen, LLP;Davidson & Company LLP;Ernst & Young LLP;Fruci & Associates II, PLLC;Baker Tilly WM LLP;Dale Matheson Carr-Hilton Labonte LLP;Elliott Davis;Hall Chadwick;Cutler & Co.;RBSM LLP;MNP LLP;PricewaterhouseCoopers LLP;Saturna Group Chartered Professional Accountants LLP;DMCL Chartered Accountants;Manning Elliott LLP;BDO Canada LLP;NVS Chartered Accountants Professional Corp;TPS THAYER, LLC;Grant Thornton LLP;PricewaterhouseCoopers LLP;T. E. Lott and Company;Crowe MacKay LLP;JLKZ CPA LLP;J&S Associate;RBSM LLP;Hall Chadwick;BDO;Consultia LLC;DeVisser Gray LLP, Chartered Accountants;BDO Canada LLP;Boladale Lawal & Co (Chartered Accountants);RBSM LLP;Crowe LLP;Deloitte AS;HLB Mann Judd;Fruci & Associates II, PLLC;RSM Canada LLP;Saturna Group Chartered Professional Accountants LLP;BDO Audit Pty Ltd;Bush & Associates CPA;Buckley Dodds Parker LLP;Gregory, Sharer & Stuart, P.A.;Wei Wei & Co., LLP;DeVisser Gray LLP, Chartered Accountants;RBSM LLP;RSM Canada LLP;Get OTC Current;EisnerAmper LLP;DMCL Chartered Accountants;Demetrius Berkower LLC;Kingston Ross Pasnak LLP;Frazier & Deeter, LLC;Simon & Edward, LLP;Deloitte Accountants B.V.;M&K CPAS, PLLC;BDO USA, LLP;Hall Chadwick;EY - Perth, WA (Australia);De Joya Griffith & Company, LLC;Scarrow & Donald LLP;Pinaki & Associates LLC;K.Brice Toussaint;Eide Bailly LLP;Yount, Hyde & Barbour, P.C.;Deloitte LLP;PricewaterhouseCoopers LLP;FRUCI & ASSOCIATES, P.S.;Baker Tilly WM LLP;Crowe MacKay LLP;Dallas Consulting Services;Horne LLP;RSM Australia - Sydney, NSW (Australia);BF Borgers CPA PC;Aloba, Awomolo & Partners;Grassi & Co., CPAs, P.C.;Davidson & Company LLP;B F Borgers CPA PC;The Hall Group, CPAs;Hay & Watson;UHY McGovern Hurley LLP;Marcum LLP;Deloitte LLP;Astra Audit & Advisory, LLC;M&K CPAS, PLLC;Haynie & Company, CPA;MNP LLP;Smythe LLP;BDO USA, LLP;Hicks & Co. LLC;Davidson & Company LLP;KPMG;PricewaterhouseCoopers LLP - Ottawa, Ontario (Canada);Manning Elliott LLP;FRUCI & ASSOCIATES, P.S.;Michael T. Studer CPA P.C.;Anton & Chia LLP;Davidson & Company LLP;PricewaterhouseCoopers LLP - Edmonton, Alberta (Canada);Raymond Chabot Grant Thornton;Dale Matheson Carr-Hilton Labonte LLP;Assurance Dimensions Inc;S.R. Snodgrass, P.C.;Manning Elliott LLP;KPMG LLP - New York, New York, (USA);D&H Group LLP;Frazier & Deeter, LLC;De Visser Gray Chartered Accountants;KPMG LLP.;Davidson & Company LLP;Richter LLC.;Carr, Riggs & Ingram LLC;Mercurius & Associates LLP;M&K CPAS, PLLC;BDO Canada LLP;Griffith, Delaney, Hillman & Lett;DMCL Chartered Accountants;Davidson & Company LLP;Haynie & Company, CPA;EKS&H;FAR out Numbered, LLC;Marcum LLP;Astra Audit & Advisory, LLC;Nexia Sab & T;Astra Audit & Advisory, LLC;PricewaterhouseCoopers LLP;Grassi & Co., CPAs, P.C.;CBIZ CPAs P.C.;Pinnacle Tax Services;McGovern Hurley Cunningham, LLP;M&K CPAS, PLLC;B F Borgers CPA PC;Davidson & Company LLP;BDO LLP (UK);Elliott Davis;Davidson & Company LLP;Wolf & Company, P.C.;Simon & Edward, LLP;Audacie;Davidson & Company LLP;FORVIS, LLP;Frazier & Deeter, LLC;SingerLewak LLP;CliftonLarsonAllen LLP;Marcum LLP;Elliott Davis;Davidson & Company LLP;Schulman Wolfson & Abruzzo, LLP;Cupit, Milligan, Ogden & Williams;RSM Corporate Australia Pty Ltd;Baker Tilly WM LLP;Bush & Associates CPA;Fahn Kanne & Co.;Malone Bailey - Houstone, TX (USA);Marcum Bernstein & Pinchuk LLP;PricewaterhouseCoopers LLP;Beckles & Co;Niagara Financial Services;Equity Search Inc.;LBB & Associates Ltd., LLP;M&K CPAS, PLLC;Fruci & Associates II, PLLC;Ernst & Young LLP;Michael Gillespie & Associates, PLLC;DeVisser Gray LLP, Chartered Accountants;BDO USA, LLP;Ernst & Young LLP;Plante Moran;Main Street Consulting and Accounting;Grant Thornton UK LLP;KPMG LLP.;UHY LLP;Reeves and Co;Paris, Kreit & Chiu CPA LLP - Santa Ana, California (USA);Victor Mokuolu, CPA PLLC;PricewaterhouseCoopers LLP;H-Squared Performance Financial;Plante Moran;Manning Elliott LLP;Asesoria Global CPA;PKF Littlejohn;One Advisory Group Ltd;Friedman LLP;Grant Thornton LLP - Mississauga, Ontario (Canada);TAAD LLP;Boladale Lawal & Co (Chartered Accountants);Fruci & Associates II, PLLC;FRUCI & ASSOCIATES, P.S.;Vic Devlaeminck PC;Davidson & Company LLP;Fruci & Associates II, PLLC;McGovern Hurley Cunningham, LLP;PEEL CPA;Baker Tilly US, LLP;CFO-NOW;De Visser Gray Chartered Accountants;Mantyla McReynolds, LLC;Schulman Wolfson & Abruzzo, LLP;Moss Adams LLP;KPMG LLP.;PricewaterhouseCoopers AB;Pinnacle Accountancy Group of Utah;Barton CPA PLLC;RSM US LLP;Ernst & Young LLP;MGO CPA;KPMG LLP.;Natan & Associates, LLC;Davidson & Company LLP;Sadler, Gibb & Associates, LLC;Scott Chichester;Clearhouse LLP;M&K CPAS, PLLC;Gries & Associates, LLC;Crowe MacKay LLP;Manning Elliott LLP;Ernst & Young LLP;Whitley Penn;Accell Audit & Compliance, P.A;De Visser Gray Chartered Accountants;Ernst & Young LLP;Sadler, Gibb & Associates, LLC;MNP LLP;Sadler, Gibb & Associates, LLC;Aprio;HLB Mann Judd;Burr, Pilger & Mayer;Ernst & Young - Perth, Western Australia (Australia);KPMG LLP.;Mayer Hoffman McCann P.C.;Ernst & Young LLP;Bush & Associates CPA;Michael Gillespie & Associates, PLLC;Baker Tilly US, LLP;Raymond Chabot Grant Thornton;Frazier & Deeter, LLC;Mao & Ying LLP;Demetrius Berkower LLC;BDO USA, LLP;Forvis Mazars, LLP;Fruci & Associates II, PLLC;AJ Robbins CPA LLC;PBO Advisory Group;Dale Matheson Carr-Hilton Labonte LLP;Michael Gillespie & Associates, PLLC;S.R. Snodgrass, P.C.;WeiserMazars LLP;Smythe LLP.;CBIZ CPAs P.C.;Grant Thorton Audity Pty Ltd;Crowe MacKay LLP;SR Snodgrass, PC;Astra Audit & Advisory, LLC;Forvis Mazars, LLP;PKF Littlejohn;Silvertree Partners;Rodefer Moss & Co, PLLC;PricewaterhouseCoopers LLP;Ernst & Young LLP;WDM Chartered Accountants;Eide Bailly LLP;La Posta and Associates;Davidson & Company LLP;Moss Adams LLP;UHY LLP;Rose, Snyder & Jacobs;PAN-CHINA SINGAPORE PAC;Michael Gillespie & Associates, PLLC;McGovern Hurley LLP;Integritat Audit, Accounting & Advisory, LLC;M&K CPAS, PLLC;PKF Littlejohn;McGovern Hurley Cunningham, LLP;MNP LLP;PricewaterhouseCoopers LLP;WSRP, LLC;Coulter & Justus, P.C.;Marcum LLP;Olayinka Oyebola & Co;De Visser Gray Chartered Accountants;Lee Schlussel & Company;S.R. Snodgrass, P.C.;BF Borgers CPA PC;Factsco, LLC;M&K CPAS, PLLC;Davidson & Company LLP;Davidson & Company LLP;Davidson & Company LLP;Shim & Associates LLP - Vancouver, British Columbia (Canada);DeVisser Gray LLP, Chartered Accountants;M&K CPAS, PLLC;M&K CPAS, PLLC;HLB Mann Judd;Green Stone Group Holdings LLC;Ernst & Young LLP;Dale Matheson Carr-Hilton Labonte LLP;KPMG LLP.;Raymond Chabot Grant Thornton;Yevgeniy Grinberg CPA;DeVisser Gray LLP, Chartered Accountants;Total CFO, LLC;Ernst & Young LLP;Davidson & Company LLP;Moss Adams LLP;De Visser Gray Chartered Accountants;Marcum LLP;Fruci & Associates II, PLLC;Metcalf & Scott, Accountancy Corp.;MNP LLP;Dale Matheson Carr-Hilton Labonte LLP;Burr, Pilger & Mayer;M&K CPAS, PLLC;Boladale Lawal & Co (Chartered Accountants);PricewaterhouseCoopers LLP;GAAP Genies;Hudgens CPA, LLC;LKS & Associates, Ltd;Baker Tilly US, LLP;PricewaterhouseCoopers LLP;Deloitte LLP;Rosenberg Rich Baker Berman & Company;L J Soldinger Associates, LLC;Forvis Mazars, LLP;Lipton LLP;Scarrow & Company;Mendoza Berger & Company, LLP;Rothstein, Kass & Company, P.C.;BDO Canada LLP;Paris, Kreit & Chiu CPA LLP - Santa Ana, California (USA);Michael Gillespie & Associates, PLLC;Barton CPA PLLC;KCCW Accountancy Corp;PricewaterhouseCoopers LLP;M&K CPAS, PLLC;DeVisser Gray LLP, Chartered Accountants;Kingston Ross Pasnak LLP;BDO East Coast Partnership;Hall Chadwick;KPMG LLP.;Astra Audit & Advisory, LLC;Dale Matheson Carr-Hilton Labonte LLP;M&K CPAS, PLLC;Sadler, Gibb & Associates, LLC;M&K CPAS, PLLC;PKF Littlejohn;Davidson & Company LLP;GreenGrowth CPAs;Alexander & Williams, LLC;Ernst & Young LLP;Ernst & Young LLP;Seymour J. Weinberg, CPA;KPMG LLP - New York, New York, (USA);Kingston Ross Pasnak LLP;Plante & Moran, PLLC;Moss Adams LLP;Elliott Davis;Raymond Chabot Grant Thornton;RBSM LLP;BDO Audit Pty Ltd;Ernst & Young LLP;RBSM LLP;Partiz & Company;Rehmann Robson LLC;Smythe LLP.;Shim & Associates LLP - Vancouver, British Columbia (Canada);Heaton & Company, PLLC;Davidson & Company LLP;KWCO, P.C;Kost Forer Gabbay & Kasierer;KPMG LLP.;Manning Elliott LLP;Plante Moran;RSM Australia Partners;Hacker, Johnson & Smith PA;Stowe & Degon;Michael Gillespie & Associates, PLLC;Ernst & Young LLP;Salberg & Company, P.A.;CFO Oncall, Inc.;PricewaterhouseCoopers LLP;Crowe U.K. LLP;TPS THAYER, LLC;KPMG LLP - New York, New York, (USA);CBIZ CPAs P.C.;Hannis T. Bourgeois, LLP;Sadler, Gibb & Associates, LLC;MacKay LLP;Grant Thornton;PricewaterhouseCoopers LLP;PKF;WithumSmith + Brown PC;Vic Devlaeminck PC;Harish Belwal, CPA;DeVisser Gray LLP, Chartered Accountants;UHY LLP;The Accounting Connection;Hanul LLC;Davidson & Company LLP;Ernst & Young Bedrijfsrevisoren BVBA;Forvis Mazars, LLP;Mao & Ying LLP;BDO USA, LLP;Saturna Group Chartered Professional Accountants LLP;Interactive Edgar Corp.;MNP LLP;HDCPA Professional Corporation;Macias Gini & OConnell LLP;DeVisser Gray LLP, Chartered Accountants;Slack & Company LLC;TAAD LLP;Green Stone Group Holdings LLC;McGovern Hurley LLP;MaloneBailey, LLP;Davison & Company;Dale Matheson Carr-Hilton Labonte LLP;Moss Adams LLP;Marcum LLP;MNP LLP;MNP LLP;Davidson & Company LLP;WDM Chartered Accountants;Hall Chadwick;Coulter & Justus, P.C.;Victor Mokuolu, CPA PLLC;Seligson & Giannattasio, LLP;Baker Tilly US, LLP;MNP LLP;David Hexter, CPA, PA;Deloitte & Touche LLP;Davidson & Company LLP;MNP LLP;LBB & Associates Ltd., LLP;Eide Bailly LLP;Saturna Group Chartered Professional Accountants LLP;MNP LLP;RBSM LLP;MacKay LLP;Meyers Norris Penny, LLP;Eide Bailly LLP;M&K CPAS, PLLC;DNTW Chartered Accountants, LLP;PKF Antares;KAP Jamaludin, Ardi, Sukimto & Rekan;BDO USA, LLP;DeVisser Gray LLP, Chartered Accountants;Vandelanotte Bedrijfsrevisoren CVBA;GreenGrowth CPAs;WithumSmith+Brown;Dale Matheson Carr-Hilton Labonte LLP;PricewaterhouseCoopers LLP;Wong Johnson and Associates;Mac Accounting Group, LLP - Midvale, Utah (USA);On Point Accounting Services;Marcum LLP;Executive Industries;KPMG LLP.;Dale Matheson Carr-Hilton Labonte LLP;KPMG LLP.;CohnReznick LLP;Crowe MacKay LLP;PricewaterhouseCoopers LLP;Manning Elliott LLP;Weinberg & Company;Forvis Mazars, LLP;Smythe LLP;Dale Matheson Carr-Hilton Labonte LLP;Buckley Dodds Parker LLP;Horizon Assurance LLP;Davidson & Company LLP;Ernst & Young LLP - Toronto, Ontario (Canada);Quality Financial Services LLC;Asesoria Global CPA;RBSM LLP;T. E. Lott and Company;GreenGrowth CPAs;Richter LLC.;Frank, Rimerman & Co. LLP;GreenGrowth CPAs;Assure CPA, LLC;Mun & Associates;LAO Professionals;FRUCI & ASSOCIATES, P.S.;Rachel Boulds, CPA;KPMG LLP.;Dixon, Davis, Bagent and Company;Smythe LLP;BDO USA, LLP;PricewaterhouseCoopers LLP;Crowe MacKay LLP;Deloitte & Touche LLP;Smythe LLP.;Deloitte LLP - Calgary, Alberta (Canada);MNP LLP;Green Growth CPAs;CBIZ CPAs P.C.;Davidson & Company LLP;Cross Davis & Co. LLP;Tanner LLC;Crowe Chizek LLP;Davidson & Company LLP;Elkana Amitai CPA;Kenway Mack Slusarchuk Stewart LLP Charted Accountants;Bhamji Taxation Services Inc. CPA, CMA;Baker Tilly WM LLP;Baker Tilly US, LLP;DeVisser Gray LLP, Chartered Accountants;Davidson & Company LLP;Elderton Audit UK;McGovern Hurley Cunningham, LLP;PKF Littlejohn;WDM Chartered Accountants;Weaver and Tidwell, L.L.P.;BDO USA, LLP;NMS Inc.;MNP LLP;Dale Matheson Carr-Hilton Labonte LLP;Mahoney Sabol & Company, LLP;Urish Popeck & Co.;KPMG LLP.;RSM Australia Pty Ltd - Deakin, ACT (Australia);GreenGrowth CPAs;PwC - Southbank, Victoria (Australia);Rosenberg Rich Baker Berman & Company;Clearhouse LLP;KPMG LLP - New York, New York, (USA);Rose, Snyder & Jacobs;Smc International Tax & Accounting Services;Hall Chadwick;MNP LLP;TAAD LLP;Davidson & Company LLP;Baker Tilly WM LLP;Horne LLP;Ernst & Young LLP;M&K CPAS, PLLC;HHC;Ryanne Consulting Services Inc;Jack Runke CPA;Grant Thornton;McGovern Hurley Cunningham, LLP;EisnerAmper LLP;Heard, McElroy & Vestal, LLP;M&K CPAS, PLLC;MNP LLP;Novogradac & Company LLP;KPMG LLP.;RSM US LLP;Vogel CPAs, PC;Horne LLP;Hogan Taylor LLP;Morrison CPA Limited;Rosenfield & Co, PLC - Orlando, Florida (USA);DeVisser Gray LLP, Chartered Accountants;Forvis Mazars, LLP;Kingston Ross Pasnak LLP;KPMG LLP.;MNP LLP;MNP LLP;PKF Littlejohn;Benjamin & Ko;PKF Littlejohn;Manning Elliott LLP;RBSM LLP;Park Avenue Accounting;Natan & Associates, LLC;GZTY CPA Group LLC;GBH CPAs, PC;Pannell Kerr Forster of Texas;SRCO Professional Corporation, Charted Accountant;BDO Canada LLP;Davidson & Company LLP;Davidson & Company LLP;De Visser Gray Chartered Accountants;Fruci & Associates II, PLLC;Assurance Dimensions Inc;Davidson & Company LLP;LJ Soldinger Assoc, LLC;Windes, Inc.;MNP LLP;Mauldin & Jenkins, LLC;Cherry Bekaert LLP;Yu Certified Public Accountant PC;YWL & Company LLC;Deloitte LLP - Calgary, Alberta (Canada);PricewaterhouseCoopers LLP;PricewaterhouseCoopers LLP;Dale Matheson Carr-Hilton Labonte LLP;Reliant, CPA PC Certified Public Accountants;Deloitte Touche Tohmatsu;CohnReznick LLP;Dale Matheson Carr-Hilton Labonte LLP;Clearhouse LLP;Davidson & Company LLP;Davidson & Company LLP;BF Borgers CPA PC;Kreit & Chiu;KPMG LLP - New York, New York, (USA);DMCL Chartered Accountants;Dale Matheson Carr-Hilton Labonte LLP;Chisholm, Bierwolf, Nilson & Morrill, LLC;PricewaterhouseCoopers LLP;KBL, LLP;Brad Hacker and Company;CBIZ CPAs P.C.;Macias Gini & OConnell LLP;M&K CPAS, PLLC;Manning Elliott LLP;McConnell & Jones, LLP;MNP LLP;Thomas Leger & Co., LLP;Urish Popeck & Co.;Davidson & Company LLP;Interactive Edgar Corp.;PKF OConnor Davies, LLP;Crowe MacKay LLP;Yount, Hyde & Barbour, P.C.;Zeifmans LLP Chartered Accountants;M.N. Vijay Kumar;ATO Professionals;Davidson & Company LLP;Astra Audit & Advisory, LLC;KPMG LLP.;Manning Elliott LLP;Smythe LLP.;Davidson & Company LLP;M&K CPAS, PLLC;Haynie & Company, CPA;Wipfli LLP;Saturna Group Chartered Professional Accountants LLP;M.N. Vijay Kumar;Chang Park CPA;Brad Hacker and Company;Assurance Dimensions;Farber Hass Hurley LLP;Moore Stephens DHCL LLP;KPMG LLP.;PricewaterhouseCoopers LLP;Kost Forer Gabbay & Kasierer;Mayer Hoffman McCann P.C.;RJI International CPAs;Ernst & Young LLP.;Haynie & Company, CPA;Manning Elliott LLP;The Mercadien Group;Crowe, LLP;De Visser Gray Chartered Accountants;WithumSmith + Brown PC;MNP LLP;PricewaterhouseCoopers LLP;Sadler, Gibb & Associates, LLC;TKM Accounting Services;LKS & Associates, Ltd;Boladale Lawal & Co (Chartered Accountants);Friedman LLP;Mac Accounting Group, LLP - Midvale, Utah (USA);Crowe Horwath (HK) CPA Limited;Moore Audit S.A.;DeVisser Gray LLP, Chartered Accountants;Ernst & Young LLP;KPMG LLP - New York, New York, (USA);DMCL Chartered Accountants;PWC - Oslo, Norway;BDO Audit Pty Ltd;Shanghai Li Tong CPAs Co., LTD.;Barzily&Co Certified Public Accountants;Haynie & Company, CPA;Stephano Slack LLC;Tait, Weller & Baker;PricewaterhouseCoopers LLP;KPMG LLP.;MaloneBailey, LLP;Jewett, Schwartz, Wolfe and Associates;Thomas Howell Ferguson, P.A.;Ernst & Young LLP.;Wipfli LLP;Reliant, CPA PC Certified Public Accountants;Crowe MacKay LLP;CrossDavis & Company LLP - Vancouver, British Columbia (Canada);Davidson & Company LLP;FORVIS, LLP;Carl Kruse;Mancera SC;Victor Mokuolu, CPA PLLC;Ernst & Young LLP;Hudgens CPA, LLC;Patterson CPAs, LLC;Turner, Stone & Company, L.L.P.;WithumSmith + Brown PC;Rogoff & Company, P.C.;Tait, Weller & Baker;Davidson & Company LLP;Moss Adams LLP;Davidson & Company LLP;BDO USA, LLP;Cohen & Company, Ltd.;KBL, LLP;Forvis Mazars, LLP;J & J Consultants;BDO Australia Ltd.;Fruci & Associates II, PLLC;EisnerAmper LLP;Hacker, Johnson & Smith PA;Crowe U.K. LLP;De Visser Gray Chartered Accountants;Davidson & Company LLP;Robison, Hill & Co., APC;D&H Group LLP;Greystone Reporting, Ltd.;Ward Tax LLC;JP Centurion & Partners PLT;Hexcellence Consulting Sdn. Bhd.;Michael Gillespie & Associates, PLLC;Clearhouse LLP;RJI International CPAs;Haynie & Company, CPA;PKF Antares;PKF Antares;Crowe LLP;Hall Chadwick Melbourne Audit - Melbourne, Victoria (Australia);PKF Littlejohn;Grassi & Co., CPAs, P.C.;KPMG LLP.;MNP LLP;KPMG LLP - New York, New York, (USA);Simon & Edward, LLP;DBB McKennon;Grassi & Co., CPAs, P.C.;Yichien Yeh, CPA;Fruci & Associates II, PLLC;Yount, Hyde & Barbour, P.C.;Moore Australia Audit (WA);Dale Matheson Carr-Hilton Labonte LLP;Victor Mokuolu, CPA PLLC;Shim & Associates LLP - Vancouver, British Columbia (Canada);Exchange Group Chartered Accountants LLP;Baker Tilly HMW LLP - Winnipeg, Manitoba (Canada);JLKZ CPA LLP;Davidson & Company LLP;Clearhouse LLP;Crowe LLP;Reliant, CPA PC Certified Public Accountants;Charlton & Co.;KBL, LLP;Crowe MacKay LLP;S.R. Snodgrass, P.C.;McGovern Hurley LLP;Saturna Group Chartered Professional Accountants LLP;Dale Matheson Carr-Hilton Labonte LLP;HJ & Associates, LLC;Clearhouse LLP;EisnerAmper LLP;Baker Tilly WM LLP;M&K CPAS, PLLC;WithumSmith + Brown PC;Mercurius & Associates LLP;Ernst & Young LLP;Lake & Associates;GreenGrowth CPAs;KPMG;Shine Wing Certified Public Accountants;Dale Matheson Carr-Hilton Labonte LLP;Michael Gillespie & Associates, PLLC;Cherry Bekaert LLP;Barton CPA PLLC;Clearhouse LLP;PricewaterhouseCoopers LLP;Schulman Wolfson & Abruzzo, LLP;PricewaterhouseCoopers LLP;DFK Laurence Varnay Auditors Pty Ltd;Ernst & Young LLP;Haynie & Company, CPA;Crowe LLP;Fortune CPA Inc;DeVisser Gray LLP, Chartered Accountants;Mercurius & Associates LLP;McGovern Hurley Cunningham, LLP;Galaz, Yamazaki, Ruiz Urquiza S.C.;Plante & Moran, PLLC;Jones Simkins, P.C.;Weaver and Tidwell, L.L.P.;CF Audits LLC;M&K CPAS, PLLC;Berman & Company, P.A.;WithumSmith + Brown PC;B F Borgers CPA PC;Ernst & Young LLP;Mazars;Ernst & Young LLP;KCCW Accountancy Corp;PKF Littlejohn;PricewaterhouseCoopers LLP;Kreston GTA LLP;Michael T. Studer CPA P.C.;Consultia LLC;Davidson & Company LLP;KPMG LLP.;BPM LLP;BDO Ziv Haft;Roger Yeh, CPA;PricewaterhouseCoopers LLP - Ottawa, Ontario (Canada);Adler Shine LLP;DMCL Chartered Accountants;Manning Elliott LLP;Forvis Mazars, LLP;L&L CPAs, PA;DeVisser Gray LLP, Chartered Accountants;Baker Tilly US, LLP;PricewaterhouseCoopers LLP;Ernst & Young LLP - Toronto, Ontario (Canada);Davidson & Company LLP;Davidson & Company LLP;KB Park CPA;Smythe LLP;Turner, Stone & Company, L.L.P.;Berry, Dunn, McNeil & Parker;MaloneBailey, LLP;Raymond Chabot Grant Thornton;Deloitte GmbH - Germany;CBIZ CPAs P.C.;GBQ Partners LLC;Richard Blickstein Accounting and Taxes, Inc;BDO Canada LLP;Davidson & Company LLP;Manning Elliott LLP;The Griggs Group;Crowe LLP;Marcum LLP;Ernst & Young LLP;Moss Adams LLP;Exchange Group Chartered Accountants LLP;Smythe LLP;Kreston GTA LLP;Grant Thornton, LLP;Strohm Ballweg, LLP;Welch LLP;Deloitte AB;Elliott Davis;RSM Australia Partners;Systems Services - Mesa, Arizona (USA);MNP LLP;DFK Laurence Varnay Auditors Pty Ltd;Dale Matheson Carr-Hilton Labonte LLP;RJM Consulting, LLC;ACCOUNTING & MANAGEMENT SERVICES;PKF Littlejohn;James DiPrima;Stephano Slack LLC;Marcum LLP;KPMG LLC;CDL Consultants;Deloitte & Touche LLP;Davidson & Company LLP;HDCPA Professional Corporation;Deloitte & Touche LLP;Kenway Mack Slusarchuk Stewart LLP Charted Accountants;Wei Wei & Co., LLP;MNP LLP;Marcum LLP;CBIZ CPAs P.C.;Michael Gillespie & Associates, PLLC;Hutchins Clenney Rumsey Huckaby, PC;Carlos J. Valdes & Associates;MaloneBailey, LLP;Grant Thorton LLP;PricewaterhouseCoopers LLP;Davidson & Company LLP;James Moore & Co.;Weinberg & Company;JV CPA INC.;Victor Mokuolu, CPA PLLC;Accell Audit & Compliance, P.A;Clearhouse LLP;PricewaterhouseCoopers LLP;DMCL Chartered Accountants;Horizon Assurance LLP;Manning Elliott LLP;Smythe LLP.;McGovern Hurley Cunningham, LLP;BF Borgers CPA PC;J&S Associate;Reliant, CPA PC Certified Public Accountants;Bush & Associates CPA;Moss Adams LLP;BakerTillyVirchow;MNP LLP;KPMG LLP.;K. R. Margetson Ltd.;KPMG Accountants N.V.;Robert Adams, CPA;Factsco, LLC;Davidson & Company LLP;PricewaterhouseCoopers LLP;Deloitte LLP;Rose, Snyder & Jacobs;UHY McGovern Hurley LLP;KPMG Accountants N.V.;Yount, Hyde & Barbour, P.C.;Victor Mokuolu, CPA PLLC;Kreston GTA LLP;Deloitte Touche Tohmatsu;Fruci & Associates II, PLLC;MNP LLP;Goldstein Franklin, Inc.;KPMG Accountants N.V.;Crowe MacKay LLP;Astra Audit & Advisory, LLC;Davidson & Company LLP;Cooper Parry Group;Rowbotham & Company LLP;Olayinka Oyebola & Co;BDO USA, LLP;Smythe LLP.;Kreit & Chiu;Grassi & Co., CPAs, P.C.;Dale Matheson Carr-Hilton Labonte LLP;Raymond Chabot Grant Thornton;UHY McGovern Hurley LLP;BPM LLP;DBB McKennon;Burr Pilger Mayer, Inc.;JP Centurion & Partners PLT;DMCL Chartered Accountants;MNP LLP;Ernst & Young LLP;Siskos & Associates - CPA Tax & Accounting Services;M&K CPAS, PLLC;McGovern Hurley LLP;Fruci & Associates II, PLLC;M&K CPAS, PLLC;BDO USA, LLP;Anton & Chia LLP;Haynie & Company, CPA;CohnReznick LLP;Shim & Associates LLP - Vancouver, British Columbia (Canada);Remote Books Online;Ernst & Young LLP;Deloitte & Touche LLP;Davidson & Company LLP;Davidson & Company LLP;MNP LLP;CohnReznick LLP;Davidson & Company LLP;Meyers Norris Penny, LLP;KPMG LLP.;UHY LLP;CS&S Enterprises;Mauldin & Jenkins, LLC;Saturna Group Chartered Professional Accountants LLP;McGovern Hurley Cunningham, LLP;PricewaterhouseCoopers LLP;Marcum LLP;Barzily&Co Certified Public Accountants;McGovern Hurley Cunningham, LLP;Imowitz Koenig & Co.,LLP;Kurt Streams;Li & Company, PC;Stephano Slack LLC;BDO Audit (WA) Pty Ltd - Subiaco, Western Australia (Australia);Crowe MacKay LLP;Paul Gibbons & Associates, LLC;Whitley Penn;Davidson & Company LLP;Don D Meyers, Associates;RSM US LLP;Liggett & Webb, P.A.;Mallett & Barnes Tax Service;Davidson & Company LLP;Accounting Business Solutions Pty Ltd;D&H Group LLP;Marcum LLP;YCM CPA INC.;TAAD LLP;Davidson & Company LLP;Kingston Ross Pasnak LLP;Buckley Dodds Parker LLP;Bonadio & Co., LLP;MacKay LLP;Interactive Edgar Corp.;FRUCI & ASSOCIATES, P.S.;CFGI;Grant Thornton LLP - Mississauga, Ontario (Canada);Salberg & Company, P.A.;BDO Audit (WA) Pty Ltd - Subiaco, Western Australia (Australia);Clearhouse LLP;Accell Audit & Compliance, P.A;Freed Maxick CPAs, P.C.;Davidson & Company LLP;Grassi & Co., CPAs, P.C.;Smythe LLP;GZTY CPA Group LLC;Aventure Consultancy, LLC.;MNP LLP;Yount, Hyde & Barbour, P.C.;UHY LLP;MNP LLP;MNP LLP;JP Centurion & Partners PLT;GreenGrowth CPAs;Rosenberg Rich Baker Berman & Company;MGO CPA;CBIZ CPAs P.C.;KPMG;Ernst & Young LLP;LBB & Associates Ltd., LLP;TPS THAYER, LLC;Smythe LLP.;DeVisser Gray LLP, Chartered Accountants;Marcum LLP;Haynie & Company, CPA;Ernst & Young LLP;KMJ Corbin & Company LLP;WithumSmith+Brown;Plymale & Gillespie CPAs, PLLC;MaloneBailey, LLP;PricewaterhouseCoopers LLP;Mao & Ying LLP;Benjamine Leung & Co.,Ltd.;KPMG Accountants N.V.;MNP LLP;PricewaterhouseCoopers LLP;RSM US LLP;De Joya Griffith & Company, LLC;Deloitte LLP;MNP LLP;Accell Audit & Compliance, P.A;Liggett & Webb, P.A.;KPMG AB;Factsco, LLC;Astra Audit & Advisory, LLC;Victor Mokuolu, CPA PLLC;Natan & Associates, LLC.;Urish Popeck & Co.;Manning Elliott LLP;PricewaterhouseCoopers LLP;M&K CPAS, PLLC;Saturna Group Chartered Professional Accountants LLP;RBSM LLP;BDO USA, LLP;Abu-Farah Professional Corporation;BDO Canada LLP;PricewaterhouseCoopers LLP;Viele Solimano Swagler & Chapman;BF Borgers CPA PC;PKF Littlejohn;Plante & Moran, PLLC;M&K CPAS, PLLC;Eide Bailly LLP;Elkana Amitai CPA;Fruci & Associates II, PLLC;Stephano Slack LLC;Sadler, Gibb & Associates, LLC;Ernst & Young LLP;BCRG Group Inc.;MNP LLP;The Accounting Connection;Strothman+CO;Vic Devlaeminck PC;DBB McKennon;Cohen & Company, Ltd.;DMCL Chartered Accountants;Crowe MacKay LLP;DeVisser Gray LLP, Chartered Accountants;McGovern Hurley Cunningham, LLP;Michael T. Studer CPA P.C.;Maggart & Associates, P.C.;Dale Matheson Carr-Hilton Labonte LLP;Dale Matheson Carr-Hilton Labonte LLP;Plante Moran;Turner Stone & Co.;RBSM LLP;CFO-NOW;KLJ & Associates, LLP;Davidson & Company LLP;Davidson & Company LLP;BDO Australia Ltd.;M&K CPAS, PLLC;L & L CPAs PA;Davidson & Company LLP;EY GLOBAL;Dale Matheson Carr-Hilton Labonte LLP;BCRG Group Inc.;Raymond Chabot Grant Thornton;PricewaterhouseCoopers LLP;Deloitte GmbH - Germany;Deloitte LLP;Sutton Robinson Freeman & Co., P.C.;Russell, Craft & Schulz;Interactive Edgar Corp.;Freed Maxick CPAs, P.C.;Davidson & Company LLP;Vic Devlaeminck PC;Davidson & Company LLP;Eide Bailly LLP;MaloneBailey, LLP;WWC, Professional Corporation;Pubco Reporting Services Inc;EC Barrett, LLC;HJ & Associates, LLC;Assentsure PAC.;Fruci & Associates II, PLLC;BDO USA, LLP;Simon & Edward, LLP;DILIGENCY ACCOUNTANCY CORPORATION;Semple, Marchal & Cooper, LLP;RBSM LLP;Marcum LLP;PMB Helin Donovan, LLP;Dale Matheson Carr-Hilton Labonte LLP;Schechter Dokken Kanter Andrews & Selcer Ltd;TWC Consulting, LLC.;Fruci & Associates II, PLLC;DBB McKennon;Trust Net CPA Firm;PricewaterhouseCoopers LLP;Stephano Slack LLC;Armanino LLP - Woodland Hills, California (USA);Hogan Taylor LLP;Langley, Williams & Company, LLC;Ankit Consulting Services, Inc.;KPMG LLP.;Simon & Edward, LLP;Duncan Lee, CPA;Assentsure PAC.;RBSM LLP;Freed Maxick CPAs, P.C.;Forvis Mazars, LLP;Smythe LLP.;Abu-Farah Professional Corporation;Total Asia Associates;MNP LLP;PricewaterhouseCoopers LLP;Ovadia Kriheli & Co.;WithumSmith+Brown;Crowe LLP;CBIZ CPAs P.C.;Shim & Associates LLP - Vancouver, British Columbia (Canada);Jones Simkins, P.C.;Wipfli LLP;GBH CPAs, PC;RSM US LLP;Madsen & Associates CPAs, Inc.;PricewaterhouseCoopers LLP;Grant Thornton LLP;Elliott Davis;Dale Matheson Carr-Hilton Labonte LLP;Ernst & Young LLP.;CBIZ CPAs P.C.;DMCL Chartered Accountants;JP Centurion & Partners PLT;KPMG LLP - New York, New York, (USA);Bush & Associates CPA;KPMG LLP.;Bush & Associates CPA;Clark, Schaefer, Hackett & Co.;Scarrow & Donald LLP;Mayer Hoffman McCann P.C.;Paritz & Company, P.A.;Mayer Hoffman McCann P.C.;Will Stephenson Advisory LLC;Laquerre Audi;Smythe LLP.;Campbell & Lineberry;Plante Moran;Rehmann Robson LLC;Ernst & Young LLP;DMCL Chartered Accountants;MNP LLP;Davidson & Company LLP;KPMG Accountants N.V.;Barton CPA PLLC;Yu Certified Public Accountant PC;Davidson & Company LLP;HJ & Associates, LLC;BDJ Partners - Sydney, NSW (Australia);M&K CPAS, PLLC;BF Borgers CPA PC;BDO Canada LLP;Smythe LLP.;KCoe Isom, LLP;Grant Thornton LLP;KPMG LLP.;BDO Australia Ltd.;Deloitte Touche Tohmatsu;McGovern Hurley LLP;Fruci & Associates II, PLLC;RSM Canada LLP - Calgary, Alberta (Canada);MNP LLP;MNP LLP;De Visser Gray Chartered Accountants;Guimond Lavallee;Ernst & Young LLP;Davidson & Company LLP;McGovern Hurley LLP;Baker Tilly WM LLP;Dale Matheson Carr-Hilton Labonte LLP;Deloitte LLP;Michael T. Studer CPA P.C.;Ernst & Young LLP;MNP LLP;Baker Tilly WM LLP;Beckles & Co;FRUCI & ASSOCIATES, P.S.;BDO Australia Ltd.;EMS Consulting Services, LLC.;PricewaterhouseCoopers LLP;Brunet Roy Dube - Montreal, Quebec (Canada);RJM Consulting, LLC;S.R. Snodgrass, P.C.;Simon & Edward, LLP;Shim & Associates LLP - Vancouver, British Columbia (Canada);Ernst & Young LLP.;Mclean Delmo Bentleys Audit Pty Ltd;Kost Forer Gabbay & Kasierer;Hein & Associates LLP;Ernst & Young LLP;Victor Mokuolu, CPA PLLC;Centurion ZD CPA Limited;Haynie & Company, CPA;Wipfli LLP;Deloitte LLP;PricewaterhouseCoopers LLP;McGovern Hurley Cunningham, LLP;Auxilium Financial Services;Grant Thornton;Dale Matheson Carr-Hilton Labonte LLP;B F Borgers CPA PC;PricewaterhouseCoopers LLP;Friedman LLP;Dale Matheson Carr-Hilton Labonte LLP;Yarel + Partners, CPAs;Brightman Almagor & Co.;MaloneBailey, LLP;Liggett & Webb, P.A.;Michael Gillespie & Associates, PLLC;BDO Ziv Haft;Smythe LLP;Lancaster & David, Chartered Accountants;MNP LLP;J & J Consultants;Rose, Snyder & Jacobs;Crowe MacKay LLP;Kingston Ross Pasnak LLP;Kost Forer Gabbay & Kasierer;Haskell & White LLP;Clearhouse LLP;Yount, Hyde & Barbour, P.C.;WDM Chartered Accountants;Galaz, Yamazaki, Ruiz Urquiza S.C.;Crowe Horwath, LLP;Smythe LLP.;BF Borgers CPA PC;Pubco Reporting Services Inc;JP Centurion & Partners PLT;Eide Bailly LLP;Davidson & Company LLP;KBL, LLP;Lake & Associates CPAS LLC;Vic Devlaeminck PC;Mac Accounting Group, LLP - Midvale, Utah (USA);KPMG LLP.;Boladale Lawal & Co (Chartered Accountants);John Scholz CA;Watson Dauphinee & Musuch;Baker Tilly WM LLP;Julie Siska CPA;Mayer Hoffman McCann P.C.;McGovern Hurley LLP;MaloneBailey, LLP;Berkowitz Pollack Brant Advisors and Accountants, LLP;Hecker and Associates;Brooks Mitchell, CPA;Saltmarsh, Cleaveland & Gund;Hays Macintyre - London, England (United Kingdom);KPMG AZSA LLC;BDO Audit Pty Ltd;Davidson & Company LLP;MNP LLP;MNP LLP;Hannis T. Bourgeois, LLP;Saturna Group Chartered Professional Accountants LLP;HLB Mann Judd;Craig Ainge;FORVIS, LLP;Forvis Mazars, LLP;Don D Meyers, Associates;Mark Shelly International LLC;Audirevi S.P.A.;Davidson & Company LLP;RBSM LLP;PricewaterhouseCoopers AS;MNP LLP;Davidson & Company LLP;DeVisser Gray LLP, Chartered Accountants;M&K CPAS, PLLC;Crowe MacKay LLP;DBB McKennon;HJ & Associates, LLC;Deloitte LLP;The Accounting Connection;Baker Tilly US, LLP;PricewaterhouseCoopers LLP;Fruci & Associates II, PLLC;Centri Business Consulting, LLC;Haynie & Company, CPA;M&K CPAS, PLLC;Wipfli LLP;KPMG Accountants N.V.;T. St. Denis, Inc.;Baker Tilly WM LLP;SRCO Professional Corporation, Charted Accountant;MNP LLP;Vavrinek, Trine, Day & Co., LLP;WithumSmith + Brown PC;M.S. Mahava Rao;DMCL Chartered Accountants;PricewaterhouseCoopers LLP;RSM UK Audit LLP - Leeds, England (United Kingdom);MaloneBailey, LLP;Baker Tilly US, LLP;Boladale Lawal & Co (Chartered Accountants);Simon & Edward, LLP;Davidson & Company LLP;Forvis Mazars, LLP;Albin, Randall & Bennett, CPAs;Marcum LLP;PWC LLP - Vancouver, British Columbia (Canada);HLB Mann Judd;Dale Matheson Carr-Hilton Labonte LLP;DMCL Chartered Accountants;MGO CPA;Dale Matheson Carr-Hilton Labonte LLP;MNP LLP;McConnell & Jones, LLP;Kyle and Company, PC;Marcum LLP;KPMG LLP.;Simon & Edward, LLP;Manning Elliott LLP;WWC, Professional Corporation;McGovern Hurley Cunningham, LLP;WWC, Professional Corporation;Michael T. Studer CPA P.C.;Pablo Malana & Co.;KPMG LLP.;Davidson & Company LLP;Yvonne Lai;Salberg & Company, P.A.;MICHAEL K FISH CPA PA;BDO Audit Pty Ltd;Hacker, Johnson & Smith PA;Reliant, CPA PC Certified Public Accountants;Victor Mokuolu, CPA PLLC;Crowe LLP;AMN Professionals;Boladale Lawal & Co (Chartered Accountants);Davidson & Company LLP;Davidson & Company LLP;Grant Thorton Audity Pty Ltd;Haskell & White LLP;Comprehensive Accounting;Anderson Bradshaw PLLC;Marcum LLP;Smythe LLP.;S.R. Snodgrass, P.C.;Davidson & Company LLP;Mercurius & Associates LLP;Davidson & Company LLP;KPMG Accountants N.V.;DeVisser Gray LLP, Chartered Accountants;KPMG LLP.;TAAD LLP;EisnerAmper LLP;PricewaterhouseCoopers LLP;Grant Thornton, LLP;BPM LLP;McGovern Hurley LLP;Goldstein Franklin, Inc.;Fruci & Associates II, PLLC;AOGB CPA Limited;Rachel Boulds, CPA;Manning Elliott LLP;PKF;Wipfli LLP;MNP LLP;RSM Canada LLP;Enterprise CPAs, Ltd.;Dale Matheson Carr-Hilton Labonte LLP;Heaton & Company, PLLC;Pinnacle Accountancy Group of Utah;Wipfli LLP;Davidson & Company LLP;PKF Littlejohn;Davidson & Company LLP;Saturna Group Chartered Professional Accountants LLP;SmartBooks;Reconta, Ernst & Young S.p.A.;Davidson & Company LLP;Blue Chip Accounting, LLC;Beckles & Company;The Accounting Connection;HKCMCPA Company Limited;Shim & Associates LLP - Vancouver, British Columbia (Canada);Davidson & Company LLP;Davidson & Company LLP;Ankit Consulting Services, Inc.;GreenGrowth CPAs;KPMG;Ronald R. Chadwick, P.C.;Ruth Abady-Soltanovici , CPA;Pinnacle Accountancy Group of Utah;MNP LLP;My CPA, PA;DMCL Chartered Accountants;Solutions Group Accounting Firm;Fahn Kanne & Co.;Manning Elliott LLP;L J Soldinger Associates, LLC;MNP LLP;Baker Tilly US, LLP;CBIZ CPAs P.C.;A Chan & Company LLP;Kreston GTA LLP;M&K CPAS, PLLC;CliftonLarsonAllen LLP;RBSM LLP;Frank Artz Tax & Accounting;Euro-American Finance Network, Inc.;Cherry Bekaert LLP;The Accounting Connection;Boladale Lawal & Co (Chartered Accountants);Milhouse Neal LLP;PKF Littlejohn;Crowe LLP;Davidson & Company LLP;Whitley Penn;WWC, Professional Corporation;Citrin Cooperman & Company LLC;BDO London - London, England (United Kingdom);TAAD LLP;CBIZ CPAs P.C.;Pitcher Partners Queensland;BDO USA, LLP;McGovern Hurley LLP;M&K CPAS, PLLC;NOW CFO;McGovern Hurley LLP;Sadler, Gibb & Associates, LLC;SaxBST LLP;CBIZ CPAs P.C.;Assurance Dimensions Inc;MNP LLP;William Buck Audit and Assurance;A-Frame Accounting & Advisory, Inc>CPA,CA;MNP LLP;Davidson & Company LLP;Wolf & Company, P.C.;steuerbord Steuerberatungges. mbH;DLA, LLC;EMS Consulting Services, LLC.;Integritat Audit, Accounting & Advisory, LLC;Moore & Associates, Chartered;Fruci & Associates II, PLLC;Turner, Stone & Company, L.L.P.;Charles E. Heath CPA, P.A.;Davidson & Company LLP;L Damora CGA;M&K CPAS, PLLC;Deloitte LLP;Harbourside CPA LLP;DNTW Chartered Accountants, LLP;Integritat Audit, Accounting & Advisory, LLC;PricewaterhouseCoopers LLP;EisnerAmper LLP;Pasternack & Company, LLP;Malone Bailey LLP;Marcum LLP;HJ & Associates, LLC;Greentree Financial Group, Inc.;McGovern Hurley LLP;McGladrey LLP;Semple, Marchal & Cooper, LLP;PricewaterhouseCoopers LLP;Boladale Lawal & Co (Chartered Accountants);KCCW Accountancy Corp;CL Partners CPA Limited;Wolf & Company, P.C.;UHY McGovern Hurley LLP;MS PARTNERS LLP;Tait, Weller & Baker;MaloneBailey, LLP;Ernst & Young LLP;MNP LLP;KPMG LLP.;Grant Thornton UK LLP;NOW CFO;Grant Thornton LLP;BDO Audit Pty Ltd;PricewaterhouseCoopers LLP;Marcum LLP;CBIZ CPAs P.C.;Davidson & Company LLP;BF Borgers CPA PC;PricewaterhouseCoopers LLP;MNP LLP;David E. Severson, CPA;McGovern Hurley LLP;DBB McKennon;Sadler, Gibb & Associates, LLC;PricewaterhouseCoopers LLP;PricewaterhouseCoopers LLP - Ottawa, Ontario (Canada);Hacker, Johnson & Smith PA;Hein & Associates LLP;Dale Matheson Carr-Hilton Labonte LLP;UHY LLP;Pannell Kerr Forster of Texas;Weaver Martin & Samyn;LL Bradford LLC;MNP LLP;HLB Mann Judd;Dale Matheson Carr-Hilton Labonte LLP;D&H Group LLP;Forvis Mazars, LLP;PricewaterhouseCoopers AB;Assurance Dimensions;Grassi & Co., CPAs, P.C.;Davidson & Company LLP;Friedman LLP;Fruci & Associates II, PLLC;PKF Littlejohn;Elliott Davis;Yount, Hyde & Barbour, P.C.;D. Brooks and Associates CPAs, P.A.;MICHAEL K FISH CPA PA;Davidson & Company LLP;RSM US LLP;Alexander & Williams, LLC;RBSM LLP;McGovern Hurley LLP;Meyers Norris Penny, LLP;Payne & Smith, LLC;KPMG LLP.;Grossman St. Amour CPAs;PricewaterhouseCoopers LLP;Astra Audit & Advisory, LLC;KPMG AZSA LLC;MNP LLP;Salberg & Company, P.A.;Smythe LLP.;BCRG Group Inc.;Davidson & Company LLP;UHY LLP;L J Soldinger Associates, LLC;Yount, Hyde & Barbour, P.C.;Crowe LLP;DBB McKennon;Davidson & Company LLP;Freed Maxick CPAs, P.C.;CBIZ CPAs P.C.;
Audit StatusAUDITED
Reporting StatusU.S. Reporting: SEC Reporting
CIK0000353278
Description

Novo-Nordisk is the parent company of a group engaged in the development, production and marketing of pharmaceuticals, biological solutions to industrial problems; vitamins, dietary supplements and digestive aids. Co. operates on a worldwide basis in two business segments: Diabetes care: discovery, development, manufacturing and marketing of products within the areas of insulin and delivery systems and oral antidiabetic products (OAD). Biopharmaceuticals: discovery, development, manufacturing and marketing of products within the therapy areas haemostasis management (NovoSeven(R) RT), growth hormone therapy, hormone replacement therapy and other products.

Additional info from NASDAQ:
Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Additional info from OTC:
Novo-Nordisk is the parent company of a group engaged in the development, production and marketing of pharmaceuticals, biological solutions to industrial problems; vitamins, dietary supplements and digestive aids. Co. operates on a worldwide basis in two business segments: Diabetes care: discovery, development, manufacturing and marketing of products within the areas of insulin and delivery systems and oral antidiabetic products (OAD). Biopharmaceuticals: discovery, development, manufacturing and marketing of products within the therapy areas haemostasis management (NovoSeven(R) RT), growth hormone therapy, hormone replacement therapy and other products.

2026-03-17 11:10

NOVO-NORDISK A/S (NONOF) Files Form 6-K

Read more
2026-03-09 11:53

NOVO-NORDISK A/S (NONOF) Files Form 6-K

Read more
2026-03-02 16:47

NOVO-NORDISK A/S (NONOF) Files Form 6-K

Read more
2026-03-02 12:57

NOVO-NORDISK A/S (NONOF) Files Form 6-K

Read more
2026-02-23 13:19

Novo-Nordisk A/S (NONOF) Files Form 6-K

Read more
2026-02-23 11:28

Novo-Nordisk A/S (NONOF) Files Form 6-K

Read more
2026-02-20 12:45

Novo-Nordisk A/S (NONOF) Files Form 6-K

Read more
2026-02-11 21:09

Novo-Nordisk A/S (NONOF) Files Form 6-K

Read more
2026-02-10 11:16

Novo-Nordisk A/S (NONOF) Files Form 6-K

Read more
2026-02-09 13:32

Novo-Nordisk A/S (NONOF) Files Form 6-K

Read more
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Nicotinamide Riboside 1g (oral) Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Quercetin 1.250 mg (oral) Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Dasatinib 100 Mg Oral Tablet Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Placebo Other Phase PHASE1 Type 1 Diabetes (T1D) NOT_YET_RECRUITING NCT07578584
NNC0497-0040 Other Phase PHASE1 Type 1 Diabetes (T1D) NOT_YET_RECRUITING NCT07578584
Insuline glargine U100 (titrated) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Insuline glargine U100 (reduced) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Insuline glargine U100 (titrated) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Insuline glargine U100 (reduced) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Placebo Other Phase PHASE1 Type 1 Diabetes (T1D) NOT_YET_RECRUITING NCT07578584
NNC0497-0040 Other Phase PHASE1 Type 1 Diabetes (T1D) NOT_YET_RECRUITING NCT07578584
Nicotinamide Riboside 1g (oral) Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Quercetin 1.250 mg (oral) Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Dasatinib 100 Mg Oral Tablet Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Insuline glargine U100 (titrated) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Insuline glargine U100 (reduced) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Placebo Other Phase PHASE1 Type 1 Diabetes (T1D) NOT_YET_RECRUITING NCT07578584
NNC0497-0040 Other Phase PHASE1 Type 1 Diabetes (T1D) NOT_YET_RECRUITING NCT07578584
Nicotinamide Riboside 1g (oral) Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Quercetin 1.250 mg (oral) Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Dasatinib 100 Mg Oral Tablet Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Insuline glargine U100 (titrated) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Insuline glargine U100 (reduced) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Placebo Other Phase PHASE1 Type 1 Diabetes (T1D) NOT_YET_RECRUITING NCT07578584
NNC0497-0040 Other Phase PHASE1 Type 1 Diabetes (T1D) NOT_YET_RECRUITING NCT07578584
Nicotinamide Riboside 1g (oral) Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Quercetin 1.250 mg (oral) Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Dasatinib 100 Mg Oral Tablet Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Insuline glargine U100 (titrated) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Insuline glargine U100 (reduced) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Placebo Other Phase PHASE1 Type 1 Diabetes (T1D) NOT_YET_RECRUITING NCT07578584
NNC0497-0040 Other Phase PHASE1 Type 1 Diabetes (T1D) NOT_YET_RECRUITING NCT07578584
Nicotinamide Riboside 1g (oral) Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Quercetin 1.250 mg (oral) Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Dasatinib 100 Mg Oral Tablet Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Insuline glargine U100 (titrated) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Insuline glargine U100 (reduced) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Placebo Other Phase PHASE1 Type 1 Diabetes (T1D) NOT_YET_RECRUITING NCT07578584
NNC0497-0040 Other Phase PHASE1 Type 1 Diabetes (T1D) NOT_YET_RECRUITING NCT07578584
Nicotinamide Riboside 1g (oral) Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Quercetin 1.250 mg (oral) Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Dasatinib 100 Mg Oral Tablet Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
sodium chloride 0.9% w/v Other Phase PHASE1 Diabetes COMPLETED NCT01730014
insulin glargine Other Phase PHASE1 Diabetes COMPLETED NCT01730014
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01730014
148-0287-A-4.2mM-cartridge Other Phase PHASE1 Diabetes COMPLETED NCT01730014
placebo Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01848002
catridecacog Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01848002
placebo Other Phase PHASE1 Inflammation TERMINATED NCT01689025
NNC0114-0006 Other Phase PHASE1 Inflammation TERMINATED NCT01689025
placebo Other Phase PHASE1 Acquired Bleeding Disorder COMPLETED NCT01153997
catridecacog Other Phase PHASE1 Acquired Bleeding Disorder COMPLETED NCT01153997
Norditropin NordiFlex® Other Preclinical Growth Hormone Disorder COMPLETED NCT01327924
gastric bypass Other Preclinical Obesity COMPLETED NCT01463449
Genotropin Pen® Other Phase PHASE1 Growth Disorder COMPLETED NCT01943084
Norditropin® FlexPro® pen Other Phase PHASE1 Growth Disorder COMPLETED NCT01943084
placebo Other Approved Hyperglycemia COMPLETED NCT01472640
liraglutide Other Approved Hyperglycemia COMPLETED NCT01472640
Placebo semaglutide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Placebo cagrilintide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Semaglutide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Cagrilintide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Placebo Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
NNC0662-0419 Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
Placebo (semaglutide) Other Phase PHASE3 Obesity COMPLETED NCT05035095
Oral semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05035095
Placebo semaglutide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Placebo cagrilintide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Semaglutide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Cagrilintide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Placebo Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
NNC0662-0419 Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
Placebo (semaglutide) Other Phase PHASE3 Obesity COMPLETED NCT05035095
Oral semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05035095
Placebo (semaglutide) Other Phase PHASE3 Obesity COMPLETED NCT05035095
Oral semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05035095
Placebo (semaglutide) Other Phase PHASE3 Obesity COMPLETED NCT05035095
Oral semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05035095
Placebo Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
NNC0662-0419 Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
Placebo semaglutide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Placebo cagrilintide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Semaglutide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Cagrilintide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Placebo (semaglutide) Other Phase PHASE3 Obesity COMPLETED NCT05035095
Oral semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05035095
Placebo Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
NNC0662-0419 Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
Placebo semaglutide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Placebo cagrilintide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Semaglutide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Cagrilintide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Placebo (semaglutide) Other Phase PHASE3 Obesity COMPLETED NCT05035095
Oral semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05035095
Placebo Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
NNC0662-0419 Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
Placebo semaglutide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Placebo cagrilintide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Semaglutide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Cagrilintide Other Phase PHASE1 Obesity RECRUITING NCT07527195
Standard of Care (SOC) Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 50 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 15 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571109
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571109
Placebo Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07570992
NNC1679-0001 Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07570992
Placebo Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
Semaglutide Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
NNC0662-0419 Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571005
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571005
Placebo (ziltivekimab) Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Ziltivekimab Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Standard of Care (SOC) Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 50 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 15 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571109
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571109
Placebo Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07570992
NNC1679-0001 Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07570992
Placebo Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
Semaglutide Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
NNC0662-0419 Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571005
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571005
Placebo (ziltivekimab) Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Ziltivekimab Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Standard of Care (SOC) Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 50 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 15 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571109
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571109
Placebo Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07570992
NNC1679-0001 Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07570992
Placebo Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
Semaglutide Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
NNC0662-0419 Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571005
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571005
Placebo (ziltivekimab) Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Ziltivekimab Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Standard of Care (SOC) Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 50 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 15 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571109
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571109
Placebo Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07570992
NNC1679-0001 Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07570992
Placebo Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
Semaglutide Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
NNC0662-0419 Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571005
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571005
Placebo (ziltivekimab) Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Ziltivekimab Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Standard of Care (SOC) Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 50 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 15 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571109
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571109
Placebo Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07570992
NNC1679-0001 Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07570992
Placebo Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
Semaglutide Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
NNC0662-0419 Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571005
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571005
Placebo (ziltivekimab) Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Ziltivekimab Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Standard of Care (SOC) Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 50 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 15 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571109
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571109
Placebo Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07570992
NNC1679-0001 Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07570992
Placebo Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
Semaglutide Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
NNC0662-0419 Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571005
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571005
Placebo (ziltivekimab) Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Ziltivekimab Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Standard of Care (SOC) Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 50 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 15 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571109
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571109
Placebo Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07570992
NNC1679-0001 Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07570992
Placebo Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
Semaglutide Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
NNC0662-0419 Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571005
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571005
Placebo (ziltivekimab) Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Ziltivekimab Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Placebo Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
NNC0113-5840 Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
Placebo Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Standard of Care (SOC) Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 50 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 15 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT05689372
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571109
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571109
Placebo Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07570992
NNC1679-0001 Other Phase PHASE1 Healthy Volunteers NOT_YET_RECRUITING NCT07570992
Placebo Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
Semaglutide Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
NNC0662-0419 Other Phase PHASE2 Diabetes Mellitus, Type 2 RECRUITING NCT07415954
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571005
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07571005
Placebo (ziltivekimab) Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Ziltivekimab Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Tirzepatide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Cagrilintide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity RECRUITING NCT07503210
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07503210
Tirzepatide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Cagrilintide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Placebo Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
NNC0113-5840 Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity RECRUITING NCT07503210
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07503210
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT05689372
Placebo Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
Tirzepatide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Cagrilintide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Placebo Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
NNC0113-5840 Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity RECRUITING NCT07503210
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07503210
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT05689372
Placebo Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
Tirzepatide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Cagrilintide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Placebo Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
NNC0113-5840 Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity RECRUITING NCT07503210
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07503210
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT05689372
Placebo Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
Tirzepatide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Cagrilintide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Placebo Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
NNC0113-5840 Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity RECRUITING NCT07503210
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07503210
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT05689372
Placebo Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
Tirzepatide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Cagrilintide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Placebo Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
NNC0113-5840 Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity RECRUITING NCT07503210
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07503210
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT05689372
Placebo Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
Tirzepatide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Cagrilintide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Placebo Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
NNC0113-5840 Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity RECRUITING NCT07503210
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07503210
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT05689372
Placebo Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
Tirzepatide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Cagrilintide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Placebo Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
NNC0113-5840 Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity RECRUITING NCT07503210
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07503210
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT05689372
Placebo Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
Tirzepatide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Cagrilintide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Placebo Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
NNC0113-5840 Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity RECRUITING NCT07503210
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07503210
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT05689372
Placebo Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
Tirzepatide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Cagrilintide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Placebo Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
NNC0113-5840 Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity RECRUITING NCT07503210
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07503210
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT05689372
Placebo Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
Tirzepatide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Cagrilintide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Placebo Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
NNC0113-5840 Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity RECRUITING NCT07503210
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07503210
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT05689372
No treatment given Drug Preclinical Overweight, Obesity COMPLETED NCT06805539
Placebo Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Cagrisema Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
Tirzepatide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Cagrilintide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Placebo Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
NNC0113-5840 Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity RECRUITING NCT07503210
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07503210
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT05689372
No treatment given Drug Preclinical Overweight, Obesity COMPLETED NCT06805539
Placebo Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Cagrisema Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
Tirzepatide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Cagrilintide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Placebo Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
NNC0113-5840 Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity RECRUITING NCT07503210
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07503210
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT05689372
No treatment given Drug Preclinical Overweight, Obesity COMPLETED NCT06805539
Placebo Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Cagrisema Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
Placebo Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Cagrisema Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT05689372
No treatment given Drug Preclinical Overweight, Obesity COMPLETED NCT06805539
Placebo Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Cagrisema Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
Semaglutide Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Cagrisema Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
Tirzepatide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Cagrilintide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Placebo Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
NNC0113-5840 Other Phase PHASE1 Obesity NOT_YET_RECRUITING NCT07566390
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity RECRUITING NCT07503210
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07503210
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT05689372
No treatment given Drug Preclinical Overweight, Obesity COMPLETED NCT06805539
Placebo Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06388187
Semaglutide Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Cagrisema Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Placebo Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07567001
No treatment given Drug Preclinical Overweight, Obesity COMPLETED NCT06805539
Semaglutide Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Cagrisema Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
No treatment given Drug Preclinical Overweight, Obesity COMPLETED NCT06805539
Semaglutide Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Cagrisema Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
No treatment given Drug Preclinical Overweight, Obesity COMPLETED NCT06805539
Semaglutide Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Cagrisema Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
No treatment given Drug Preclinical Overweight, Obesity COMPLETED NCT06805539
Semaglutide Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
Cagrisema Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07564414
insulin degludec/insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01868581
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01868581
NNC 0128-0000-2011 Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01288391
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01530048
insulin detemir Other Phase PHASE1 Diabetes COMPLETED NCT01498939
repaglinide Other Preclinical Diabetes COMPLETED NCT01498900
insulin aspart Other Preclinical Diabetes COMPLETED NCT01490112
placebo Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT01789086
liraglutide Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT01789086
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT02100475
insulin degludec/liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT02100475
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01880736
turoctocog alfa Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01692925
somatropin Other Phase PHASE4 Growth Hormone Disorder TERMINATED NCT01698944
placebo Other Phase PHASE1 Inflammation COMPLETED NCT01611688
NNC0215-0384 Other Phase PHASE1 Inflammation COMPLETED NCT01611688
eptacog alfa (activated) Other Preclinical Congenital Bleeding Disorder COMPLETED NCT01586936
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT01572753
activated recombinant human factor VII Other Phase PHASE2 Acquired Bleeding Disorder TERMINATED NCT01564563
placebo Other Phase PHASE2 Acquired Bleeding Disorder TERMINATED NCT01564563
standard therapy Drug Phase PHASE2 Acquired Bleeding Disorder TERMINATED NCT01564563
somatropin Other Phase PHASE4 Genetic Disorder COMPLETED NCT01734486
somatropin Other Phase PHASE4 Foetal Growth Problem COMPLETED NCT01734447
17-beta estradiol Other Phase PHASE3 Genetic Disorder COMPLETED NCT01710696
placebo Other Phase PHASE3 Diabetes COMPLETED NCT01836523
liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT01836523
turoctocog alfa Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT01138501
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01814137
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01814137
insulin degludec/insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01814137
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02060266
Early intervention Other Approved Health Behavior COMPLETED NCT01799447
placebo Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02235961
liraglutide Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02235961
NNC9204-0530 Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02235961
liraglutide Other Preclinical Diabetes COMPLETED NCT02321878
placebo Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02300844
NNC0174-0833 Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02300844
placebo Other Phase PHASE3 Diabetes COMPLETED NCT02054897
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT02054897
basal insulin Other Phase PHASE3 Diabetes COMPLETED NCT01850615
Faster-acting insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01850615
Liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT03191396
Semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT03191396
Insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT02906917
Insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT02906917
Insulin degludec/insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT02906917
Placebo (NNC0113-2023) Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03617081
NNC0113-2023 Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03617081
somatropin Other Phase PHASE3 Genetic Disorder COMPLETED NCT01927861
placebo Other Phase PHASE1 Diabetes COMPLETED NCT02773381
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02773381
somatropin Other Phase PHASE1 Growth Hormone Disorder COMPLETED NCT01973244
somapacitan Other Phase PHASE1 Growth Hormone Disorder COMPLETED NCT01973244
Insulin glargine Other Phase PHASE4 Diabetes Mellitus, Type 2 COMPLETED NCT03687827
Insulin degludec Other Phase PHASE4 Diabetes Mellitus, Type 2 COMPLETED NCT03687827
Liraglutide or Placebo Other Phase PHASE4 Diabetes Mellitus, Non-Insulin-Dependent COMPLETED NCT02299388
MEDI5117 Placebo Other Phase PHASE1 Rheumatoid Arthritis TERMINATED NCT01559103
MEDI5117 Other Phase PHASE1 Rheumatoid Arthritis TERMINATED NCT01559103
Placebo (NNC0165-1562) Other Phase PHASE1 Metabolism and Nutrition Disorders COMPLETED NCT03574584
Semaglutide Other Phase PHASE1 Metabolism and Nutrition Disorders COMPLETED NCT03574584
NNC0165-1562 Other Phase PHASE1 Metabolism and Nutrition Disorders COMPLETED NCT03574584
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT03648281
Placebo Other Phase PHASE4 Obesity, Visceral COMPLETED NCT03038620
Liraglutide Other Phase PHASE4 Obesity, Visceral COMPLETED NCT03038620
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 WITHDRAWN NCT04287179
Fiasp® Other Preclinical Diabetes Mellitus, Type 1 COMPLETED NCT03895515
Cross-over study Other Approved Diabetes Mellitus, Type 2 COMPLETED NCT05375656
Cross-over study Other Approved Diabetes Mellitus, Type 2 COMPLETED NCT05375656
placebo Other Phase PHASE3 Diabetes COMPLETED NCT02692716
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT02692716
placebo Other Phase PHASE3 Diabetes COMPLETED NCT02607865
sitagliptin Other Phase PHASE3 Diabetes COMPLETED NCT02607865
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT02607865
DV3395 C1 Other Phase PHASE1 Healthy Volunteers, Medical Device COMPLETED NCT05314283
Long BPL RYGB Other Approved Obesity UNKNOWN NCT04196348
Short BPL RYGB Other Approved Obesity UNKNOWN NCT04196348
Long BPL RYGB Other Approved Obesity UNKNOWN NCT04196348
Short BPL RYGB Other Approved Obesity UNKNOWN NCT04196348
LANTUS® SOLOSTAR® INSULIN PEN Other Phase PHASE4 Diabetes Mellitus, Type 1 COMPLETED NCT03668808
TRESIBA® FLEXTOUCH® Other Phase PHASE4 Diabetes Mellitus, Type 1 COMPLETED NCT03668808
Insulin Glargine Other Phase PHASE4 Diabetes Mellitus, Type 1 COMPLETED NCT03668808
Insulin Degludec Other Phase PHASE4 Diabetes Mellitus, Type 1 COMPLETED NCT03668808
No treatment given Drug Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT05317845
HM-PRO Other Approved Hematologic Malignancy COMPLETED NCT04757545
NNC0385-0434 B Other Phase PHASE1 Healthy Volunteers; High Cholesterol COMPLETED NCT05333107
NNC0385-0434 F Other Phase PHASE1 Healthy Volunteers; High Cholesterol COMPLETED NCT05333107
NNC0385-0434 G Other Phase PHASE1 Healthy Volunteers; High Cholesterol COMPLETED NCT05333107
Sterile Normal Saline (0.9% NaCl) Other Phase PHASE1 Primary Hyperoxaluria Type 3 COMPLETED NCT04555486
DCR-PHXC Other Phase PHASE1 Primary Hyperoxaluria Type 3 COMPLETED NCT04555486
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05087342
Semaglutide 2.4mg Other Phase PHASE3 Obesity COMPLETED NCT05087342
Moxifloxacin Placebo Other Phase PHASE1 Obesity COMPLETED NCT05804162
Moxifloxacin Other Phase PHASE1 Obesity COMPLETED NCT05804162
Cagrilintide Placebo Other Phase PHASE1 Obesity COMPLETED NCT05804162
Cagrilintide Other Phase PHASE1 Obesity COMPLETED NCT05804162
NNC0148-0287 Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03789578
Semaglutide Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03789578
NNC0148-0287sema Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03789578
No tretament given Other Preclinical Type 2 Diabetes Mellitus (T2D) and Chronic Kidney Disease (CKD) COMPLETED NCT06769646
Placebo Other Phase PHASE3 Obesity COMPLETED NCT04889183
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT04889183
No treatment given Drug Preclinical Overweight COMPLETED NCT06874751
Placebo A (NNC0174 1213 A) Other Phase PHASE1 Obesity RECRUITING NCT06719011
Cagrilintide B Other Phase PHASE1 Obesity RECRUITING NCT06719011
NNC0174-1213 A Other Phase PHASE1 Obesity RECRUITING NCT06719011
Semaglutide Other Phase PHASE1 Healthy Participants COMPLETED NCT06097390
Placebo (NNC0560-0004) Other Phase PHASE1 Healthy Volunteers - Liver Diseases COMPLETED NCT06133270
NNC0560-0004 Other Phase PHASE1 Healthy Volunteers - Liver Diseases COMPLETED NCT06133270
recombinant factor XIII Other Preclinical Congenital Bleeding Disorder COMPLETED NCT02670213
Semaglutide Other Phase PHASE4 Diabetes Mellitus, Type 2 COMPLETED NCT05533632
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT05443334
Placebo GIP Other Phase PHASE1 Overweight RECRUITING NCT07411560
Cagrilintide Other Phase PHASE1 Overweight RECRUITING NCT07411560
Glucose-dependent Insulinotropic Polypeptide (GIP) Other Phase PHASE1 Overweight RECRUITING NCT07411560
Carbohydrate Other Approved Type 1 Diabetes COMPLETED NCT01223560
Exercise Other Approved Type 1 Diabetes COMPLETED NCT01223560
Insulin Aspart Other Approved Type 1 Diabetes COMPLETED NCT01223560
neutral protamine insulin Other Approved Type 2 Diabetes Mellitus UNKNOWN NCT01310452
insulin detemir Other Approved Type 2 Diabetes Mellitus UNKNOWN NCT01310452
Victoza® Other Phase PHASE4 Diabetes Mellitus, Type 2 COMPLETED NCT01208012
administration of autologous stored platelets Other Phase PHASE2 Bleeding COMPLETED NCT01248351
autologous stored platelets Other Phase PHASE2 Bleeding COMPLETED NCT01248351
DexCom CGM Other Phase PHASE4 Diabetes Type 2 COMPLETED NCT01076842
SenseWear Pro3® armband Other Phase PHASE4 Diabetes Type 2 COMPLETED NCT01076842
Insulin-Levemir and Exenatide-Bayetta Other Phase PHASE4 Diabetes Type 2 COMPLETED NCT01076842
Exenatide-Bayetta Other Phase PHASE4 Diabetes Type 2 COMPLETED NCT01076842
Insulin-Levemir Other Phase PHASE4 Diabetes Type 2 COMPLETED NCT01076842
Insulin detemir Other Phase PHASE4 Diabetes Mellitus, Type 1 UNKNOWN NCT01440439
Insulin glargine Other Phase PHASE4 Diabetes Mellitus, Type 1 UNKNOWN NCT01440439
Isotone NaCl Other Approved Kidney Functional COMPLETED NCT01333163
Human GLP-1 (7-36) amide Other Approved Kidney Functional COMPLETED NCT01333163
Health counseling and exercise Other Phase EARLY_PHASE1 Acute Leukemia COMPLETED NCT01557686
biphasic insulin aspart 30 Other Preclinical Diabetes COMPLETED NCT01542060
insulin aspart Other Phase PHASE4 Diabetes COMPLETED NCT01649570
Blast Traumatic Brain Injury Other Preclinical Traumatic Brain Injury UNKNOWN NCT01666964
counseling and behavioral therapy for weight loss Drug Approved Obesity COMPLETED NCT01312090
Whole body cryotherapy Drug Approved Obesity COMPLETED NCT01312090
Open-loop control Other Approved Type 1 Diabetes COMPLETED NCT01444443
Closed-loop control Other Approved Type 1 Diabetes COMPLETED NCT01444443
Atenolol Other Approved Healthy UNKNOWN NCT01795235
Placebo Other Approved Healthy UNKNOWN NCT01795235
Glucagon Other Approved Healthy UNKNOWN NCT01795235
Saline Other Approved Healthy UNKNOWN NCT01795235
Basal-bolus detemir-aspart insulin regimen Other Phase PHASE4 Diabetes Mellitus COMPLETED NCT01828970
Personal instruction Other Approved Musculoskeletal Disorders COMPLETED NCT01543893
Video instruction Other Approved Musculoskeletal Disorders COMPLETED NCT01543893
Glimepiride Other Phase PHASE2 Maturity-onset Diabetes of the Young COMPLETED NCT01610934
liraglutide Other Phase PHASE2 Maturity-onset Diabetes of the Young COMPLETED NCT01610934
somatropin Other Phase PHASE1 Growth Disorder WITHDRAWN NCT01512095
Liraglutide Other Phase PHASE4 Type 2 Diabetes Mellitus COMPLETED NCT01394341
insulin degludec/liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01916174
insulin degludec Other Phase PHASE1 Diabetes TERMINATED NCT01467414
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01193387
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01173926
insulin degludec/insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01173926
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01173926
biphasic insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT01134224
insulin degludec/insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01134224
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT00992537
insulin degludec/insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT00992537
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT00992537
oral placebo Other Phase PHASE1 Diabetes COMPLETED NCT01405261
I.v. NNC 0113-0987 Other Phase PHASE1 Diabetes COMPLETED NCT01405261
oral NNC 0113-0987 Other Phase PHASE1 Diabetes COMPLETED NCT01405261
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01121289
NN1218 Other Phase PHASE1 Diabetes COMPLETED NCT01121289
insulin 338 (GIPET I) Other Phase PHASE1 Diabetes COMPLETED NCT01931137
Norditropin SimpleXx (growth hormone) Other Phase PHASE2 Growth Hormone Deficiency COMPLETED NCT01090778
activated recombinant human factor VII Other Preclinical Acquired Bleeding Disorder COMPLETED NCT01285089
Placebo Other Phase PHASE1 Healthy COMPLETED NCT01550653
liraglutide Other Phase PHASE1 Healthy COMPLETED NCT01550653
Placebo-liraglutide Other Phase PHASE4 Type 2 Diabetes Mellitus COMPLETED NCT01664676
Liraglutide Other Phase PHASE4 Type 2 Diabetes Mellitus COMPLETED NCT01664676
eptacog alfa (activated) Other Phase PHASE1 Congenital Bleeding Disorder WITHDRAWN NCT02084810
activated recombinant human factor VII Other Phase PHASE1 Congenital Bleeding Disorder WITHDRAWN NCT02084810
Soccer training Other Approved Prostatic Neoplasms COMPLETED NCT01711892
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01866748
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT01866748
No treatment given Drug Preclinical Diabetes COMPLETED NCT01934686
human soluble insulin Other Phase PHASE1 Diabetes COMPLETED NCT02162407
insulin detemir Other Phase PHASE1 Diabetes COMPLETED NCT02162407
insulin human Other Phase PHASE1 Diabetes COMPLETED NCT01269606
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01269606
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01967589
NNC0113-0987 Other Phase PHASE1 Diabetes COMPLETED NCT01967589
insulin detemir Other Preclinical Diabetes COMPLETED NCT01487421
insulin aspart Other Preclinical Diabetes COMPLETED NCT01487421
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT01766245
estradiol, 25 mcg Other Phase PHASE1 Menopause COMPLETED NCT01085877
repaglinide Other Preclinical Diabetes COMPLETED NCT01077570
No treatment given Drug Preclinical Growth Hormone Disorder WITHDRAWN NCT01068639
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01978613
NNC0113-0987 Other Phase PHASE1 Diabetes COMPLETED NCT01978613
gliclazide Other Phase PHASE4 Diabetes COMPLETED NCT01022762
repaglinide Other Phase PHASE4 Diabetes COMPLETED NCT01022762
repaglinide Other Preclinical Diabetes COMPLETED NCT01355718
placebo Other Phase PHASE2 Inflammation WITHDRAWN NCT02097264
Adalimumab Other Phase PHASE2 Inflammation WITHDRAWN NCT02097264
NNC0109-0012 Other Phase PHASE2 Inflammation WITHDRAWN NCT02097264
placebo Other Phase PHASE1 Inflammation WITHDRAWN NCT01018238
NNC 0151-0000-0000 Other Phase PHASE1 Inflammation WITHDRAWN NCT01018238
NNC 0128-0000-2021 Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01272206
NNC 0128-0000-2011 Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01272206
placebo Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT01270789
Liraglutide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT01270789
IVGTT Other Approved Hypoglycaemia COMPLETED NCT01347801
OGTT Other Approved Hypoglycaemia COMPLETED NCT01347801
TNF-alfa Other Approved Hypoglycaemia COMPLETED NCT01347801
Placebo (Saline) Other Approved Hypoglycaemia COMPLETED NCT01347801
GLP-1 Other Approved Hypoglycaemia COMPLETED NCT01347801
No treatment given Drug Preclinical Diabetes WITHDRAWN NCT01957592
placebo Other Phase PHASE2 Inflammation TERMINATED NCT01706159
catridecacog Other Phase PHASE2 Inflammation TERMINATED NCT01706159
placebo Other Phase PHASE1 Inflammation COMPLETED NCT01955603
NNC0215-0384 Other Phase PHASE1 Inflammation COMPLETED NCT01955603
activated recombinant human factor VII Other Preclinical Congenital Bleeding Disorder COMPLETED NCT01312636
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02172313
metformin Other Phase PHASE4 Diabetes COMPLETED NCT01278160
biphasic insulin aspart 30 Other Phase PHASE4 Diabetes COMPLETED NCT01278160
0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) Other Preclinical Menopause COMPLETED NCT01076621
biphasic insulin aspart 30 Other Phase PHASE4 Diabetes COMPLETED NCT01215435
eptacog alfa (activated) Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01949792
activated recombinant human factor VII Other Preclinical Congenital Bleeding Disorder COMPLETED NCT01234545
observational study Other Preclinical Hemorrhage COMPLETED NCT01532661
No treatment given Drug Preclinical Diabetes COMPLETED NCT01934673
placebo Other Phase PHASE1 Diabetes COMPLETED NCT02161588
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02161588
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01507389
activated recombinant human factor VII Other Preclinical Congenital Bleeding Disorder COMPLETED NCT01476423
somatropin Other Preclinical Growth Hormone Disorder COMPLETED NCT01109017
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01515553
insulin detemir Other Phase PHASE1 Diabetes COMPLETED NCT01498926
No treatment given Drug Preclinical Diabetes COMPLETED NCT01877200
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02231684
NNC0113-0987 Other Phase PHASE1 Diabetes COMPLETED NCT02094521
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01515579
liraglutide Other Phase PHASE4 Type 2 Diabetes COMPLETED NCT01499108
Placebo Other Phase PHASE2 Type 2 Diabetes Mellitus COMPLETED NCT02113332
Liraglutide Other Phase PHASE2 Type 2 Diabetes Mellitus COMPLETED NCT02113332
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01623375
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT01619345
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01469143
Faster-acting insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01469143
insulin degludec/insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01455142
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01296438
Faster-acting insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01296438
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01272973
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT01272973
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01773798
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01773798
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01773798
insulin degludec/insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01773798
insulin degludec/insulin aspart 15 Other Phase PHASE1 Diabetes COMPLETED NCT01773798
insulin human Other Preclinical Diabetes TERMINATED NCT02382757
2 mg estradiol / 1 mg norethisterone acetate (NETA) Other Phase PHASE1 Menopause COMPLETED NCT01596010
biphasic human insulin 30 Other Phase PHASE1 Diabetes COMPLETED NCT01486888
Placebo Other Phase PHASE4 Type 2 Diabetes COMPLETED NCT01755572
Liraglutide Other Phase PHASE4 Type 2 Diabetes COMPLETED NCT01755572
insulin human Other Phase PHASE1 Diabetes COMPLETED NCT01511159
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01511159
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01511159
somatropin Other Preclinical Growth Hormone Disorder COMPLETED NCT01543867
Placebo Other Phase PHASE4 Partial Corticotrope Insufficiency TERMINATED NCT01089075
Hydrocortisone Other Phase PHASE4 Partial Corticotrope Insufficiency TERMINATED NCT01089075
No treatment given Drug Preclinical Diabetes COMPLETED NCT02230631
activated recombinant human factor VII Other Preclinical Congenital Bleeding Disorder COMPLETED NCT01220141
isophane human insulin Other Phase PHASE1 Diabetes COMPLETED NCT01486901
somatropin Other Preclinical Growth Hormone Disorder COMPLETED NCT01543880
Other: 4. Usual care Other Approved Lung Cancer TERMINATED NCT01893580
Experimental: 3. Experimental Other Approved Lung Cancer TERMINATED NCT01893580
Experimental: 2. Experimental Other Approved Lung Cancer TERMINATED NCT01893580
Experimental: 1. Experimental Other Approved Lung Cancer TERMINATED NCT01893580
liraglutide Other Preclinical Diabetes COMPLETED NCT01890993
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01597713
insulin glargine Other Phase PHASE1 Diabetes COMPLETED NCT01597713
NNC 0148-0000-0362 Other Phase PHASE1 Diabetes COMPLETED NCT01597713
biphasic insulin aspart 50 Other Phase PHASE1 Diabetes COMPLETED NCT01242826
NovoPen® 3 Other Preclinical Diabetes COMPLETED NCT01454024
FlexPen® Other Preclinical Diabetes COMPLETED NCT01454024
somatropin Other Preclinical Growth Hormone Disorder COMPLETED NCT01604161
biphasic human insulin 50 Other Phase PHASE4 Diabetes COMPLETED NCT01892020
biphasic insulin aspart 50 Other Phase PHASE4 Diabetes COMPLETED NCT01892020
No treatment given Drug Preclinical Congenital Bleeding Disorder COMPLETED NCT02241694
Remote ischemic conditioning Other Approved Kidney Transplantation UNKNOWN NCT01395719
Subcutaneous insertions of needles Other Approved Diabetes Mellitus, Type 2 COMPLETED NCT02531776
Placebo Other Phase PHASE2 Kidney Failure, Chronic WITHDRAWN NCT02284230
Liraglutide Other Phase PHASE2 Kidney Failure, Chronic WITHDRAWN NCT02284230
No treatment given Drug Preclinical Diabetes COMPLETED NCT01846312
insulin degludec/insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01125553
insulin glargine Other Phase PHASE1 Diabetes COMPLETED NCT01868529
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01868529
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT00966368
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01319240
insulin degludec/liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01319240
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01319240
insulin glargine Other Phase PHASE1 Diabetes COMPLETED NCT01865292
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01865292
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01868568
biphasic insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT01868568
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01868568
insulin degludec/insulin aspart 55 Other Phase PHASE1 Diabetes COMPLETED NCT01868568
insulin degludec/insulin aspart 45 Other Phase PHASE1 Diabetes COMPLETED NCT01868568
insulin degludec/insulin aspart 40 Other Phase PHASE1 Diabetes COMPLETED NCT01868568
insulin degludec/insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT01868568
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01868568
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01868555
insulin degludec/insulin aspart 45 Other Phase PHASE1 Diabetes COMPLETED NCT01868555
insulin degludec/insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT01868555
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01868555
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01865318
biphasic insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT01865305
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01865305
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01865305
insulin degludec/insulin aspart 50 Other Phase PHASE1 Diabetes COMPLETED NCT01865305
insulin degludec/insulin aspart 40 Other Phase PHASE1 Diabetes COMPLETED NCT01865305
insulin degludec/insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT01865305
isophane human insulin Other Phase PHASE1 Diabetes COMPLETED NCT01865279
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01865279
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01865279
No treatment given Drug Preclinical Diabetes COMPLETED NCT02608853
No treatment given Drug Preclinical Congenital Bleeding Disorder COMPLETED NCT01959555
Exercise based multimodal intervention Other Approved Acute Leukemia COMPLETED NCT01404520
Liraglutide Other Phase PHASE4 Diabetes Mellitus Type 2 TERMINATED NCT01542242
No treatment given Drug Preclinical Haemostasis COMPLETED NCT02568202
insulin degludec/insulin aspart 50 Other Phase PHASE1 Diabetes COMPLETED NCT01865331
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01865331
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01865331
1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA) Other Phase PHASE1 Menopause COMPLETED NCT01477632
0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) Other Phase PHASE1 Menopause COMPLETED NCT01477632
0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) Other Phase PHASE1 Menopause COMPLETED NCT01477632
placebo injection Other Phase PHASE3 Type 2 Diabetes TERMINATED NCT01628445
liraglutide Other Phase PHASE3 Type 2 Diabetes TERMINATED NCT01628445
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT01135992
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01135992
insulin detemir Other Phase PHASE1 Diabetes COMPLETED NCT01490099
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT01569841
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01569841
insulin detemir Other Phase PHASE3 Diabetes COMPLETED NCT01709929
insulin detemir Other Preclinical Diabetes COMPLETED NCT01542476
insulin detemir Other Preclinical Diabetes COMPLETED NCT01542463
insulin aspart Other Preclinical Diabetes COMPLETED NCT01487408
insulin aspart Other Preclinical Diabetes COMPLETED NCT01487382
insulin aspart Other Preclinical Diabetes COMPLETED NCT01487369
insulin aspart Other Preclinical Diabetes COMPLETED NCT01538589
insulin aspart Other Preclinical Diabetes COMPLETED NCT01538576
biphasic insulin aspart 30 Other Preclinical Diabetes COMPLETED NCT01536652
biphasic insulin aspart 30 Other Preclinical Diabetes COMPLETED NCT01536613
Physical activity intervention Other Approved Type 2 Diabetes COMPLETED NCT02371239
Liraglutide-placebo Other Phase PHASE2 Nonalcoholic Steatohepatitis COMPLETED NCT01237119
Liraglutide Other Phase PHASE2 Nonalcoholic Steatohepatitis COMPLETED NCT01237119
Liraglutide - Placebo Other Phase PHASE4 Diabetes Mellitus Type 2 COMPLETED NCT01761318
Liraglutide Other Phase PHASE4 Diabetes Mellitus Type 2 COMPLETED NCT01761318
activated recombinant human factor VII Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01562457
catridecacog Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT01253811
None, observational study Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT02486237
Meal Test Other Preclinical Bone Remodeling COMPLETED NCT02518737
Meal Test Other Preclinical Bone Remodeling COMPLETED NCT02518737
placebo Other Phase PHASE1 Diabetes COMPLETED NCT02479022
insulin glargine Other Phase PHASE1 Diabetes COMPLETED NCT02479022
Insulin 320 Other Phase PHASE1 Diabetes COMPLETED NCT02479022
Outdoor weather Other Preclinical Nonshivering Thermogenisis COMPLETED NCT02486419
placebo Other Phase PHASE4 Diabetic Kidney Disease COMPLETED NCT02545738
Liraglutide Other Phase PHASE4 Diabetic Kidney Disease COMPLETED NCT02545738
Mixed Meal Tolerance Test with paracetamol Other Phase PHASE2 Type 1 Diabetes Mellitus COMPLETED NCT02408705
Placebo Other Phase PHASE2 Type 1 Diabetes Mellitus COMPLETED NCT02408705
Liraglutide Other Phase PHASE2 Type 1 Diabetes Mellitus COMPLETED NCT02408705
recombinant factor XIII Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01082406
catridecacog Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01082406
Insulin detemir and pre-meal insulin aspart. Other Phase PHASE4 Type 2 Diabetes COMPLETED NCT00998335
Long-acting bedtime insulin detemir (Levemir) Other Phase PHASE4 Type 2 Diabetes COMPLETED NCT00998335
Neutral drinking-water Other Approved Healthy Participants COMPLETED NCT02917616
Alkaline drinking-water Other Approved Healthy Participants COMPLETED NCT02917616
Neutral drinking-water Other Approved Healthy Participants COMPLETED NCT02917616
Alkaline drinking-water Other Approved Healthy Participants COMPLETED NCT02917616
No treatment given Drug Preclinical Diabetes COMPLETED NCT01900834
insulin human Other Preclinical Diabetes COMPLETED NCT01492205
Marketed low dose hormone replacement therapy Drug Preclinical Menopause COMPLETED NCT01487304
insulin detemir Other Preclinical Diabetes COMPLETED NCT01545791
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01464099
biphasic insulin aspart 30 Other Preclinical Diabetes COMPLETED NCT01565733
No treatment given Drug Preclinical Diabetes COMPLETED NCT01516242
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01992588
Faster-acting insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01992588
NordiFlex PenMate™ Other Preclinical Growth Hormone Disorder COMPLETED NCT01500486
placebo Other Phase PHASE1 Haemostasis TERMINATED NCT01561950
clopidogrel Other Phase PHASE1 Haemostasis TERMINATED NCT01561950
eptacog alfa (activated) Other Phase PHASE1 Haemostasis TERMINATED NCT01561950
eptacog alfa (activated) Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01561924
placebo Other Phase PHASE1 Haemostasis COMPLETED NCT01603342
clopidogrel Other Phase PHASE1 Haemostasis COMPLETED NCT01603342
placebo Other Phase PHASE1 Haemostasis COMPLETED NCT01561937
eptacog alfa (activated) Other Phase PHASE1 Haemostasis COMPLETED NCT01561937
warfarin Other Phase PHASE1 Haemostasis COMPLETED NCT01561937
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT01045707
insulin degludec/insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01045707
liraglutide Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02207348
biphasic human insulin 30 Other Preclinical Diabetes COMPLETED NCT01492166
insulin glargine Other Phase PHASE1 Diabetes COMPLETED NCT01704417
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01704417
liraglutide Other Preclinical Diabetes COMPLETED NCT01212133
placebo Other Phase PHASE1 Diabetes COMPLETED NCT02557620
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02557620
biphasic human insulin 30 Other Phase PHASE1 Diabetes COMPLETED NCT01707160
biphasic insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT01707160
insulin NPH Other Phase PHASE3 Diabetes COMPLETED NCT01707134
human soluble insulin Other Phase PHASE3 Diabetes COMPLETED NCT01707134
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01707134
biphasic human insulin 30 Other Phase PHASE2 Diabetes COMPLETED NCT01697618
biphasic insulin aspart 30 Other Phase PHASE2 Diabetes COMPLETED NCT01697618
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01520831
biphasic insulin aspart 70 Other Phase PHASE1 Diabetes COMPLETED NCT01520831
biphasic insulin aspart 50 Other Phase PHASE1 Diabetes COMPLETED NCT01520831
biphasic insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT01520831
biphasic human insulin 30 Other Phase PHASE3 Diabetes COMPLETED NCT01520818
biphasic insulin aspart 70 Other Phase PHASE3 Diabetes COMPLETED NCT01520818
biphasic insulin aspart 50 Other Phase PHASE3 Diabetes COMPLETED NCT01520818
biphasic insulin aspart 50 Other Phase PHASE3 Diabetes COMPLETED NCT01520753
biphasic insulin aspart 70 Other Phase PHASE3 Diabetes COMPLETED NCT01520753
biphasic human insulin Other Phase PHASE3 Diabetes COMPLETED NCT01467323
biphasic insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01467323
No treatment given Drug Preclinical Growth Hormone Disorder COMPLETED NCT02005198
biphasic insulin aspart 50 Other Phase PHASE1 Diabetes COMPLETED NCT01620424
biphasic insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT01620424
biphasic insulin aspart 70 Other Phase PHASE1 Diabetes COMPLETED NCT01620333
biphasic insulin aspart 50 Other Phase PHASE1 Diabetes COMPLETED NCT01620333
biphasic human insulin 30 Other Phase PHASE2 Diabetes COMPLETED NCT01526980
biphasic insulin aspart 70 Other Phase PHASE2 Diabetes COMPLETED NCT01526980
biphasic insulin aspart 30 Other Phase PHASE2 Diabetes COMPLETED NCT01526980
biphasic insulin aspart 70 Other Phase PHASE1 Diabetes COMPLETED NCT01526941
biphasic insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT01526941
biphasic insulin aspart 70 Other Phase PHASE1 Diabetes COMPLETED NCT01524809
biphasic insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT01524809
biphasic insulin aspart 30 Other Preclinical Diabetes COMPLETED NCT01548235
biphasic insulin aspart 30 Other Preclinical Diabetes COMPLETED NCT01536600
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01536028
biphasic insulin aspart 70 Other Phase PHASE1 Diabetes COMPLETED NCT01536028
biphasic insulin aspart 50 Other Phase PHASE1 Diabetes COMPLETED NCT01536028
biphasic insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT01536028
biphasic insulin aspart 70 Other Phase PHASE1 Diabetes COMPLETED NCT01527656
biphasic insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT01487811
biphasic insulin aspart 30 Other Phase PHASE4 Diabetes COMPLETED NCT01487798
biphasic human insulin 30 Other Phase PHASE4 Diabetes COMPLETED NCT01487798
biphasic insulin aspart 30 Other Preclinical Diabetes COMPLETED NCT01486875
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01682902
Faster-acting insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01682902
biphasic insulin aspart 30 Other Preclinical Diabetes COMPLETED NCT01536639
placebo Other Phase PHASE1 Acquired Bleeding Disorder COMPLETED NCT02239146
catridecacog Other Phase PHASE1 Acquired Bleeding Disorder COMPLETED NCT02239146
placebo Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01847989
catridecacog Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01847989
placebo Other Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01601613
activated recombinant human factor VII Other Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01601613
placebo Other Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01562158
activated recombinant human factor VII Other Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01562158
standard therapy Drug Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01562158
Plasma-derived FVII conc. (pdFVII PFL) Other Preclinical Congenital Bleeding Disorder COMPLETED NCT01779921
Plasma-derived FVII conc. (pdFVII Baxter) Other Preclinical Congenital Bleeding Disorder COMPLETED NCT01779921
Prothrombin Complex conc. (PCC) Other Preclinical Congenital Bleeding Disorder COMPLETED NCT01779921
Plasma-derived FVII (LFB) Other Preclinical Congenital Bleeding Disorder COMPLETED NCT01779921
Fresh frozen plasma (Source unspecified) Other Preclinical Congenital Bleeding Disorder COMPLETED NCT01779921
activated recombinant human factor VII Other Preclinical Congenital Bleeding Disorder COMPLETED NCT01779921
placebo Other Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01566786
activated recombinant human factor VII Other Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01566786
activated recombinant human factor VII Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01562587
placebo Other Phase PHASE3 Acquired Bleeding Disorder COMPLETED NCT01562574
activated recombinant human factor VII Other Phase PHASE3 Acquired Bleeding Disorder COMPLETED NCT01562574
activated recombinant human factor VII Other Phase PHASE2 Other Haemostasis Disorder COMPLETED NCT01561352
survey Other Preclinical Diabetes COMPLETED NCT01950637
No treatment given Drug Preclinical Diabetes COMPLETED NCT01950637
placebo Other Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01601457
activated recombinant human factor VII Other Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01601457
placebo Other Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01563523
activated recombinant human factor VII Other Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01563523
placebo Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01563471
activated recombinant human factor VII Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01563471
placebo Other Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01563458
activated recombinant human factor VII Other Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01563458
placebo Other Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01563445
activated recombinant human factor VII Other Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01563445
placebo Other Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01562821
activated recombinant human factor VII Other Phase PHASE2 Acquired Bleeding Disorder COMPLETED NCT01562821
metformin Other Phase PHASE4 Diabetes COMPLETED NCT01068652
biphasic insulin aspart 30 Other Phase PHASE4 Diabetes COMPLETED NCT01068652
insulin aspart Other Phase PHASE4 Diabetes COMPLETED NCT01068652
insulin detemir Other Phase PHASE4 Diabetes COMPLETED NCT01068652
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT02131246
Faster-acting insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT02131246
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT02033239
Faster-acting insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT02033239
No treatment given Drug Preclinical Congenital Bleeding Disorder COMPLETED NCT01988532
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01924637
Faster-acting insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01924637
somatropin Other Phase PHASE4 Foetal Growth Problem COMPLETED NCT01697644
somatropin Other Phase PHASE3 Genetic Disorder COMPLETED NCT01529840
oestrogen Other Phase PHASE4 Genetic Disorder COMPLETED NCT01518062
somatropin Other Phase PHASE4 Genetic Disorder COMPLETED NCT01518062
No treatment given Drug Preclinical Congenital Bleeding Disorder COMPLETED NCT01503567
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01121276
Faster-acting insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01121276
insulin Other Preclinical Diabetes COMPLETED NCT01628341
activated recombinant human factor VII Other Phase PHASE1 Acquired Bleeding Disorder COMPLETED NCT01561417
No treatment given Drug Preclinical Diabetes COMPLETED NCT01507116
insulin Other Preclinical Diabetes COMPLETED NCT01493388
No treatment given Drug Preclinical Diabetes COMPLETED NCT01437072
No treatment given Drug Preclinical Diabetes COMPLETED NCT01351922
No treatment given Drug Preclinical Diabetes COMPLETED NCT01435642
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01154881
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01151072
insulin detemir Other Phase PHASE1 Diabetes COMPLETED NCT01135927
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01135927
insulin glargine Other Phase PHASE1 Diabetes COMPLETED NCT01030926
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01030926
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01006057
insulin glargine Other Phase PHASE1 Diabetes COMPLETED NCT01002768
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01002768
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT00976326
glucose clamp Other Phase PHASE1 Diabetes COMPLETED NCT01780272
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01076634
insulin detemir Other Phase PHASE1 Diabetes COMPLETED NCT01043510
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01043510
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01620463
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01620463
glimepiride Other Phase PHASE2 Diabetes COMPLETED NCT01509755
liraglutide Other Phase PHASE2 Diabetes COMPLETED NCT01509755
placebo Other Phase PHASE2 Diabetes COMPLETED NCT01509755
placebo Other Phase PHASE2 Diabetes COMPLETED NCT01508923
liraglutide Other Phase PHASE2 Diabetes COMPLETED NCT01508923
levonorgestrel / ethinylestradiol Other Phase PHASE1 Diabetes COMPLETED NCT01508858
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01508858
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01508858
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01508806
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01507337
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01507311
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01507311
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01507272
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01507272
somatropin Other Phase PHASE1 Chronic Kidney Disease COMPLETED NCT01502137
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01620476
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01620476
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01615978
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01615978
digoxin Other Phase PHASE1 Diabetes COMPLETED NCT01518166
griseofulvin Other Phase PHASE1 Diabetes COMPLETED NCT01518166
lisinopril Other Phase PHASE1 Diabetes COMPLETED NCT01518166
atorvastatin Other Phase PHASE1 Diabetes COMPLETED NCT01518166
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01518166
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01518166
electrocardiogram (ECG) Other Phase PHASE1 Diabetes COMPLETED NCT01516255
moxifloxacin Other Phase PHASE1 Diabetes COMPLETED NCT01516255
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01516255
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01516255
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01515592
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01515592
glimepiride Other Phase PHASE1 Diabetes COMPLETED NCT01511692
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01511692
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01511692
glimepiride Other Phase PHASE2 Diabetes COMPLETED NCT01511172
placebo Other Phase PHASE2 Diabetes COMPLETED NCT01511172
metformin Other Phase PHASE2 Diabetes COMPLETED NCT01511172
liraglutide Other Phase PHASE2 Diabetes COMPLETED NCT01511172
liraglutide [3H] Other Phase PHASE1 Diabetes COMPLETED NCT01517568
paracetamol Other Phase PHASE1 Diabetes COMPLETED NCT01517555
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01517555
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01517555
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01513525
metformin Other Phase PHASE2 Diabetes COMPLETED NCT01511198
liraglutide Other Phase PHASE2 Diabetes COMPLETED NCT01511198
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01511185
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01511185
liraglutide Other Preclinical Diabetes COMPLETED NCT01288326
placebo Other Phase PHASE1 Diabetes COMPLETED NCT00993304
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT00993304
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01697657
insulin NPH Other Phase PHASE3 Diabetes COMPLETED NCT01697657
insulin detemir Other Phase PHASE3 Diabetes COMPLETED NCT01697657
insulin NPH Other Phase PHASE1 Diabetes COMPLETED NCT01542450
insulin detemir Other Phase PHASE1 Diabetes COMPLETED NCT01542450
insulin NPH Other Phase PHASE1 Diabetes COMPLETED NCT01497600
insulin detemir Other Phase PHASE1 Diabetes COMPLETED NCT01497600
insulin NPH Other Phase PHASE1 Diabetes COMPLETED NCT01497561
insulin detemir Other Phase PHASE1 Diabetes COMPLETED NCT01497561
human soluble insulin Other Phase PHASE3 Diabetes COMPLETED NCT01486940
insulin NPH Other Phase PHASE3 Diabetes COMPLETED NCT01486940
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01486940
insulin detemir Other Phase PHASE3 Diabetes COMPLETED NCT01486940
insulin glargine Other Phase PHASE1 Diabetes COMPLETED NCT01497574
insulin detemir Other Phase PHASE1 Diabetes COMPLETED NCT01497574
insulin aspart Other Preclinical Diabetes COMPLETED NCT01548248
insulin detemir Other Preclinical Diabetes COMPLETED NCT01548248
human soluble insulin Other Preclinical Diabetes COMPLETED NCT01542489
insulin aspart Other Preclinical Diabetes COMPLETED NCT01542489
insulin detemir Other Preclinical Diabetes COMPLETED NCT01542489
insulin detemir Other Preclinical Diabetes COMPLETED NCT01542424
biphasic insulin aspart 30 Other Preclinical Diabetes COMPLETED NCT01542424
insulin detemir Other Phase PHASE1 Diabetes COMPLETED NCT01497587
placebo Other Phase PHASE2 Inflammation COMPLETED NCT01647451
NNC0114-0006 Other Phase PHASE2 Inflammation COMPLETED NCT01647451
placebo Other Phase PHASE1 Inflammation COMPLETED NCT01565408
NNC0114-0006 Other Phase PHASE1 Inflammation COMPLETED NCT01565408
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01536665
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01536665
estradiol, 25 mcg Other Preclinical Menopause COMPLETED NCT01507454
estradiol, 25 mcg Other Phase PHASE1 Menopause COMPLETED NCT01486979
estradiol, 10 mcg Other Phase PHASE1 Menopause COMPLETED NCT01486979
Microgyn® Other Phase PHASE1 Diabetes COMPLETED NCT01324505
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01324505
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT01324505
placebo Other Phase PHASE1 Inflammation COMPLETED NCT01208506
NNC0114-0000-0005 Other Phase PHASE1 Inflammation COMPLETED NCT01208506
NovoPen Echo® Other Preclinical Diabetes COMPLETED NCT01180530
placebo Other Phase PHASE1 Diabetes COMPLETED NCT00983021
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT00983021
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT00983021
insulin degludec/liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT00983021
placebo Other Phase PHASE1 Inflammation COMPLETED NCT02151409
NNC 0151-0000-0000 Other Phase PHASE1 Inflammation COMPLETED NCT02151409
placebo Other Phase PHASE3 Diabetes COMPLETED NCT02098395
liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT02098395
lixisenatide Other Phase PHASE4 Diabetes COMPLETED NCT01973231
liraglutide Other Phase PHASE4 Diabetes COMPLETED NCT01973231
placebo Other Phase PHASE2 Inflammation COMPLETED NCT01282255
NNC109-0012 Other Phase PHASE2 Inflammation COMPLETED NCT01282255
placebo Other Phase PHASE1 Inflammation TERMINATED NCT01261767
anti-IL-20 Other Phase PHASE1 Inflammation TERMINATED NCT01261767
placebo Other Phase PHASE2 Inflammation COMPLETED NCT01223911
NNC 0151-0000-0000 Other Phase PHASE2 Inflammation COMPLETED NCT01223911
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01079234
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT01079234
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01079234
placebo Other Phase PHASE1 Inflammation COMPLETED NCT01038674
anti-IL-20 Other Phase PHASE1 Inflammation COMPLETED NCT01038674
placebo Other Phase PHASE1 Growth Hormone Disorder COMPLETED NCT01034202
Norditropin® SimpleXx® Other Phase PHASE1 Growth Hormone Disorder COMPLETED NCT01034202
NNC126-0083 Other Phase PHASE1 Growth Hormone Disorder COMPLETED NCT01034202
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT01006291
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01006291
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT00982644
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT00982644
insulin degludec/insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01590836
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01590836
repaglinide and metformin combination tablet Other Phase PHASE1 Diabetes COMPLETED NCT01490658
metformin Other Phase PHASE1 Diabetes COMPLETED NCT01490658
repaglinide Other Phase PHASE1 Diabetes COMPLETED NCT01490658
repaglinide and metformin combination tablet Other Phase PHASE1 Diabetes COMPLETED NCT01489644
metformin Other Phase PHASE1 Diabetes COMPLETED NCT01489644
repaglinide Other Phase PHASE1 Diabetes COMPLETED NCT01489644
turoctocog alfa Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01365520
turoctocog alfa Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01238367
turoctocog alfa pegol Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01205724
biphasic insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT01174303
insulin degludec/insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01174303
insulin degludec/insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01138488
biphasic insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT01051102
insulin degludec/insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01051102
biphasic insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT00993096
insulin degludec/insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT00993096
liraglutide Other Preclinical Diabetes COMPLETED NCT01226966
Faster-acting insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT02089451
insulin detemir Other Phase PHASE4 Diabetes COMPLETED NCT01165684
insulin aspart Other Phase PHASE4 Diabetes COMPLETED NCT01165684
insulin Other Phase PHASE4 Diabetes COMPLETED NCT01720303
isophane human insulin Other Phase PHASE4 Diabetes COMPLETED NCT01720303
repaglinide Other Phase PHASE4 Diabetes COMPLETED NCT01720303
metformin Other Phase PHASE4 Diabetes COMPLETED NCT01720290
repaglinide Other Phase PHASE4 Diabetes COMPLETED NCT01720290
placebo Other Phase PHASE4 Diabetes COMPLETED NCT01698931
glyburide Other Phase PHASE4 Diabetes COMPLETED NCT01698931
repaglinide Other Phase PHASE4 Diabetes COMPLETED NCT01698931
glyburide Other Phase PHASE4 Diabetes COMPLETED NCT01605773
repaglinide Other Phase PHASE4 Diabetes COMPLETED NCT01605773
insulin NPH Other Phase PHASE3 Diabetes COMPLETED NCT01562561
repaglinide Other Phase PHASE3 Diabetes COMPLETED NCT01562561
repaglinide Other Preclinical Diabetes COMPLETED NCT01498913
repaglinide Other Phase PHASE4 Diabetes COMPLETED NCT01465152
metformin Other Phase PHASE4 Diabetes COMPLETED NCT01465152
isophane human insulin Other Phase PHASE4 Diabetes COMPLETED NCT01467141
human insulin Other Phase PHASE4 Diabetes COMPLETED NCT01467141
insulin aspart Other Phase PHASE4 Diabetes COMPLETED NCT01467141
No treatment given Drug Preclinical Congenital Bleeding Disorder COMPLETED NCT01322620
biphasic insulin aspart Other Phase PHASE4 Diabetes COMPLETED NCT01704378
insulin aspart Other Phase PHASE4 Diabetes COMPLETED NCT01697631
biphasic insulin aspart 30 Other Phase PHASE4 Diabetes COMPLETED NCT01697631
biphasic human insulin 50 Other Phase PHASE3 Diabetes COMPLETED NCT01650129
biphasic insulin aspart 50 Other Phase PHASE3 Diabetes COMPLETED NCT01650129
biphasic insulin aspart 50 Other Phase PHASE1 Diabetes COMPLETED NCT01620437
biphasic insulin aspart 30 Other Phase PHASE4 Diabetes COMPLETED NCT01618214
eptacog alfa (activated) Other Preclinical Congenital Bleeding Disorder COMPLETED NCT01579968
eptacog alfa (activated) Other Preclinical Congenital Bleeding Disorder COMPLETED NCT01579955
biphasic insulin aspart 30 Other Preclinical Diabetes COMPLETED NCT01536626
biphasic insulin aspart 50 Other Phase PHASE1 Diabetes COMPLETED NCT01527643
biphasic insulin aspart 50 Other Phase PHASE1 Diabetes COMPLETED NCT01527630
biphasic insulin aspart 70 Other Phase PHASE1 Diabetes COMPLETED NCT01527565
biphasic insulin aspart 50 Other Phase PHASE1 Diabetes COMPLETED NCT01527552
biphasic insulin aspart 30 Other Phase PHASE3 Diabetes COMPLETED NCT01527539
biphasic insulin aspart 50 Other Phase PHASE1 Diabetes COMPLETED NCT01523041
biphasic insulin aspart 70 Other Phase PHASE1 Diabetes COMPLETED NCT01523041
metformin Other Phase PHASE4 Diabetes COMPLETED NCT01519674
sitagliptin Other Phase PHASE4 Diabetes COMPLETED NCT01519674
biphasic insulin aspart 30 Other Phase PHASE4 Diabetes COMPLETED NCT01519674
insulin glargine Other Phase PHASE1 Diabetes COMPLETED NCT01497535
insulin detemir Other Phase PHASE1 Diabetes COMPLETED NCT01497535
biphasic insulin aspart 30 Other Phase PHASE3 Diabetes COMPLETED NCT01486381
biphasic human insulin Other Phase PHASE4 Diabetes COMPLETED NCT01467401
biphasic insulin aspart Other Phase PHASE4 Diabetes COMPLETED NCT01467401
biphasic insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01467375
biphasic insulin aspart 30 Other Phase PHASE4 Diabetes COMPLETED NCT01427920
somatropin Other Phase PHASE1 Genetic Disorder COMPLETED NCT01401244
catridecacog Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT01230021
insulin glargine Other Phase PHASE4 Diabetes COMPLETED NCT01123980
glimepiride Other Phase PHASE4 Diabetes COMPLETED NCT01123980
metformin Other Phase PHASE4 Diabetes COMPLETED NCT01123980
biphasic insulin aspart 30 Other Phase PHASE4 Diabetes COMPLETED NCT01123980
autocover needle Other Phase PHASE4 Diabetes COMPLETED NCT01024218
NovoFine® needle 8 mm Other Phase PHASE4 Diabetes COMPLETED NCT01024218
somatropin Other Phase PHASE3 Growth Hormone Disorder COMPLETED NCT01563926
placebo Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01555749
NNC172-2021 Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01555749
somatropin Other Preclinical Genetic Disorder COMPLETED NCT01516229
human insulin Other Phase PHASE1 Diabetes COMPLETED NCT01448070
Norditropin NordiFlex® Other Phase PHASE4 Growth Hormone Disorder COMPLETED NCT01245374
1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA) Other Phase PHASE4 Menopause COMPLETED NCT01705249
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01690169
NNC0113-0987 Other Phase PHASE1 Diabetes COMPLETED NCT01690169
somatropin Other Phase PHASE3 Genetic Disorder COMPLETED NCT01518036
somatropin Other Phase PHASE3 Growth Hormone Disorder COMPLETED NCT01502124
insulin human Other Preclinical Diabetes COMPLETED NCT01492959
biphasic human insulin 30 Other Preclinical Diabetes COMPLETED NCT01492218
human soluble insulin Other Preclinical Diabetes COMPLETED NCT01492153
isophane human insulin Other Preclinical Diabetes COMPLETED NCT01492153
biphasic human insulin Other Preclinical Diabetes COMPLETED NCT01492153
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01087645
NN9925 (i.v.) Other Phase PHASE1 Diabetes COMPLETED NCT01087645
NN9925 (oral) Other Phase PHASE1 Diabetes COMPLETED NCT01087645
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01809184
insulin glargine Other Phase PHASE1 Diabetes COMPLETED NCT01809184
insulin 287 Other Phase PHASE1 Diabetes COMPLETED NCT01809184
insulin glargine Other Phase PHASE1 Diabetes COMPLETED NCT01796366
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01796366
insulin 338 (GIPET I) Other Phase PHASE1 Diabetes COMPLETED NCT01796366
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01698697
biphasic human insulin 30 Other Phase PHASE1 Diabetes COMPLETED NCT01620450
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01514487
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01486914
insulin glargine Other Phase PHASE1 Diabetes COMPLETED NCT01334034
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01334034
NNC 0123-0000-0338 Other Phase PHASE1 Diabetes COMPLETED NCT01334034
insulin detemir Other Phase PHASE4 Diabetes COMPLETED NCT01868542
sodium chloride 0.9% solution Other Phase PHASE1 Diabetes COMPLETED NCT01680328
19 injections Other Phase PHASE1 Diabetes COMPLETED NCT01680328
sitagliptin Other Phase PHASE3 Diabetes COMPLETED NCT01046110
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01046110
liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT01388361
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01388361
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01388361
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01364428
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01326026
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT01076647
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01076647
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01074268
insulin detemir Other Phase PHASE3 Diabetes COMPLETED NCT01074268
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01074268
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT01068678
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01068678
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT01068665
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01068665
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT01570751
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01570751
placebo Other Phase PHASE3 Diabetes COMPLETED NCT01617434
liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT01617434
sitagliptin Other Phase PHASE4 Diabetes COMPLETED NCT02008682
liraglutide Other Phase PHASE4 Diabetes COMPLETED NCT02008682
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT02035371
Faster-acting insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT02035371
metformin Other Phase PHASE4 Diabetes TERMINATED NCT01486966
human soluble insulin Other Phase PHASE4 Diabetes TERMINATED NCT01486966
insulin NPH Other Phase PHASE4 Diabetes TERMINATED NCT01486966
insulin aspart Other Phase PHASE4 Diabetes TERMINATED NCT01486966
insulin detemir Other Phase PHASE4 Diabetes TERMINATED NCT01486966
insulin degludec/insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01365507
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT01272193
insulin degludec/insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01272193
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT01045447
insulin degludec/insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01045447
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT00978627
insulin detemir Other Phase PHASE3 Diabetes COMPLETED NCT00978627
insulin degludec/insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT00978627
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01473953
liraglutide-depot Other Phase PHASE1 Diabetes COMPLETED NCT01473953
placebo Other Phase PHASE2 Diabetes TERMINATED NCT01206101
liraglutide Other Phase PHASE2 Diabetes TERMINATED NCT01206101
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT01059799
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01059799
placebo Other Phase PHASE2 Inflammation COMPLETED NCT01751152
NNC0114-0006 Other Phase PHASE2 Inflammation COMPLETED NCT01751152
atorvastatin Other Phase PHASE1 Diabetes COMPLETED NCT02243098
digoxin Other Phase PHASE1 Diabetes COMPLETED NCT02243098
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02243098
warfarin Other Phase PHASE1 Diabetes COMPLETED NCT02022254
metformin Other Phase PHASE1 Diabetes COMPLETED NCT02022254
placebo Other Phase PHASE1 Diabetes COMPLETED NCT02022254
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02022254
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT00982228
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT00982228
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT00982228
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT00972283
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT00972283
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT00972283
Insulin Glargine Other Phase PHASE3 Diabetes COMPLETED NCT01849289
Insulin Degludec Other Phase PHASE3 Diabetes COMPLETED NCT01849289
somatropin Other Preclinical Growth Hormone Disorder COMPLETED NCT01009905
survey Other Preclinical Diabetes COMPLETED NCT01950650
No treatment given Drug Preclinical Diabetes COMPLETED NCT01950650
Dietary regimen Other Phase PHASE4 Diabetes COMPLETED NCT01232491
Insulin detemir Other Phase PHASE4 Diabetes COMPLETED NCT01232491
somatropin Other Preclinical Genetic Disorder COMPLETED NCT01435629
Placebo Other Phase PHASE1 Diabetes COMPLETED NCT03144271
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT03144271
eptacog alfa (activated) Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT01392547
vatreptacog alfa (activated) Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT01392547
insulin degludec/liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT02298192
sitagliptin Other Preclinical Diabetes COMPLETED NCT02077946
liraglutide Other Preclinical Diabetes COMPLETED NCT02077946
somatropin Other Phase PHASE3 Growth Disorder COMPLETED NCT01778023
somapacitan Other Phase PHASE1 Healthy COMPLETED NCT02962440
Microgynon® Other Phase PHASE1 Diabetes COMPLETED NCT02845219
SNAC Other Phase PHASE1 Diabetes COMPLETED NCT02845219
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02845219
eptacog alfa (activated) Other Preclinical Congenital Bleeding Disorder COMPLETED NCT01876745
biphasic insulin aspart 30 Other Phase PHASE4 Diabetes COMPLETED NCT01589653
Placebo Other Phase PHASE2 Psoriatic Arthritis WITHDRAWN NCT02472717
liraglutide Other Phase PHASE2 Psoriatic Arthritis WITHDRAWN NCT02472717
NPH insulin Other Phase PHASE3 Diabetes Mellitus, Type 1 COMPLETED NCT03220425
Insulin detemir Other Phase PHASE3 Diabetes Mellitus, Type 1 COMPLETED NCT03220425
placebo Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT02490787
Concizumab Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT02490787
Epidemiological intervention Other Preclinical Diabetes Mellitus COMPLETED NCT01117831
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01028404
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01028404
NN1952 Other Phase PHASE1 Diabetes COMPLETED NCT01028404
placebo Other Phase PHASE1 Metabolism and Nutrition Disorder TERMINATED NCT01044108
'2-0453 Other Phase PHASE1 Metabolism and Nutrition Disorder TERMINATED NCT01044108
NNC 0070-0002-0453 Other Phase PHASE1 Metabolism and Nutrition Disorder TERMINATED NCT01044108
turoctocog alfa Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT00984126
liraglutide Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT00978393
nonacog beta pegol Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT01333111
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT02594033
insulin degludec Other Preclinical Diabetes COMPLETED NCT02117622
Insulin Degludec 100 UNT/ML [Tresiba] Other Phase PHASE4 Type 2 Diabetes Mellitus UNKNOWN NCT03244241
liraglutide Other Preclinical Diabetes COMPLETED NCT01821846
nonacog beta pegol Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT01386528
sulphonylurea Other Phase PHASE4 Diabetes COMPLETED NCT01917656
metformin Other Phase PHASE4 Diabetes COMPLETED NCT01917656
liraglutide Other Phase PHASE4 Diabetes COMPLETED NCT01917656
insulin degludec/liraglutide Other Preclinical Diabetes WITHDRAWN NCT03070704
liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT01664247
placebo Other Phase PHASE3 Diabetes COMPLETED NCT01664247
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01664247
biphasic insulin aspart 30 Other Phase PHASE1 Diabetes COMPLETED NCT01538511
biphasic insulin aspart 70 Other Phase PHASE1 Diabetes COMPLETED NCT01538511
insulin glargine Other Phase PHASE1 Diabetes COMPLETED NCT01114542
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01114542
Placebo Other Phase PHASE2 Obesity COMPLETED NCT02647944
Liraglutide Other Phase PHASE2 Obesity COMPLETED NCT02647944
placebo Other Phase PHASE3 Diabetes COMPLETED NCT01618162
insulin degludec/liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT01618162
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01999322
Faster-acting insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01999322
placebo Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT01557166
liraglutide Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT01557166
placebo Other Phase PHASE1 Diabetes COMPLETED NCT02079870
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02079870
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT02612844
NNC0143-0406 Other Phase PHASE1 Diabetes COMPLETED NCT02612844
insulin glargine Other Phase PHASE1 Healthy COMPLETED NCT02220296
placebo Other Phase PHASE1 Healthy COMPLETED NCT02220296
Insulin 338 Other Phase PHASE1 Healthy COMPLETED NCT02220296
Placebo Other Phase PHASE1 Diabetes COMPLETED NCT02920385
Levothyroxine Other Phase PHASE1 Diabetes COMPLETED NCT02920385
SNAC Other Phase PHASE1 Diabetes COMPLETED NCT02920385
Semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02920385
turoctocog alfa pegol Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT02920398
oral anti-diabetic drug Drug Phase PHASE3 Diabetes COMPLETED NCT01512108
liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT01512108
Semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT03010475
SNAC Other Phase PHASE1 Diabetes COMPLETED NCT03010475
Rosuvastatin Other Phase PHASE1 Diabetes COMPLETED NCT03010475
Furosemide Other Phase PHASE1 Diabetes COMPLETED NCT03010475
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02210871
placebo Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT01272232
liraglutide Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT01272232
Placebos Other Phase PHASE4 Type 1 Diabetes COMPLETED NCT01787916
Liraglutide Other Phase PHASE4 Type 1 Diabetes COMPLETED NCT01787916
placebo Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02835235
NNC9204-0530 Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02835235
Moxifloxacin Other Phase PHASE1 Healthy COMPLETED NCT02911870
Placebo Other Phase PHASE1 Healthy COMPLETED NCT02911870
SNAC Other Phase PHASE1 Healthy COMPLETED NCT02911870
insulin degludec/liraglutide Other Preclinical Diabetes COMPLETED NCT02754817
glucose clamp Other Phase PHASE1 Diabetes COMPLETED NCT01789593
Saline Other Phase PHASE4 Type 2 Diabetes Mellitus COMPLETED NCT01505673
Liraglutide Other Phase PHASE4 Type 2 Diabetes Mellitus COMPLETED NCT01505673
placebo Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT01272219
liraglutide Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT01272219
catridecacog Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT00978380
Aspart flexible dose Other Phase PHASE4 Diabetes COMPLETED NCT01101867
Aspart fixed dose Other Phase PHASE4 Diabetes COMPLETED NCT01101867
Placebo Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02958085
NNC0174-0833 Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02958085
placebo Other Phase PHASE1 Diabetes COMPLETED NCT02627287
DV3316 pen-injector Other Phase PHASE1 Diabetes COMPLETED NCT02627287
FlexPen® Other Phase PHASE1 Diabetes COMPLETED NCT02627287
No treatment given Drug Preclinical Diabetes COMPLETED NCT01585506
insulin Other Phase PHASE3 Diabetes COMPLETED NCT01572740
placebo Other Phase PHASE3 Diabetes COMPLETED NCT01572740
liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT01572740
liraglutide Other Preclinical Diabetes COMPLETED NCT01403025
liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT01336023
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01336023
insulin degludec/liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT01336023
Insulin Aspart Other Phase PHASE1 Diabetes COMPLETED NCT02938572
NNC0143-0406 Other Phase PHASE1 Diabetes COMPLETED NCT02938572
placebo Other Phase PHASE1 Diabetes COMPLETED NCT02212067
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02212067
insulin degludec/insulin aspart Other Preclinical Diabetes COMPLETED NCT02230618
Liraglutide - Placebo Other Phase PHASE4 Diabetes Mellitus Type 2 COMPLETED NCT02660047
Liraglutide Other Phase PHASE4 Diabetes Mellitus Type 2 COMPLETED NCT02660047
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT02420262
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT02420262
insulin degludec/liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT02420262
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01713530
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01713530
insulin degludec/insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01713530
insulin degludec/insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01680341
liraglutide Other Preclinical Diabetes COMPLETED NCT02255266
placebo Other Phase PHASE1 Diabetes COMPLETED NCT02146079
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02146079
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02014259
Cardiac CT Other Approved Diabetes UNKNOWN NCT03022344
Cardiac CT Other Approved Diabetes UNKNOWN NCT03022344
Cardiac CT Other Approved Diabetes UNKNOWN NCT03022344
nonacog beta pegol Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT01395810
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02016911
moxifloxacin Other Phase PHASE1 Diabetes COMPLETED NCT02064348
placebo Other Phase PHASE1 Diabetes COMPLETED NCT02064348
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02064348
Indocyanine Green (ICG) Other Approved Secondary Lymphedema UNKNOWN NCT03572998
placebo Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02717858
liraglutide Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02717858
placebo Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02568306
NNC0165-1562 Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02568306
Omeprazole Other Phase PHASE1 Diabetes COMPLETED NCT02249871
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02249871
placebo Other Phase PHASE1 Diabetes COMPLETED NCT02147431
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02147431
BIAsp 30 Other Preclinical Diabetes COMPLETED NCT03374774
Placebo Other Phase PHASE1 Diabetes COMPLETED NCT03444467
Glucagon Other Phase PHASE1 Diabetes COMPLETED NCT03444467
NNC9204-1513 Other Phase PHASE1 Diabetes COMPLETED NCT03444467
No treatment given Drug Preclinical Haemophilia A, Haemophilia B, Obesity COMPLETED NCT03430154
Placebo Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT03015207
NNC0194-0499 Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT03015207
Placebo Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02941042
NNC9204-1177 Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02941042
placebo Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02870231
liraglutide Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02870231
NNC9204-0530 Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02870231
liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT02505334
placebo Other Phase PHASE2 Inflammation TERMINATED NCT01636843
NNC0109-0012 Other Phase PHASE2 Inflammation TERMINATED NCT01636843
placebo Other Phase PHASE2 Inflammation TERMINATED NCT01636817
NNC0109-0012 Other Phase PHASE2 Inflammation TERMINATED NCT01636817
Diet/exercise Other Phase PHASE3 Diabetes TERMINATED NCT02131272
Insulin NPH Other Phase PHASE3 Diabetes TERMINATED NCT02131272
Insulin detemir Other Phase PHASE3 Diabetes TERMINATED NCT02131272
biphasic insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT02648217
insulin degludec/insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT02648217
sitagliptin Other Phase PHASE3 Diabetes COMPLETED NCT02254291
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT02254291
N-acetylcysteine Other Phase PHASE1 Drug-Induced Acute Liver Injury COMPLETED NCT03679442
Placebo Other Phase PHASE4 Diabetes Complications COMPLETED NCT02473809
Liraglutide Other Phase PHASE4 Diabetes Complications COMPLETED NCT02473809
placebo Other Phase PHASE4 Diabetes COMPLETED NCT01907854
sitagliptin Other Phase PHASE4 Diabetes COMPLETED NCT01907854
liraglutide Other Phase PHASE4 Diabetes COMPLETED NCT01907854
Placebo Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT03095807
NNC9204-1706 A Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT03095807
insulin Other Preclinical Diabetes COMPLETED NCT01484262
liraglutide Other Preclinical Diabetes COMPLETED NCT01484262
Pancreatic clamp Other Approved Non-alcoholic Fatty Liver Disease COMPLETED NCT02337660
Liver biopsy Other Approved Non-alcoholic Fatty Liver Disease COMPLETED NCT02337660
Pancreatic clamp Other Approved Non-alcoholic Fatty Liver Disease COMPLETED NCT02337660
Liver biopsy Other Approved Non-alcoholic Fatty Liver Disease COMPLETED NCT02337660
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT02568280
Faster-acting insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT02568280
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT02003677
Faster-acting insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT02003677
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01934712
Faster-acting insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01934712
No treatment given Drug Preclinical Diabetes COMPLETED NCT01696266
insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01618188
Faster-acting insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT01618188
liraglutide Other Preclinical Diabetes COMPLETED NCT01345734
biphasic insulin aspart 30 Other Phase PHASE3 Diabetes COMPLETED NCT01009580
insulin degludec/insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01009580
biphasic insulin aspart 30 Other Phase PHASE3 Diabetes COMPLETED NCT01059812
insulin degludec/insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01059812
Control Group Other Approved Type 1 Diabetes TERMINATED NCT02617160
MD-Logic Pump Advisor Other Approved Type 1 Diabetes TERMINATED NCT02617160
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT02034513
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT02034513
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT02034513
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT01952145
insulin degludec/liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT01952145
exenatide Other Phase PHASE3 Diabetes COMPLETED NCT01676116
liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT01676116
insulin degludec/liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT01676116
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01392573
insulin degludec/liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT01392573
NN9924 (i.v.) Other Phase PHASE1 Diabetes COMPLETED NCT01037582
NN9924 (s.c.) Other Phase PHASE1 Diabetes COMPLETED NCT01037582
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01037582
NN9924 (oral) Other Phase PHASE1 Diabetes COMPLETED NCT01037582
No treatment given Drug Phase PHASE2 Congenital Bleeding Disorder COMPLETED NCT02541942
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01686945
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT01686945
DPP-4 inhibitor Other Phase PHASE3 Diabetes COMPLETED NCT02207374
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT02207374
somatropin Other Preclinical Foetal Growth Problem COMPLETED NCT01110928
turoctocog alfa Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT02941354
Insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT01819129
Insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01819129
Faster-acting insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01819129
insulin aspart Other Phase PHASE4 Diabetes COMPLETED NCT02453685
insulin glargine Other Phase PHASE4 Diabetes COMPLETED NCT02453685
biphasic insulin aspart 30 Other Phase PHASE4 Diabetes COMPLETED NCT02453685
standard antenatal care Other Phase PHASE4 Diabetes COMPLETED NCT02617693
lifestyle intervention Other Phase PHASE4 Diabetes COMPLETED NCT02617693
No treatment given Drug Preclinical Diabetes COMPLETED NCT02306681
placebo Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02696148
liraglutide Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02696148
placebo Other Phase PHASE2 Diabetes COMPLETED NCT02470039
insulin glargine Other Phase PHASE2 Diabetes COMPLETED NCT02470039
insulin 338 (GIPET I) Other Phase PHASE2 Diabetes COMPLETED NCT02470039
placebo Other Phase PHASE3 Diabetes COMPLETED NCT01620489
liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT01620489
Liraglutide 3 mg placebo Other Phase PHASE4 Osteoarthritis COMPLETED NCT02905864
Liraglutide 3 mg (Saxenda) Other Phase PHASE4 Osteoarthritis COMPLETED NCT02905864
insulin degludec/insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01513590
Insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT03215498
Faster-acting insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT03215498
biphasic insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT02762578
insulin degludec/insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT02762578
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02877355
insulin glargine Other Phase PHASE1 Diabetes COMPLETED NCT02536859
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT02536859
No treatment given Drug Preclinical Diabetes COMPLETED NCT02662114
Extension Study CMS-recommended lifestyle counseling Other Phase PHASE4 Obesity COMPLETED NCT02911818
Phentermine 15 MG Other Phase PHASE4 Obesity COMPLETED NCT02911818
Placebo Oral Tablet Other Phase PHASE4 Obesity COMPLETED NCT02911818
Portion-Controlled Diet Other Phase PHASE4 Obesity COMPLETED NCT02911818
Liraglutide 3.0mg Other Phase PHASE4 Obesity COMPLETED NCT02911818
CMS-recommended lifestyle counseling Other Phase PHASE4 Obesity COMPLETED NCT02911818
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT02030600
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT02030600
NNC172-2021 Other Phase PHASE1 Congenital Bleeding Disorder TERMINATED NCT01631942
placebo Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01228669
NNC 0172-0000-2021 Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01228669
No treatment given Drug Preclinical Obesity COMPLETED NCT03584191
Somapacitan Other Phase PHASE1 Growth Hormone Disorder COMPLETED NCT03212131
Insulin Aspart Other Phase PHASE1 Diabetes COMPLETED NCT02933853
Faster-acting insulin aspart Other Phase PHASE1 Diabetes COMPLETED NCT02933853
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT01437592
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT02670915
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT02670915
Faster-acting insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT02670915
biphasic insulin aspart 30 Other Phase PHASE4 Diabetes COMPLETED NCT02582242
placebo Other Phase PHASE3 Diabetes COMPLETED NCT02305381
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT02305381
insulin detemir Other Phase PHASE3 Diabetes COMPLETED NCT01835431
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01835431
insulin degludec/insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01835431
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT02500706
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT02500706
Faster-acting insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT02500706
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01831765
insulin detemir Other Phase PHASE3 Diabetes COMPLETED NCT01831765
Faster-acting insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01831765
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT02128932
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT02128932
placebo Other Phase PHASE3 Diabetes COMPLETED NCT01930188
sitagliptin Other Phase PHASE3 Diabetes COMPLETED NCT01930188
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT01930188
exenatide Other Phase PHASE3 Diabetes COMPLETED NCT01885208
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT01885208
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT01513473
insulin detemir Other Phase PHASE3 Diabetes COMPLETED NCT01513473
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01513473
Ciclosporin Other Phase PHASE1 Diabetes COMPLETED NCT03466567
Probenecid Other Phase PHASE1 Diabetes COMPLETED NCT03466567
Semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT03466567
Insulin aspart (NovoRapid®) Other Phase PHASE1 Diabetes COMPLETED NCT03407599
Faster aspart Other Phase PHASE1 Diabetes COMPLETED NCT03407599
Placebo (NNC0174-0833) Other Phase PHASE1 Obesity COMPLETED NCT03787225
NNC0174-0833 Other Phase PHASE1 Obesity COMPLETED NCT03787225
Placebo Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT03479892
NNC0194-0499 Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT03479892
placebo Other Phase PHASE3 Diabetes COMPLETED NCT01720446
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT01720446
insulin 338 (GIPET I) Other Phase PHASE1 Diabetes COMPLETED NCT02304627
catridecacog Other Preclinical Congenital Bleeding Disorder COMPLETED NCT01862367
placebo Other Phase PHASE3 Diabetes COMPLETED NCT01179048
liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT01179048
Insulin detemir Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT03960814
No treatment given Drug Preclinical Metabolism and Nutrition Disorder COMPLETED NCT03235102
No treatment given Drug Preclinical Metabolism and Nutrition Disorder COMPLETED NCT03223493
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT01959529
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT01959529
Metformin XR plus liraglutide Other Phase PHASE3 Gestational Diabetes Mellitus COMPLETED NCT01234649
Metformin XR plus placebo Other Phase PHASE3 Gestational Diabetes Mellitus COMPLETED NCT01234649
placebo Other Phase PHASE2 Diabetes COMPLETED NCT02461589
liraglutide Other Phase PHASE2 Diabetes COMPLETED NCT02461589
semaglutide Other Phase PHASE2 Diabetes COMPLETED NCT02461589
somapacitan Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03905850
liraglutide plus insulin detemir Other Approved Type 2 Diabetes COMPLETED NCT01232946
insulin detemir Other Approved Type 2 Diabetes COMPLETED NCT01232946
liraglutide Other Approved Type 2 Diabetes COMPLETED NCT01232946
placebo Other Phase PHASE4 Gestational Diabetes Mellitus UNKNOWN NCT02394158
Metformin Other Phase PHASE4 Gestational Diabetes Mellitus UNKNOWN NCT02394158
placebo Other Phase PHASE4 Gestational Diabetes Mellitus UNKNOWN NCT02394158
Metformin Other Phase PHASE4 Gestational Diabetes Mellitus UNKNOWN NCT02394158
Empagliflozin 25 MG Other Phase PHASE4 Type 2 Diabetes With Renal Manifestations UNKNOWN NCT04061200
Placebo, 1,34 mg/mL Other Phase PHASE4 Type 2 Diabetes With Renal Manifestations UNKNOWN NCT04061200
Semaglutide, 1.34 mg/mL Other Phase PHASE4 Type 2 Diabetes With Renal Manifestations UNKNOWN NCT04061200
Semaglutide Other Phase PHASE1 Obesity and Overweight COMPLETED NCT03707990
Placebo (NNC0165-1875) Other Phase PHASE1 Obesity and Overweight COMPLETED NCT03707990
NNC0165-1875 Other Phase PHASE1 Obesity and Overweight COMPLETED NCT03707990
Normal physical activity Other Approved Type 2 Diabetes Mellitus COMPLETED NCT02982408
Exercise Other Approved Type 2 Diabetes Mellitus COMPLETED NCT02982408
High carbohydrate overfeeding Other Approved Type 2 Diabetes Mellitus COMPLETED NCT02982408
No treatment given Drug Preclinical Growth Hormone Deficiency in Children COMPLETED NCT03672617
insulin degludec Other Preclinical Diabetes COMPLETED NCT02392117
insulin degludec/insulin aspart Other Preclinical Diabetes COMPLETED NCT02821052
Dulaglutide Other Phase PHASE3 Diabetes COMPLETED NCT02648204
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT02648204
Placebo (NNC9204-1706) Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT03661879
NNC9204-1706 Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT03661879
Semaglutide (administered by PDS290 pen) Other Phase PHASE1 Overweight TERMINATED NCT04012255
Semaglutide (administered by DV3396 pen) Other Phase PHASE1 Overweight TERMINATED NCT04012255
No treatment given Drug Preclinical Diabetes COMPLETED NCT02066766
somatropin Other Preclinical Growth Hormone Disorder COMPLETED NCT01580605
Semaglutide D 7 mg Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03638778
Semaglutide D 3 mg Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03638778
Semaglutide C 7 mg Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03638778
Semaglutide C 3 mg Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03638778
Semaglutide B 7 mg Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03638778
Semaglutide B 3 mg Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03638778
Semaglutide 7 mg Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03638778
Semaglutide 3 mg Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03638778
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT03292185
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT03292185
insulin degludec/liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT03292185
other injectable antidiabetic treatment regimens Drug Preclinical Diabetes Mellitus COMPLETED NCT01892319
insulin detemir Other Preclinical Diabetes Mellitus COMPLETED NCT01892319
insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT02825251
Faster-acting insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT02825251
No treatment given Drug Preclinical Haemophilia A COMPLETED NCT03660774
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT02501161
insulin degludec/liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT02501161
Insulin degludec Other Preclinical Diabetes Mellitus, Type 1 COMPLETED NCT03674866
Insulin Degludec/Insulin Aspart Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT03745157
PDS290 pen-injector Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03611322
DV3372 Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03611322
Semaglutide, 1.0 mg Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03611322
Semaglutide, 0.5 mg Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03611322
Semaglutide, 0.25 mg Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03611322
NovoPen®4 Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03598621
PDS290 Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03598621
DV3372, 1.0 mg/mL Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03598621
DV3372, 0.5 mg/mL Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03598621
Semaglutide, 2.0 mg/mL Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03598621
Semaglutide, 1.34 mg/mL Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03598621
Semaglutide, 1.0 mg/mL Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03598621
Semaglutide, 0.5 mg/mL Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03598621
Synthetic mesh Other Approved Abdominal Donor-site COMPLETED NCT02076724
Biological mesh Other Approved Abdominal Donor-site COMPLETED NCT02076724
Placebo (semaglutide) Other Phase PHASE3 Diabetes COMPLETED NCT03136484
Placebo (canagliflozin) Other Phase PHASE3 Diabetes COMPLETED NCT03136484
Canagliflozin Other Phase PHASE3 Diabetes COMPLETED NCT03136484
Semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT03136484
Cocktail of 5 already approved drugs Drug Phase PHASE1 Healthy Volunteers COMPLETED NCT04059367
NNC9204-1177 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04059367
Sitagliptin Other Phase PHASE3 Type 2 Diabetes Mellitus COMPLETED NCT02043054
Liraglutide Other Phase PHASE3 Type 2 Diabetes Mellitus COMPLETED NCT02043054
turoctocog alfa pegol Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT02994407
Starter Kit Algorithm Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT03365180
insulin degludec/insulin aspart Other Phase PHASE1 Healthy COMPLETED NCT02844790
placebo Other Phase PHASE3 Diabetes COMPLETED NCT02827708
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT02827708
placebo Other Phase PHASE1 Diabetes COMPLETED NCT02249910
digoxin Other Phase PHASE1 Diabetes COMPLETED NCT02249910
metformin Other Phase PHASE1 Diabetes COMPLETED NCT02249910
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02249910
placebo Other Phase PHASE1 Diabetes COMPLETED NCT02070510
warfarin Other Phase PHASE1 Diabetes COMPLETED NCT02070510
lisinopril Other Phase PHASE1 Diabetes COMPLETED NCT02070510
semaglutide Other Phase PHASE1 Diabetes COMPLETED NCT02070510
placebo Other Phase PHASE3 Diabetes COMPLETED NCT03021187
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT03021187
CMS Intensive Behavior Therapy Drug Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT02963935
placebo Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT02963935
liraglutide Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT02963935
Faster aspart 100 U/mL Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT03723759
Faster Aspart 200 U/mL Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT03723759
Fast-acting insulin aspart Other Preclinical Diabetes COMPLETED NCT03450863
Insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT03175120
Insulin degludec/liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT03175120
Placebo Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT02963922
Liraglutide 3.0 mg Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT02963922
turoctocog alfa Other Phase PHASE4 Congenital Bleeding Disorder COMPLETED NCT03449342
Somapacitan Other Phase PHASE1 Growth Hormone Disorder COMPLETED NCT03186495
placebo Other Phase PHASE2 Metabolism and Nutrition Disorder COMPLETED NCT02453711
liraglutide Other Phase PHASE2 Metabolism and Nutrition Disorder COMPLETED NCT02453711
semaglutide Other Phase PHASE2 Metabolism and Nutrition Disorder COMPLETED NCT02453711
insulin degludec Other Preclinical Diabetes COMPLETED NCT02779413
Placebo Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT02918279
Liraglutide Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT02918279
turoctocog alfa Other Preclinical Congenital Bleeding Disorder COMPLETED NCT02035384
no treatment Drug Preclinical Quality of Life COMPLETED NCT02965144
No treatment given Drug Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT03811288
Insulin Glargine Other Phase PHASE4 Type2 Diabetes TERMINATED NCT03349840
Insulin Degludec U100 Other Phase PHASE4 Type2 Diabetes TERMINATED NCT03349840
iLet™ Other Phase PHASE2 Diabetes Mellitus, Type 1 COMPLETED NCT03816761
Fast-acting insulin aspart Other Phase PHASE2 Diabetes Mellitus, Type 1 COMPLETED NCT03816761
Turoctocog alfa Other Phase PHASE3 Haemophilia A TERMINATED NCT03588741
thiazolidinediones Other Phase PHASE4 Diabetes COMPLETED NCT02730377
sulphonylurea Other Phase PHASE4 Diabetes COMPLETED NCT02730377
SGLT-2 inhibitors Other Phase PHASE4 Diabetes COMPLETED NCT02730377
meglitinides Other Phase PHASE4 Diabetes COMPLETED NCT02730377
DPP-4 inhibitors Other Phase PHASE4 Diabetes COMPLETED NCT02730377
alpha-glucosidase inhibitors Other Phase PHASE4 Diabetes COMPLETED NCT02730377
liraglutide Other Phase PHASE4 Diabetes COMPLETED NCT02730377
somatropin Other Phase PHASE3 Adult Growth Hormone Deficiency COMPLETED NCT02382939
somapacitan Other Phase PHASE3 Adult Growth Hormone Deficiency COMPLETED NCT02382939
BIAsp 30 Other Preclinical Diabetes Mellitus, Type 2 WITHDRAWN NCT03862690
NNC0090-2746 Other Phase PHASE2 Diabetes COMPLETED NCT02205528
Placebo Other Phase PHASE2 Diabetes COMPLETED NCT02205528
Metformin Other Phase PHASE2 Diabetes COMPLETED NCT02205528
Liraglutide Other Phase PHASE2 Diabetes COMPLETED NCT02205528
turoctocog alfa Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT02938585
Semaglutide (administered by PDS290 pen) Other Phase PHASE2 Healthy Volunteers Diabetes Mellitus, Type 2 COMPLETED NCT04007107
Semaglutide (administered by DV3396 pen) Other Phase PHASE2 Healthy Volunteers Diabetes Mellitus, Type 2 COMPLETED NCT04007107
insulin degludec Other Preclinical Diabetes Mellitus, Type 1 COMPLETED NCT01984372
turoctocog alfa pegol Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT01489111
insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT02773368
insulin degludec/liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT02773368
No treatment given Drug Preclinical Growth Disorder COMPLETED NCT02580032
Needs assesment tool integrated in nursing consultation. Other Approved Head and Neck Neoplasms COMPLETED NCT03443258
Placebo Other Phase PHASE4 Gestational Diabetes Mellitus COMPLETED NCT01795248
Liraglutide Other Phase PHASE4 Gestational Diabetes Mellitus COMPLETED NCT01795248
placebo Other Phase PHASE3 Diabetes COMPLETED NCT02964247
liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT02964247
Semaglutide (administered by PDS290 pen-injector) Other Phase PHASE1 Overweight COMPLETED NCT04238962
Semaglutide (administered by DV3396 pen-injector) Other Phase PHASE1 Overweight COMPLETED NCT04238962
No treatment given Drug Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT03797885
Norditropin Other Phase PHASE3 Growth Hormone Disorder COMPLETED NCT03075644
somapacitan Other Phase PHASE3 Growth Hormone Disorder COMPLETED NCT03075644
placebo Other Phase PHASE3 Growth Hormone Disorder COMPLETED NCT02229851
somatropin Other Phase PHASE3 Growth Hormone Disorder COMPLETED NCT02229851
somapacitan Other Phase PHASE3 Growth Hormone Disorder COMPLETED NCT02229851
turoctocog alfa pegol Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT01731600
turoctocog alfa pegol Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT01480180
Placebo Other Phase PHASE3 Binge-Eating Disorder TERMINATED NCT03279731
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml Other Phase PHASE3 Binge-Eating Disorder TERMINATED NCT03279731
Cross-over study Other Approved T2D COMPLETED NCT04011904
turoctocog alfa Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT01493778
Placebo Other Phase PHASE1 Overweight COMPLETED NCT03842202
Semaglutide Other Phase PHASE1 Overweight COMPLETED NCT03842202
Norditropin NordiFlex® Other Phase PHASE1 Growth Hormone Disorder COMPLETED NCT01706783
somapacitan Other Phase PHASE1 Growth Hormone Disorder COMPLETED NCT01706783
placebo (somapacitan) Other Phase PHASE1 Growth Hormone Disorder COMPLETED NCT01514500
somapacitan Other Phase PHASE1 Growth Hormone Disorder COMPLETED NCT01514500
3D-Transit after Malone appendicostomy Other Approved Diabetic Autonomic Neuropathy TERMINATED NCT02573519
3D-Transit during treatment with Pyridostigmine Drug Approved Diabetic Autonomic Neuropathy TERMINATED NCT02573519
3D-Transit Other Approved Diabetic Autonomic Neuropathy TERMINATED NCT02573519
11C Donepezil PET/CT scan Other Approved Diabetic Autonomic Neuropathy TERMINATED NCT02573519
insulin glargine Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT03965013
Placebo Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT03965013
NNC0268-0965 Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT03965013
Placebo Other Phase PHASE4 Diabetes Mellitus Type 2 COMPLETED NCT02655770
Liraglutide Other Phase PHASE4 Diabetes Mellitus Type 2 COMPLETED NCT02655770
Liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT03018028
Placebo Other Phase PHASE3 Diabetes COMPLETED NCT03018028
Semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT03018028
oral placebo Other Phase PHASE2 Diabetes COMPLETED NCT01923181
semaglutide Other Phase PHASE2 Diabetes COMPLETED NCT01923181
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT03876015
Semaglutide (administered by PDS290 pen) Other Phase PHASE2 Healthy Volunteers Diabetes Mellitus, Type 2 COMPLETED NCT04143945
Semaglutide (administered by DV3396 pen) Other Phase PHASE2 Healthy Volunteers Diabetes Mellitus, Type 2 COMPLETED NCT04143945
Together on Diabetes Other Approved Type 2 Diabetes Mellitus COMPLETED NCT04722289
NNC0174-0833 Other Phase PHASE1 Overweight COMPLETED NCT04209049
Standard of care Other Preclinical Severe Postpartum Haemorrhage COMPLETED NCT04444856
Eptacog alfa (activated) Other Preclinical Severe Postpartum Haemorrhage COMPLETED NCT04444856
Forxiga Other Phase PHASE4 Nephropathy COMPLETED NCT04193566
Oral semaglutide Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04109508
Promestriene Vaginal Other Phase PHASE3 Vulvovaginal Atrophy COMPLETED NCT04232813
Estradiol 10 MCG Vaginal Tablet [VAGIFEM] Other Phase PHASE3 Vulvovaginal Atrophy COMPLETED NCT04232813
Placebo (semaglutide 1.0 mg) Other Phase PHASE1 Diabetes COMPLETED NCT03288740
Semaglutide 1.0 mg Other Phase PHASE1 Diabetes COMPLETED NCT03288740
Placebo (semaglutide 0.5 mg) Other Phase PHASE1 Diabetes COMPLETED NCT03288740
Semaglutide 0.5 mg Other Phase PHASE1 Diabetes COMPLETED NCT03288740
Aspart Other Phase PHASE4 Type1 Diabetes Mellitus COMPLETED NCT04409587
placebo Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT02889510
liraglutide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT02889510
Semaglutide placebo 1.0 mg Other Phase PHASE3 Diabetes COMPLETED NCT03061214
Semaglutide placebo 0.5 mg Other Phase PHASE3 Diabetes COMPLETED NCT03061214
Sitagliptin Other Phase PHASE3 Diabetes COMPLETED NCT03061214
Sitagliptin placebo Other Phase PHASE3 Diabetes COMPLETED NCT03061214
Semaglutide 1.0 mg Other Phase PHASE3 Diabetes COMPLETED NCT03061214
Semaglutide 0.5 mg Other Phase PHASE3 Diabetes COMPLETED NCT03061214
Dulaglutide Other Phase PHASE3 Diabetes COMPLETED NCT03015220
Semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT03015220
Insulin glargine U100 Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT03766854
insulin icodec Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT03766854
placebo Other Phase PHASE1 Diabetes COMPLETED NCT02148861
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT02148861
Insulin icodec Other Phase PHASE1 Diabetes COMPLETED NCT02148861
Exercise Other Approved Physical Exercise Behavior (Liking/Aversion) COMPLETED NCT02615756
Placebo Other Phase PHASE3 Type 2 Diabetes WITHDRAWN NCT04057261
Liraglutide Pen Injector [Victoza] Other Phase PHASE3 Type 2 Diabetes WITHDRAWN NCT04057261
Placebo (insulin glargine) Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT03751657
Insulin glargine Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT03751657
Dipeptidyl peptidase-4 inhibitors Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT03751657
Metformin Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT03751657
Placebo (insulin 287) Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT03751657
Insulin icodec Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT03751657
Insulin Glargine Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT03951805
Insulin icodec Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT03951805
Insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT02911948
Insulin degludec/liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT02911948
liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT02607306
insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT02607306
insulin degludec/liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT02607306
placebo Other Phase PHASE2 Diabetes COMPLETED NCT02443155
liraglutide Other Phase PHASE2 Diabetes COMPLETED NCT02443155
NNC0114-0006 Other Phase PHASE2 Diabetes COMPLETED NCT02443155
Insulin degludec Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT03785522
Placebo Liraglutide Pen Injector Other Phase PHASE3 Pre Diabetes COMPLETED NCT03480022
Liraglutide Pen Injector [Saxenda] Other Phase PHASE3 Pre Diabetes COMPLETED NCT03480022
Placebo Other Phase PHASE2 Anorexia Nervosa COMPLETED NCT01626833
SOMATROPINE* : Norditropine® simplexx® Other Phase PHASE2 Anorexia Nervosa COMPLETED NCT01626833
Aerobic exercise training Other Approved Diabetes Mellitus, Type 2 UNKNOWN NCT04945551
Placebo Other Phase PHASE3 Diabetes COMPLETED NCT03086330
Semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT03086330
Low carbohydrate diet high in monounsaturated fats Other Approved Type2 Diabetes COMPLETED NCT03068078
metformin Other Phase PHASE3 Diabetes COMPLETED NCT01541215
placebo Other Phase PHASE3 Diabetes COMPLETED NCT01541215
liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT01541215
Liraglutide Other Preclinical Obesity COMPLETED NCT03560336
Liraglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT03888157
Cilofexor Other Phase PHASE2 Nonalcoholic Steatohepatitis COMPLETED NCT03987074
Firsocostat Other Phase PHASE2 Nonalcoholic Steatohepatitis COMPLETED NCT03987074
Semaglutide Other Phase PHASE2 Nonalcoholic Steatohepatitis COMPLETED NCT03987074
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT03631186
Placebo Other Phase PHASE1 Anemia COMPLETED NCT02868229
COR-001 Other Phase PHASE1 Anemia COMPLETED NCT02868229
Liraglutide treatment Drug Approved Diabetes Mellitus, Type 1 COMPLETED NCT02138045
Placebo treatment Drug Approved Diabetes Mellitus, Type 1 COMPLETED NCT02138045
insulin degludec Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04315688
insulin degludec Other Phase PHASE1 Diabetes COMPLETED NCT02964104
placebo Other Phase PHASE1 Diabetes COMPLETED NCT02964104
Insulin icodec Other Phase PHASE1 Diabetes COMPLETED NCT02964104
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT03457012
Insulin degludec/liraglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT03823339
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04067999
Ryzodeg® Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04656106
Trial product 12 Other Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 10 Other Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 9 Other Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 8 Other Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 7 Other Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 6 Other Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 5 Other Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 4 Other Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 3 Other Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 2 Other Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 1 Other Phase PHASE1 Obesity COMPLETED NCT04482725
Eptacog alfa Other Phase PHASE2 Congenital Bleeding Disorder COMPLETED NCT03196284
Concizumab Other Phase PHASE2 Congenital Bleeding Disorder COMPLETED NCT03196284
Placebo (ziltivekimab) Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Ziltivekimab Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Glargine + OADs Other Phase PHASE4 Type 2 Diabetes COMPLETED NCT01919489
Liraglutide + OADs Other Phase PHASE4 Type 2 Diabetes COMPLETED NCT01919489
Placebo II (Semaglutide) Other Phase PHASE3 Obesity COMPLETED NCT03552757
Placebo I (Semaglutide) Other Phase PHASE3 Obesity COMPLETED NCT03552757
Semaglutide 2.4 mg Other Phase PHASE3 Obesity COMPLETED NCT03552757
Semaglutide 1.0 mg Other Phase PHASE3 Obesity COMPLETED NCT03552757
Semaglutide Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04152915
Insulin degludec /insulin aspart Other Preclinical Diabetes COMPLETED NCT03416855
Semaglutide Other Phase PHASE1 Overweight COMPLETED NCT04187300
Placebo (semaglutide) Other Phase PHASE3 Overweight COMPLETED NCT03611582
Semaglutide Other Phase PHASE3 Overweight COMPLETED NCT03611582
turoctocog alfa Other Preclinical Congenital Bleeding Disorder COMPLETED NCT03179748
turoctocog alfa Other Preclinical Congenital Bleeding Disorder COMPLETED NCT02207218
Turoctocog alfa Other Phase PHASE2 Haemostasis COMPLETED NCT03196297
Concizumab Other Phase PHASE2 Haemostasis COMPLETED NCT03196297
Placebo Other Phase PHASE2 Hepatobiliary Disorders COMPLETED NCT02970942
Semaglutide Other Phase PHASE2 Hepatobiliary Disorders COMPLETED NCT02970942
Placebo (NNC0174-0833) Other Phase PHASE1 Obesity COMPLETED NCT03600480
Semaglutide Other Phase PHASE1 Obesity COMPLETED NCT03600480
NNC0174-0833 Other Phase PHASE1 Obesity COMPLETED NCT03600480
Placebo (semaglutide) Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT03548935
Semaglutide Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT03548935
Placebo Other Phase PHASE1 Hepatobiliary Disorders COMPLETED NCT03357380
Semaglutide Other Phase PHASE1 Hepatobiliary Disorders COMPLETED NCT03357380
No treatment given Drug Preclinical Haemophilia A COMPLETED NCT03741881
Detemir Other Approved Diabetes COMPLETED NCT01186003
PLACEBO Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT03308721
NNC9204-1177 A 1.0 mg/mL Other Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT03308721
Placebo (NNC0385-0434) Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04058834
NNC0385-0434 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04058834
Semaglutide Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04228354
Acetaminophen Other Phase PHASE1 Overweight COMPLETED NCT04074174
Oral contraceptive (OC) tablets Other Phase PHASE1 Overweight COMPLETED NCT04074174
NNC0174-0833 Other Phase PHASE1 Overweight COMPLETED NCT04074174
Metformin Other Phase PHASE3 Diabetes COMPLETED NCT03268005
Insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT03268005
Insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT03268005
Faster-acting insulin aspart Other Phase PHASE3 Diabetes COMPLETED NCT03268005
Insulin glargine Other Phase PHASE3 Diabetes COMPLETED NCT03078478
Insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT03078478
Insulin glargine U100 Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT03922750
Insulin icodec Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT03922750
Placebo Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT03548987
Semaglutide Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT03548987
No treatment given Drug Preclinical Obesity COMPLETED NCT05013359
Beetroot Juice Other Approved Preeclampsia UNKNOWN NCT05241327
Placebo (semaglutide) Other Phase PHASE3 Overweight COMPLETED NCT03811574
Semaglutide Other Phase PHASE3 Overweight COMPLETED NCT03811574
Aspart Other Phase PHASE4 Type 2 Diabetes COMPLETED NCT03336528
Glargine Other Phase PHASE4 Type 2 Diabetes COMPLETED NCT03336528
Degludec Other Phase PHASE4 Type 2 Diabetes COMPLETED NCT03336528
Placebo (NNC0194-0499 ) Other Phase PHASE1 Non-alcoholic Steatohepatitis COMPLETED NCT04722653
NNC0194-0499 Other Phase PHASE1 Non-alcoholic Steatohepatitis COMPLETED NCT04722653
Clinical and demographic data Other Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Blood samples Other Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Dual Energy X-ray Absorptiometry (DEXA) scan Other Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Intra venous glucose infusion (IIGI) Other Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Oral glucose tolerance test (OGTT) Other Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Continuous glucose monitoring (CGM) for four days. Other Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Fibroscan of the liver Other Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
MR spectroscopy of the liver Other Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Clinical and demographic data Other Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Blood samples Other Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Dual Energy X-ray Absorptiometry (DEXA) scan Other Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Intra venous glucose infusion (IIGI) Other Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Oral glucose tolerance test (OGTT) Other Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Continuous glucose monitoring (CGM) for four days. Other Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Fibroscan of the liver Other Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
MR spectroscopy of the liver Other Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Standard of care Other Preclinical Post Partum Hemorrhage COMPLETED NCT04723979
Eptacog alfa Other Preclinical Post Partum Hemorrhage COMPLETED NCT04723979
Placebo Other Phase PHASE2 Type 2 Diabetes Mellitus COMPLETED NCT02415556
Regular Human Insulin Other Phase PHASE2 Type 2 Diabetes Mellitus COMPLETED NCT02415556
No treatment given Drug Preclinical Obesity COMPLETED NCT05250427
Placebo Other Phase PHASE2 Obesity COMPLETED NCT03523273
Liraglutide Other Phase PHASE2 Obesity COMPLETED NCT03523273
placebo Other Phase PHASE3 Diabetes COMPLETED NCT02906930
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT02906930
placebo Other Phase PHASE3 Diabetes COMPLETED NCT02863419
liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT02863419
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT02863419
empagliflozin Other Phase PHASE3 Diabetes COMPLETED NCT02863328
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT02863328
sitagliptin Other Phase PHASE3 Diabetes COMPLETED NCT02849080
semaglutide Other Phase PHASE3 Diabetes COMPLETED NCT02849080
BPD-DS as a revisional procedure Procedure Approved Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures UNKNOWN NCT04712409
SADI-S as a revisional procedure Procedure Approved Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures UNKNOWN NCT04712409
Biliopancreatic diversion with duodenal switch Other Approved Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures UNKNOWN NCT04712409
Single anastomosis duodeno-ileal bypass Other Approved Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures UNKNOWN NCT04712409
BPD-DS as a revisional procedure Procedure Approved Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures UNKNOWN NCT04712409
SADI-S as a revisional procedure Procedure Approved Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures UNKNOWN NCT04712409
Biliopancreatic diversion with duodenal switch Other Approved Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures UNKNOWN NCT04712409
Single anastomosis duodeno-ileal bypass Other Approved Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures UNKNOWN NCT04712409
Insulin aspart (standard of care insulin) + closed loop device Device Approved Diabetes Mellitus, Type 1 COMPLETED NCT03579615
FIASP + closed loop device Device Approved Diabetes Mellitus, Type 1 COMPLETED NCT03579615
SOS-PD Other Preclinical Pediatric Delirium COMPLETED NCT04774211
Omics markers Other Approved Liver Diseases, Alcoholic RECRUITING NCT03308916
Cytokeratin 18 Other Approved Liver Diseases, Alcoholic RECRUITING NCT03308916
LiverTRAIL Other Approved Liver Diseases, Alcoholic RECRUITING NCT03308916
Direct serum markers of liver fibrosis Other Approved Liver Diseases, Alcoholic RECRUITING NCT03308916
Indirect serum markers of liver fibrosis Other Approved Liver Diseases, Alcoholic RECRUITING NCT03308916
Enhanced liver fibrosis test Other Approved Liver Diseases, Alcoholic RECRUITING NCT03308916
transient elastography Other Approved Liver Diseases, Alcoholic RECRUITING NCT03308916
insulin glargine Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04136067
NNC0268-0965 Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04136067
Oral semaglutide Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04097600
Placebo (NNC0472-0147) Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04262661
insulin glargine Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04262661
NNC0472-0147 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04262661
Oral Semaglutide Other Preclinical Diabetes Mellitus, Type 2 WITHDRAWN NCT05473286
Standardised meals Other Approved Type 2 Diabetes COMPLETED NCT01053234
somatropin Other Preclinical Growth Disorder COMPLETED NCT01578135
No treatment given Drug Preclinical Obesity COMPLETED NCT05232786
IDegLira Other Preclinical Diabetes Mellitus, Type 2 WITHDRAWN NCT05479591
Cardiopulmonary exercise test, NT-proBNP, Echocardiography, 6 minute walk test, Right heart catheterization Other Preclinical Heart Failure With Reduced Ejection Fraction UNKNOWN NCT05299879
Insulin detemir Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT05134987
NNC0363-0845 Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT05134987
Dulaglutide Other Phase PHASE4 Healthy Volunteers COMPLETED NCT04189848
Semaglutide Other Phase PHASE4 Healthy Volunteers COMPLETED NCT04189848
Physical activity Other Approved Intellectual Disability UNKNOWN NCT05336487
IDegLira Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT05324462
Empagliflozin Other Phase PHASE3 Diabetes Mellitus, Type 2 WITHDRAWN NCT05444153
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 WITHDRAWN NCT05444153
Insulin Degludec/Insulin Aspart Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04892069
Medication for chronic weight management (Rx) Drug Phase PHASE4 Obesity COMPLETED NCT03799198
Weight Management Program (WMP) Other Phase PHASE4 Obesity COMPLETED NCT03799198
Insulin glargine U100 Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT03689374
Insulin aspart Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT03689374
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT03689374
Somatropin Other Preclinical Genetic Disorder COMPLETED NCT03435627
Saxenda® Other Preclinical Obesity or Overweight COMPLETED NCT05153590
Continuous Glucose Monitor (CGM) alone Other Approved Type1 Diabetes Mellitus COMPLETED NCT03093636
Continuous Glucose Monitor (CGM)+Decision Support System (DSS) Other Approved Type1 Diabetes Mellitus COMPLETED NCT03093636
Liraglutide Other Preclinical Obesity COMPLETED NCT03479762
Placebo Other Phase PHASE4 Obesity COMPLETED NCT03048578
Saxenda Other Phase PHASE4 Obesity COMPLETED NCT03048578
Liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT03172494
Insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT03172494
Insulin degludec/liraglutide Other Phase PHASE3 Diabetes COMPLETED NCT03172494
Turoctocog alfa pegol Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT03528551
Non-Vagifem® LDVE, Estradiol Other Preclinical Postmenopausal Vaginal Atrophy COMPLETED NCT05243823
Vagifem® Other Preclinical Postmenopausal Vaginal Atrophy COMPLETED NCT05243823
Fast-acting insulin aspart Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT04655690
NNC0471-0119 Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT04655690
Insulin icodec Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04582448
semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT03929679
Insulin detemir Other Phase PHASE3 Diabetes COMPLETED NCT03377699
Insulin Aspart Other Phase PHASE3 Diabetes COMPLETED NCT03377699
Insulin degludec Other Phase PHASE3 Diabetes COMPLETED NCT03377699
liraglutide Other Preclinical Metabolism and Nutrition Disorder COMPLETED NCT02967757
Liraglutide Other Preclinical Obesity WITHDRAWN NCT05438186
Biopsy Other Preclinical Diabetes UNKNOWN NCT05209061
Biopsy Other Preclinical Diabetes UNKNOWN NCT05209061
Biopsy Other Preclinical Diabetes UNKNOWN NCT05195502
Biopsy Other Preclinical Diabetes UNKNOWN NCT05195502
Placebo Other Phase PHASE2 TBI (Traumatic Brain Injury) RECRUITING NCT04121780
Growth Hormone Other Phase PHASE2 TBI (Traumatic Brain Injury) RECRUITING NCT04121780
Placebo (semaglutide) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT03989232
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT03989232
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT05468632
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04094415
Standard heart failure medical therapy Drug Phase PHASE4 Advanced Heart Failure UNKNOWN NCT05284955
CardioMEMS HF System Other Phase PHASE4 Advanced Heart Failure UNKNOWN NCT05284955
semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04261933
semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04083820
Omron Walking Style pro. 20 Other Approved Colorectal Cancer COMPLETED NCT02522520
Pedometer + hospital based intervention Other Approved Colorectal Cancer COMPLETED NCT02522520
Pedometer intervention Other Approved Colorectal Cancer COMPLETED NCT02522520
NNC0113-6891 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04676906
NNC0113-6860 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04676906
NNC0113-6861 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04676906
Nutritional Psycho-Behavioral Reeducation Program Other Preclinical Overweight and Obesity NOT_YET_RECRUITING NCT05857319
No treatment given Drug Preclinical Obesity COMPLETED NCT05736120
Primed tracer infusion Other Approved Chronic Kidney Diseases COMPLETED NCT05056584
Glucagon infusion Other Approved Chronic Kidney Diseases COMPLETED NCT05056584
Primed tracer infusion Other Approved Chronic Kidney Diseases COMPLETED NCT05056584
Glucagon infusion Other Approved Chronic Kidney Diseases COMPLETED NCT05056584
Oral Semaglutide Other Phase PHASE1 Healthy Volunteers Type 2 Diabetes COMPLETED NCT04513704
No treatment given Drug Preclinical Type 2 Diabetes COMPLETED NCT05737810
Placebo (Semaglutide) Other Phase PHASE1 Healthy Volunteers Type 2 Diabetes COMPLETED NCT04878406
Semaglutide Other Phase PHASE1 Healthy Volunteers Type 2 Diabetes COMPLETED NCT04878406
Placebo (NNC0480-0389) Other Phase PHASE1 Healthy Volunteers Type 2 Diabetes COMPLETED NCT04878406
NNC0480-0389 Other Phase PHASE1 Healthy Volunteers Type 2 Diabetes COMPLETED NCT04878406
insulin icodec Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04857398
Vira mobile app intervention + coaching Other Approved Mental Health Disorder COMPLETED NCT05638516
Vira mobile app intervention Other Approved Mental Health Disorder COMPLETED NCT05638516
Placebo (liraglutide) Other Phase PHASE3 Overweight COMPLETED NCT04074161
Liraglutide Other Phase PHASE3 Overweight COMPLETED NCT04074161
Placebo (semaglutide) Other Phase PHASE3 Overweight COMPLETED NCT04074161
Semaglutide Other Phase PHASE3 Overweight COMPLETED NCT04074161
Heparin Other Phase EARLY_PHASE1 Healthy Volunteers COMPLETED NCT05178550
Fresh organic vegetables Other Phase PHASE4 Diabetes Mellitus, Type 2 TERMINATED NCT04938388
Semaglutide Pill Other Phase PHASE4 Diabetes Mellitus, Type 2 TERMINATED NCT04938388
ALPROLIX® Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT03075670
N9-GP Other Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT03075670
No treatment given Drug Preclinical Atherosclerotic Cardiovascular Disease (ASCVD) COMPLETED NCT05755373
No treatment given Drug Preclinical Diabetes ENROLLING_BY_INVITATION NCT01511393
No treatment given Drug Preclinical Obesity COMPLETED NCT05690789
No treatment given Drug Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT03786406
Insulin degludec Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04569994
Placebo (NNC0363-0845) Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04569994
NNC0363-0845 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04569994
NNC0480-0389 A 10 mg/mL Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05046873
Semaglutide 1.34 mg/mL Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05046873
semaglutide 1.34 mg/mL (placebo) Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05046873
Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05046873
Placebo (Semaglutide) Other Phase PHASE3 Overweight COMPLETED NCT03693430
Semaglutide Other Phase PHASE3 Overweight COMPLETED NCT03693430
placebo Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT02527200
liraglutide Other Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT02527200
Chronic care multidisciplinary intervention of childhood obesity Other Preclinical Childhood Obesity COMPLETED NCT00823277
FT-7051 Other Phase PHASE1 Metastatic Castration-resistant Prostate Cancer TERMINATED NCT04575766
somatropin Other Phase PHASE3 Genetic Disorder COMPLETED NCT01529944
Insulin glargine Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03945656
insulin icodec Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03945656
Insulin Aspart Other Phase PHASE3 Diabetes Mellitus COMPLETED NCT03737240
Insulin Degludec (U-100) Other Phase PHASE3 Diabetes Mellitus COMPLETED NCT03737240
IDegLira Other Phase PHASE3 Diabetes Mellitus COMPLETED NCT03737240
Insulin Icodec Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04582435
Smoking Cessation Counseling Other Phase PHASE2 Smoking Cessation COMPLETED NCT03712098
Placebo Other Phase PHASE2 Smoking Cessation COMPLETED NCT03712098
Liraglutide Other Phase PHASE2 Smoking Cessation COMPLETED NCT03712098
Oral semaglutide Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04524832
No treatment given Drug Preclinical Non-alcoholic Steatohepatitis (MASH) COMPLETED NCT05765890
NO intervention - observational study Other Preclinical Diabetes Mellitus, Type 1 COMPLETED NCT04304963
Faster aspart Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT05262595
NNC0471-0119 D Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT05262595
NNC0471-0119 B Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT05262595
NNC0471-0119 A Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT05262595
Lifestyle Therapy Drug Phase PHASE3 Type 2 Diabetes Mellitus COMPLETED NCT03862716
Metformin Other Phase PHASE3 Type 2 Diabetes Mellitus COMPLETED NCT03862716
insulin degludec Other Phase PHASE3 Type 2 Diabetes Mellitus COMPLETED NCT03862716
IDegLira Other Phase PHASE3 Type 2 Diabetes Mellitus COMPLETED NCT03862716
Mim8 B, placebo Other Phase PHASE1 Healthy Volunteers - Haemophilia A COMPLETED NCT05127473
Mim8 B, 100 mg/mL Other Phase PHASE1 Healthy Volunteers - Haemophilia A COMPLETED NCT05127473
Mim8 B, 10 mg/mL Other Phase PHASE1 Healthy Volunteers - Haemophilia A COMPLETED NCT05127473
placebo Other Phase PHASE2 Diabetes COMPLETED NCT01508949
liraglutide Other Phase PHASE2 Diabetes COMPLETED NCT01508949
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01507285
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01507285
biphasic insulin aspart 30 Other Phase PHASE4 Diabetes COMPLETED NCT01486862
NNC0174 0833 Other Phase PHASE1 Overweight and Obesity COMPLETED NCT05254158
Microgynon® Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05153564
NNC0480-0389 30 mg/mL Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05153564
NNC0480-0389 10 mg/mL Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05153564
Semaglutide 3.0 mg/mL Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05153564
Semaglutide 1.34 mg/mL Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05153564
NNC0480-0389 Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05015894
Placebo (semaglutide) Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04259801
Placebo (NNC0480-0389) Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04259801
Semaglutide Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04259801
NNC0480-0389 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04259801
Placebo Other Phase PHASE4 Diabetes Mellitus, Type 2 TERMINATED NCT04624672
Semaglutide (1 Mg Dose) Other Phase PHASE4 Diabetes Mellitus, Type 2 TERMINATED NCT04624672
Lee Symptom Scala Other Approved GVHD, Chronic COMPLETED NCT04884204
Turoctocog alfa Other Preclinical Haemophilia A COMPLETED NCT04584892
Sooma Oy (Sham), Helsinki, Finland Other Approved Diabetic Neuropathy, Painful UNKNOWN NCT06152887
Sooma Oy (tDCS), Helsinki, Finland Other Approved Diabetic Neuropathy, Painful UNKNOWN NCT06152887
Placebo Other Approved Obesity COMPLETED NCT03795701
Saxenda® Other Approved Obesity COMPLETED NCT03795701
NNC0194-0499 Other Phase PHASE1 Non-alcoholic Steatohepatitis (NASH) COMPLETED NCT05727644
FIT FIRST Other Approved Primary Prevention UNKNOWN NCT06180772
Semaglutide Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05498610
NNC0480 0389 Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05498610
NNC0385-0434 A 100 mg Other Phase PHASE1 Chronic Kidney Disease TERMINATED NCT05094934
NNC0385-0434 Other Phase PHASE1 Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk COMPLETED NCT05091073
eptacog alfa (activated) Other Preclinical Congenital Bleeding Disorder COMPLETED NCT01830712
factor VIII Other Phase PHASE4 Congenital Bleeding Disorder COMPLETED NCT01561391
factor IX Other Phase PHASE4 Congenital Bleeding Disorder COMPLETED NCT01561391
activated recombinant human factor VII Other Phase PHASE4 Congenital Bleeding Disorder COMPLETED NCT01561391
Rybelsus® Other Preclinical Diabetes Mellitus, Type 2 UNKNOWN NCT04572165
Active Comparator Other Preclinical Diabetes Mellitus, Type 2 UNKNOWN NCT04572165
Ozempic® Other Preclinical Diabetes Mellitus, Type 2 UNKNOWN NCT04572165
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01508897
Placebo Other Phase PHASE3 Type 1 Diabetes COMPLETED NCT01722266
Liraglutide Other Phase PHASE3 Type 1 Diabetes COMPLETED NCT01722266
Placebo (insulin glargine) Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04575181
Placebo (NNC0268-0965) Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04575181
Insulin glargine Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04575181
NNC0268-0965 Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04575181
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT05716724
Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05003440
NNC0385-0434 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05003440
Placebo (NNC0247-0829) Other Phase PHASE1 Overweight COMPLETED NCT04010786
NNC0247-0829 Other Phase PHASE1 Overweight COMPLETED NCT04010786
Semaglutide D, 1.0 mg/mL Other Phase PHASE1 Healthy Volunteers (Diabetes Mellitus, Type 2) COMPLETED NCT05232708
Semaglutide B, 1.34 mg/mL Other Phase PHASE1 Healthy Volunteers (Diabetes Mellitus, Type 2) COMPLETED NCT05232708
Telemonitoring Other Approved Type 2 Diabetes Treated With Insulin COMPLETED NCT04981808
basal insulin Other Preclinical Type 2 Diabetes COMPLETED NCT06236672
GLP-1 receptor agonist Other Preclinical Type 2 Diabetes COMPLETED NCT06236672
basal insulin Other Preclinical Type 2 Diabetes COMPLETED NCT06236672
GLP-1 receptor agonist Other Preclinical Type 2 Diabetes COMPLETED NCT06236672
basal insulin Other Preclinical Type 2 Diabetes COMPLETED NCT06236672
GLP-1 receptor agonist Other Preclinical Type 2 Diabetes COMPLETED NCT06236672
Adhera® Caring digital intervention for Type 1 Diabetes Other Approved Diabetes Mellitus, Type 1 COMPLETED NCT05483803
School-based extracurricular intervention focusing on screen media use and time spent with friends Other Approved Screen Media Use COMPLETED NCT05480085
placebo Other Phase PHASE1 Diabetes COMPLETED NCT01509742
liraglutide Other Phase PHASE1 Diabetes COMPLETED NCT01509742
No treatment is given Drug Preclinical Overweight COMPLETED NCT06260696
Metformin Other Phase PHASE3 Diabetes Mellitus, Type 2 WITHDRAWN NCT06083675
Empagliflozin Other Phase PHASE3 Diabetes Mellitus, Type 2 WITHDRAWN NCT06083675
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 WITHDRAWN NCT06083675
placebo Other Phase PHASE4 Growth Hormone Disorder COMPLETED NCT01562834
somatropin Other Phase PHASE4 Growth Hormone Disorder COMPLETED NCT01562834
NNC0194-0499/Semaglutide A (40/0.33mg/mL) Other Phase PHASE1 Non-alcoholic Steatohepatitis COMPLETED NCT05766709
NNC0194-0499/Semaglutide A (40/3.20 mg/mL) Other Phase PHASE1 Non-alcoholic Steatohepatitis COMPLETED NCT05766709
Semaglutide Other Phase PHASE1 Non-alcoholic Steatohepatitis COMPLETED NCT05766709
NNC0194-0499 Other Phase PHASE1 Non-alcoholic Steatohepatitis COMPLETED NCT05766709
Placebo Other Phase PHASE2 Parkinson Disease COMPLETED NCT02953665
Liraglutide Other Phase PHASE2 Parkinson Disease COMPLETED NCT02953665
Insulin degludec Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04227431
Insulin degludec and liraglutide (IDegLira) Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04666987
Control group Other Approved Postoperative Pain, Acute RECRUITING NCT06222151
Intervention 2: Mobilization the first 4 postoperative weeks Other Approved Postoperative Pain, Acute RECRUITING NCT06222151
Intervention 1: Mobilization during hospitalization Other Approved Postoperative Pain, Acute RECRUITING NCT06222151
Placebo oral tablet Other Phase PHASE4 Diabetes Mellitus, Type 2 RECRUITING NCT05441267
Semaglutide Oral Tablet Other Phase PHASE4 Diabetes Mellitus, Type 2 RECRUITING NCT05441267
Amino acid bolus infusion Other Approved Healthy COMPLETED NCT05954923
Amino acid bolus infusion Other Approved Healthy COMPLETED NCT05954923
Sterile Normal Saline (0.9% NaCl) Other Phase PHASE2 Primary Hyperoxaluria Type 1 (PH1) COMPLETED NCT03847909
DCR-PHXC Other Phase PHASE2 Primary Hyperoxaluria Type 1 (PH1) COMPLETED NCT03847909
NNC0385-0434 E Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05129891
NNC0385-0434 D Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05129891
NNC0385-0434 C Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05129891
NNC0385-0434 B Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05129891
Semaglutide I Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05129891
Semaglutide H Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05129891
Semaglutide G Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05129891
Semaglutide D Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05129891
Placebo (semaglutide) Other Phase PHASE2 Non-alcoholic Steatohepatitis COMPLETED NCT03987451
Semaglutide Other Phase PHASE2 Non-alcoholic Steatohepatitis COMPLETED NCT03987451
Live music in the intensive care unit Other Approved Stress NOT_YET_RECRUITING NCT06442644
Placebo Other Phase PHASE4 Diabetes Mellitus, Type 2 RECRUITING NCT05780905
Semaglutide Auto-Injector Other Phase PHASE4 Diabetes Mellitus, Type 2 RECRUITING NCT05780905
Placebo Other Phase PHASE2 Intestinal Mucositis NOT_YET_RECRUITING NCT06449625
Semaglutide Pen Injector [Ozempic] Other Phase PHASE2 Intestinal Mucositis NOT_YET_RECRUITING NCT06449625
NC0194-0499 Other Phase PHASE1 Non-alcoholic Fatty Liver Disease COMPLETED NCT05742919
NNC0194-0499 Other Phase PHASE1 Non-alcoholic Fatty Liver Disease COMPLETED NCT05742919
Ryzodeg® Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT05221580
Standard of care Other Phase PHASE4 Diabetes Mellitus, Type 2 COMPLETED NCT03596450
Semaglutide Other Phase PHASE4 Diabetes Mellitus, Type 2 COMPLETED NCT03596450
Placebo (Liraglutide 3.0 mg) Other Phase PHASE2 Overweight COMPLETED NCT03856047
Liraglutide 3.0 mg Other Phase PHASE2 Overweight COMPLETED NCT03856047
Placebo (NNC0174-0833) Other Phase PHASE2 Overweight COMPLETED NCT03856047
NNC0174-0833 Other Phase PHASE2 Overweight COMPLETED NCT03856047
No treatment given Drug Preclinical Obesity COMPLETED NCT05873660
Placebo Other Phase PHASE1 Primary Hyperoxaluria Type 1 TERMINATED NCT02795325
DCR-PH1 Other Phase PHASE1 Primary Hyperoxaluria Type 1 TERMINATED NCT02795325
Placebo Other Phase PHASE1 Primary Hyperoxaluria Type 1 TERMINATED NCT02795325
DCR-PH1 Other Phase PHASE1 Primary Hyperoxaluria Type 1 TERMINATED NCT02795325
DCR-MYC Other Phase PHASE1 Hepatocellular Carcinoma TERMINATED NCT02314052
DCR-MYC Other Phase PHASE1 Hepatocellular Carcinoma TERMINATED NCT02314052
DCR-MYC Other Phase PHASE1 Solid Tumors TERMINATED NCT02110563
DCR-MYC Other Phase PHASE1 Solid Tumors TERMINATED NCT02110563
Insulin icodec Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04597697
Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04016974
Oral semaglutide Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04016974
Insulin icodec Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03723785
Sugar Pill Other Phase PHASE4 Insulin Resistance COMPLETED NCT02403284
Liraglutide Other Phase PHASE4 Insulin Resistance COMPLETED NCT02403284
Placebo Pen Injector Other Phase PHASE2 Pouchitis TERMINATED NCT04763564
Liraglutide Pen Injector Other Phase PHASE2 Pouchitis TERMINATED NCT04763564
No treatment given Drug Preclinical Atherosclerotic Cardiovascular Disease (ASCVD) COMPLETED NCT06322641
Standard face-to-face patient education Other Approved Rheumatoid Arthritis COMPLETED NCT04669340
E-learning patient education Other Approved Rheumatoid Arthritis COMPLETED NCT04669340
Semaglutide/dapagliflozin Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05429593
Dapagliflozin Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05429593
Semaglutide Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05429593
Specialist Obesity Management Services Other Phase PHASE4 Obesity COMPLETED NCT03036800
Saxenda Other Phase PHASE4 Obesity COMPLETED NCT03036800
CT-guided radiotherapy Drug Preclinical Prostate Cancer COMPLETED NCT05615909
Online MR-guided radiotherapy Drug Preclinical Prostate Cancer COMPLETED NCT05615909
No treatment given Drug Preclinical Type 2 Diabetes COMPLETED NCT06517784
Placebo (semaglutide) Other Phase PHASE3 Overweight COMPLETED NCT03574597
Semaglutide Other Phase PHASE3 Overweight COMPLETED NCT03574597
No treatment given Drug Preclinical Type-2 Diabetes Mellitus (T2DM) COMPLETED NCT06592950
No treatment given Drug Preclinical Obesity COMPLETED NCT05795166
No treatment given Drug Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT05542420
Oral semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT05502562
no treatment given Drug Preclinical Obesity COMPLETED NCT05428501
Placebo ( Semaglutide D) Other Phase PHASE1 Obesity COMPLETED NCT05236517
Placebo (Semaglutide C) Other Phase PHASE1 Obesity COMPLETED NCT05236517
Semaglutide C Dose 5 (50 mg) Other Phase PHASE1 Obesity COMPLETED NCT05236517
Semaglutide C Dose 4 Other Phase PHASE1 Obesity COMPLETED NCT05236517
Semaglutide D Dose 3 Other Phase PHASE1 Obesity COMPLETED NCT05236517
Semaglutide D Dose 2 Other Phase PHASE1 Obesity COMPLETED NCT05236517
Semaglutide D Dose 1 Other Phase PHASE1 Obesity COMPLETED NCT05236517
Semaglutide Dose 6 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05227196
Semaglutide Dose 5 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05227196
Semaglutide Dose 4 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05227196
Semaglutide D Dose 3 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05227196
Semaglutide D Dose 2 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05227196
Semaglutide D Dose 1 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05227196
Belcesiran Other Phase PHASE2 Alpha 1-Antitrypsin Deficiency WITHDRAWN NCT05146882
Belcesiran Other Phase PHASE2 Alpha 1-Antitrypsin Deficiency WITHDRAWN NCT05146882
Sterile Normal Saline (0.9% NaCl) Other Phase PHASE1 Primary Hyperoxaluria Type 3 COMPLETED NCT04555486
DCR-PHXC Other Phase PHASE1 Primary Hyperoxaluria Type 3 COMPLETED NCT04555486
Oral Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04537624
Placebo Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04109547
Oral semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04109547
Insulin Degludec/Insulin Aspart Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04042441
Placebo for DCR-HBVS Other Phase PHASE1 Hepatitis B, Chronic COMPLETED NCT03772249
DCR-HBVS Other Phase PHASE1 Hepatitis B, Chronic COMPLETED NCT03772249
Placebo Other Phase PHASE1 Primary Hyperoxaluria COMPLETED NCT03392896
DCR-PHXC Other Phase PHASE1 Primary Hyperoxaluria COMPLETED NCT03392896
Placebo Other Phase PHASE1 Primary Hyperoxaluria COMPLETED NCT03392896
DCR-PHXC Other Phase PHASE1 Primary Hyperoxaluria COMPLETED NCT03392896
RYGB Other Phase PHASE3 Obesity COMPLETED NCT03115424
Placebos Other Phase PHASE3 Obesity COMPLETED NCT03115424
Saxenda Other Phase PHASE3 Obesity COMPLETED NCT03115424
IDegLira Other Preclinical Diabetes Mellitus, Type 2 WITHDRAWN NCT06113341
Placebo (sitagliptin) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04017832
Placebo (oral semaglutide) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04017832
Sitagliptin Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04017832
Oral semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04017832
Semaglutide B, 0.68 mg/mL Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05689099
Semaglutide B, 1.34 mg/mL Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05689099
Education-First Other Phase PHASE4 Cardiovascular Diseases COMPLETED NCT06046560
SGLT2 inhibitor, GLP-1 RA Other Phase PHASE4 Cardiovascular Diseases COMPLETED NCT06046560
VIA Family 2.0 Other Approved Child RECRUITING NCT06312410
Placebo Other Phase PHASE1 Alpha 1-Antitrypsin Deficiency COMPLETED NCT04174118
belcesiran Other Phase PHASE1 Alpha 1-Antitrypsin Deficiency COMPLETED NCT04174118
Placebo Other Phase PHASE1 Alpha 1-Antitrypsin Deficiency COMPLETED NCT04174118
belcesiran Other Phase PHASE1 Alpha 1-Antitrypsin Deficiency COMPLETED NCT04174118
Placebo insulin degludec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04795531
Insulin degludec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04795531
Placebo insulin icodec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04795531
Insulin icodec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04795531
CCK Other Approved Gallbladder COMPLETED NCT04651868
Placebo Other Approved Gallbladder COMPLETED NCT04651868
GLP-2 Other Approved Gallbladder COMPLETED NCT04651868
CCK Other Approved Gallbladder COMPLETED NCT04651868
Placebo Other Approved Gallbladder COMPLETED NCT04651868
GLP-2 Other Approved Gallbladder COMPLETED NCT04651868
Placebo infusion (saline) Other Approved Fibroblast Growth Factor 21 COMPLETED NCT04232033
Fibroblast growth factor 21 infusion Other Approved Fibroblast Growth Factor 21 COMPLETED NCT04232033
Infusion of either NST or placebo at different blood glucose levels Other Approved Type 1 Diabetes COMPLETED NCT06143267
Infusion of GIP[1-42], GIP[1-30] or placebo Other Approved Type1diabetes COMPLETED NCT06137586
Infusion of GIP[1-42], GIP[1-30] or placebo Other Approved Type1diabetes COMPLETED NCT06137586
Placebo for DCR-AUD Other Phase PHASE1 Alcohol Use Disorder (AUD) COMPLETED NCT05021640
DCR-AUD Other Phase PHASE1 Alcohol Use Disorder (AUD) COMPLETED NCT05021640
Placebo for DCR-AUD Other Phase PHASE1 Alcohol Use Disorder (AUD) COMPLETED NCT05021640
DCR-AUD Other Phase PHASE1 Alcohol Use Disorder (AUD) COMPLETED NCT05021640
ethinylestradiol/levonorgestrel Other Phase PHASE1 Healthy Volunteers (Non-alcoholic Steatohepatitis) COMPLETED NCT06188026
NNC0194-0499 Other Phase PHASE1 Healthy Volunteers (Non-alcoholic Steatohepatitis) COMPLETED NCT06188026
Insulin aspart Other Phase PHASE4 Type 2 Diabetes COMPLETED NCT04538352
Insulin Degludec Other Phase PHASE4 Type 2 Diabetes COMPLETED NCT04538352
Semaglutide Other Phase PHASE4 Type 2 Diabetes COMPLETED NCT04538352
point-of-care ultrasound Other Preclinical Point-of-care Ultrasound COMPLETED NCT05523882
point-of-care ultrasound Other Preclinical Point-of-care Ultrasound COMPLETED NCT05523882
point-of-care ultrasound Other Preclinical Point-of-care Ultrasound COMPLETED NCT05523882
Motivational enhancement therapy Drug Approved Alcoholic Hepatitis (AH) RECRUITING NCT06740318
Placebo (NNC0487-0111) Other Phase PHASE1 Obesity COMPLETED NCT06049329
NNC0487-0111 Other Phase PHASE1 Obesity COMPLETED NCT06049329
Oral semaglutide Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04817644
IGlar U100 Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT03723772
Insulin icodec Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT03723772
Placebo semaglutide pen injector Other Phase PHASE4 Pre Diabetes RECRUITING NCT04873050
Semaglutide Pen Injector [Ozempic] Other Phase PHASE4 Pre Diabetes RECRUITING NCT04873050
Estradiol Vaginal Insert Other Phase PHASE4 HIV Infection COMPLETED NCT04079218
Placebo Other Phase PHASE4 Type 2 Diabetes COMPLETED NCT04979130
Semaglutide Other Phase PHASE4 Type 2 Diabetes COMPLETED NCT04979130
Placebo (semaglutide) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT03819153
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT03819153
semaglutide Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05435677
insulin icodec Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05435677
IcoSema Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05435677
Glucagon-like peptide-1 (GLP-1) Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04809311
Basal insulin Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04809311
Oral antidiabetetic drugs Drug Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04809311
NNC0487-0111 Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT06559527
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT06351748
Placebo (NNC6022-0001) Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06336005
NNC6022-0001 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06336005
Placebo (semaglutide) Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04032197
Semaglutide Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04032197
Placebo Other Phase PHASE2 Diabetes type1 RECRUITING NCT06411210
Semaglutide Pen Injector Other Phase PHASE2 Diabetes type1 RECRUITING NCT06411210
Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05979428
NNC0491-6075 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05979428
Acetaminophen - 500 mg/15 ml Other Phase PHASE1 Obesity COMPLETED NCT06461039
Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC) Other Phase PHASE1 Obesity COMPLETED NCT06461039
NNC0487-0111 C Other Phase PHASE1 Obesity COMPLETED NCT06461039
NNC0487-0111 A Other Phase PHASE1 Obesity COMPLETED NCT06461039
No treatment given Drug Preclinical Cardiovascular Risk COMPLETED NCT06122961
Warfarin Other Phase PHASE1 Obesity COMPLETED NCT06289504
Atorvastatin Other Phase PHASE1 Obesity COMPLETED NCT06289504
Semaglutide Other Phase PHASE1 Obesity COMPLETED NCT06289504
Cagrilintide Other Phase PHASE1 Obesity COMPLETED NCT06289504
Growth hormone Other Preclinical Growth Hormone Deficiency COMPLETED NCT03225755
Placebo Other Phase PHASE1 Type I Diabetes COMPLETED NCT04279613
NNC0361-0041 Other Phase PHASE1 Type I Diabetes COMPLETED NCT04279613
Insulin degludec Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT06288412
Insulin icodec Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT06288412
Control Other Approved Overweight and Obesity ACTIVE_NOT_RECRUITING NCT05768958
Exercise Other Approved Overweight and Obesity ACTIVE_NOT_RECRUITING NCT05768958
DCR-PHXC Other Phase PHASE3 Primary Hyperoxaluria Type 1 (PH1) ACTIVE_NOT_RECRUITING NCT04042402
DCR-PHXC Other Phase PHASE3 Primary Hyperoxaluria Type 1 (PH1) ACTIVE_NOT_RECRUITING NCT04042402
DCR-PHXC Other Phase PHASE3 Primary Hyperoxaluria Type 1 (PH1) ACTIVE_NOT_RECRUITING NCT04042402
Esperoct Other Preclinical Haemophilia A RECRUITING NCT05621746
Nonacog beta pegol Other Preclinical Haemophilia B ENROLLING_BY_INVITATION NCT03690336
placebo (semaglutide) Other Phase PHASE3 Overweight and Obesity COMPLETED NCT05132088
semaglutide 50 mg Other Phase PHASE3 Overweight and Obesity COMPLETED NCT05132088
Evolocumab 140 mg/mL, Repatha® Other Phase PHASE2 Atherosclerotic Cardiovascular Disease COMPLETED NCT04992065
Placebo II A (for NNC0385-0434 A 100 mg) Other Phase PHASE2 Atherosclerotic Cardiovascular Disease COMPLETED NCT04992065
Placebo I A (for NNC0385-0434 A 40 mg) Other Phase PHASE2 Atherosclerotic Cardiovascular Disease COMPLETED NCT04992065
NNC0385-0434 A 100 mg Other Phase PHASE2 Atherosclerotic Cardiovascular Disease COMPLETED NCT04992065
Placebo I A (for NNC0385-0434 A 15 mg) Other Phase PHASE2 Atherosclerotic Cardiovascular Disease COMPLETED NCT04992065
NNC0385-0434 A 40 mg Other Phase PHASE2 Atherosclerotic Cardiovascular Disease COMPLETED NCT04992065
NNC0385-0434 A 15 mg Other Phase PHASE2 Atherosclerotic Cardiovascular Disease COMPLETED NCT04992065
semaglutide Other Preclinical Obesity and Overweight ENROLLING_BY_INVITATION NCT07018544
Placebo A (NNC0487-0111 A) Other Phase PHASE1 Obesity COMPLETED NCT05369390
Placebo B (NNC0487-0111 B) Other Phase PHASE1 Obesity COMPLETED NCT05369390
NNC0487-0111 B Other Phase PHASE1 Obesity COMPLETED NCT05369390
NNC0487-0111 A Other Phase PHASE1 Obesity COMPLETED NCT05369390
Placebo Other Phase PHASE1 Healthy Participants COMPLETED NCT06069895
NNC0113-6856 Other Phase PHASE1 Healthy Participants COMPLETED NCT06069895
Placebo Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05870670
NNC0519-0130 Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05870670
No treatment given Drug Preclinical Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH) COMPLETED NCT06741111
Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06625307
NNC0537-1482 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06625307
Placebo Other Phase PHASE2 NAFLD RECRUITING NCT05424003
Semaglutide Pen Injector Other Phase PHASE2 NAFLD RECRUITING NCT05424003
matching liraglutide-placebo pre-filled pens Other Phase PHASE4 Type2 Diabetes COMPLETED NCT03260881
Liraglutide Pen Injector [Victoza] Other Phase PHASE4 Type2 Diabetes COMPLETED NCT03260881
Semaglutide 1 mg Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05259033
IcoSema Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05259033
Multi-level, Multi-component Intervention Package Other Approved Quality of Life (QOL) NOT_YET_RECRUITING NCT07061665
NaCl 0.9% Other Phase PHASE2 Acute Myocardial Infarction ACTIVE_NOT_RECRUITING NCT05350592
Dobutamine Other Phase PHASE2 Acute Myocardial Infarction ACTIVE_NOT_RECRUITING NCT05350592
Tocilizumab Other Phase PHASE2 Acute Myocardial Infarction ACTIVE_NOT_RECRUITING NCT05350592
Dasiglucagon Other Phase PHASE3 Hypoglycemia COMPLETED NCT05378672
Nedosiran Other Preclinical Primary Hyperoxaluria Type 1 (PH1) NO_LONGER_AVAILABLE NCT05993416
Nedosiran Other Preclinical Primary Hyperoxaluria Type 1 (PH1) NO_LONGER_AVAILABLE NCT05993416
Placebo semaglutide Other Phase PHASE1 Obesity RECRUITING NCT07010432
Placebo cagrilintide Other Phase PHASE1 Obesity RECRUITING NCT07010432
Semaglutide Other Phase PHASE1 Obesity RECRUITING NCT07010432
Cagrilintide Other Phase PHASE1 Obesity RECRUITING NCT07010432
Preventive treatment with oral hydration Drug Approved Contrast-induced Nephropathy RECRUITING NCT05283512
Preventive treatment with IV-hydration Drug Approved Contrast-induced Nephropathy RECRUITING NCT05283512
NNC0487-0111 (formulation C) Other Phase PHASE1 Obesity COMPLETED NCT06478563
NNC0487-0111 (formulation D) Other Phase PHASE1 Obesity COMPLETED NCT06478563
No treatment given Drug Preclinical Type 2 Diabetes Mellitus COMPLETED NCT07121114
Placebo (NNC0487-0111) Other Phase PHASE1 Overweight COMPLETED NCT06820476
NNC0487-0111 Other Phase PHASE1 Overweight COMPLETED NCT06820476
CagriSema A Other Phase PHASE1 Obesity COMPLETED NCT06716307
CagriSema (cagrilintide B and semaglutide I) Other Phase PHASE1 Obesity COMPLETED NCT06716307
Placebo Other Approved Obesity COMPLETED NCT05917873
LaKe Ester Other Approved Obesity COMPLETED NCT05917873
Concizumab Other Preclinical Haemophilia A, Haemophilia B ENROLLING_BY_INVITATION NCT06831734
Concizumab Other Preclinical Haemophilia A ENROLLING_BY_INVITATION NCT06285071
Turoctocog alfa pegol Other Preclinical Haemophilia A COMPLETED NCT04334057
Insulin aspart Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT06809621
NNC0471-0119 H Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT06809621
Insulin Glargine 300U/mL Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04760626
Insulin Degludec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04760626
Insulin Glargine 100U/mL Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04760626
Insulin icodec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04760626
Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY] Other Phase PHASE4 Obesity COMPLETED NCT05548647
Placebo Other Phase PHASE4 Obesity COMPLETED NCT05548647
Behavioral Treatment Drug Phase PHASE4 Obesity COMPLETED NCT05548647
Placebo (NNC0662-0419) Other Phase PHASE1 Overweight COMPLETED NCT06737536
NNC0662-0419 Other Phase PHASE1 Overweight COMPLETED NCT06737536
Placebo Other Phase PHASE1 Healthy Volunteers RECRUITING NCT06859073
NNC4004-0002 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT06859073
Semaglutide Other Phase PHASE1 Healthy Participants COMPLETED NCT05996874
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT05316662
Oral semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT05230615
Oral semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT05230589
Oral semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04878393
Oral semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04862923
NNC0365-3769 (Mim8) Other Phase PHASE1 Haemophilia A COMPLETED NCT05681845
DCR-PDL1 Other Phase PHASE1 Solid Tumors, Adult RECRUITING NCT06504368
DCR-PDL1 Other Phase PHASE1 Solid Tumors, Adult RECRUITING NCT06504368
NNC0519-0130 C Other Phase PHASE1 Obesity COMPLETED NCT06642571
NNC0519-0130 B Other Phase PHASE1 Obesity COMPLETED NCT06642571
NNC6019-0001 Other Phase PHASE2 Transthyretin Amyloid Cardiomyopathy (ATTR CM) ACTIVE_NOT_RECRUITING NCT06260709
Placebo (semaglutide) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04560998
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04560998
NNC0662-0419 Other Phase PHASE1 Overweight COMPLETED NCT07101783
No treatment given Drug Preclinical Parkinson Disease ENROLLING_BY_INVITATION NCT05779475
Kidney Biopsy Other Preclinical Chronic Kidney Diseases RECRUITING NCT04916132
IDegLira Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04838743
No Intervention Other Preclinical Pregnancy ENROLLING_BY_INVITATION NCT05872022
Placebo Other Phase PHASE1 Alcohol Use Disorder COMPLETED NCT05845398
DCR-AUD Other Phase PHASE1 Alcohol Use Disorder COMPLETED NCT05845398
Placebo Other Phase PHASE1 Alcohol Use Disorder COMPLETED NCT05845398
DCR-AUD Other Phase PHASE1 Alcohol Use Disorder COMPLETED NCT05845398
No treatment given Drug Preclinical Obesity COMPLETED NCT07358052
No treatment given Drug Preclinical Overweight COMPLETED NCT07141914
Telemonitoring Other Approved Type 2 Diabetes Treated With Insulin RECRUITING NCT06185296
Intelligent telemonitoring Other Approved Type 2 Diabetes Treated With Insulin RECRUITING NCT06185296
Placebo (NNC6019-0001) Other Phase PHASE2 Transthyretin Amyloid Cardiomyopathy (ATTR CM) COMPLETED NCT05442047
NNC6019-0001 Other Phase PHASE2 Transthyretin Amyloid Cardiomyopathy (ATTR CM) COMPLETED NCT05442047
Placebo semaglutide Other Phase PHASE3 Overweight COMPLETED NCT05564117
Semaglutide Other Phase PHASE3 Overweight COMPLETED NCT05564117
Eptacog alfa (NovoSeven) Other Phase PHASE4 Severe Postpartum Haemorrhage RECRUITING NCT07157423
Placebo (semaglutide) Other Phase PHASE3 Early Alzheimer´s Disease COMPLETED NCT04777409
Semaglutide Other Phase PHASE3 Early Alzheimer´s Disease COMPLETED NCT04777409
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07503210
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07503210
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07509307
NNC0487-0111 Other Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07509307
Somapacitan Other Preclinical Growth Hormone Deficiency ENROLLING_BY_INVITATION NCT06709040
Football Fitness Concept Other Phase PHASE2 Postmenopausal Women ACTIVE_NOT_RECRUITING NCT06789900
Everolimus (Afinitor®) Other Phase PHASE2 Postmenopausal Women ACTIVE_NOT_RECRUITING NCT06789900
Metformin Hydrochloride Other Phase PHASE4 Heart Failure COMPLETED NCT03514108
Placebo Oral Tablet Other Phase PHASE4 Heart Failure COMPLETED NCT03514108
Hydralazine Isosorbide Dinitrate Other Phase PHASE4 Heart Failure COMPLETED NCT03514108
Placebo (semaglutide) Other Phase PHASE3 Early Alzheimer's Disease COMPLETED NCT04777396
Semagludtide Other Phase PHASE3 Early Alzheimer's Disease COMPLETED NCT04777396
Placebo Other Phase PHASE3 Non-alcoholic Steatohepatitis ACTIVE_NOT_RECRUITING NCT04822181
Semaglutide Other Phase PHASE3 Non-alcoholic Steatohepatitis ACTIVE_NOT_RECRUITING NCT04822181
Placebo (matched to Cagrilintide) Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Cagrilintide Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Tirzepatide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Semaglutide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Cagrilintide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Oral Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04601753
Oral Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04601740
Oral Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04537637
Rosuvastatin Other Phase PHASE1 Healthy Volunteers Sickle Cell Disease, Thalassemia COMPLETED NCT06813924
Midazolam Other Phase PHASE1 Healthy Volunteers Sickle Cell Disease, Thalassemia COMPLETED NCT06813924
Metformin Other Phase PHASE1 Healthy Volunteers Sickle Cell Disease, Thalassemia COMPLETED NCT06813924
Pitavastatin Other Phase PHASE1 Healthy Volunteers Sickle Cell Disease, Thalassemia COMPLETED NCT06813924
Digoxin Other Phase PHASE1 Healthy Volunteers Sickle Cell Disease, Thalassemia COMPLETED NCT06813924
Etavopivat Other Phase PHASE1 Healthy Volunteers Sickle Cell Disease, Thalassemia COMPLETED NCT06813924
Norditropin Other Preclinical Noonan Syndrome ENROLLING_BY_INVITATION NCT05308927
Turoctocog alfa pegol Other Preclinical Haemophilia A ENROLLING_BY_INVITATION NCT04682145
Norditropin® FlexPro® Other Preclinical Growth Hormone Deficiency in Children ENROLLING_BY_INVITATION NCT03972345
DCR-STAT3 Other Phase PHASE1 Solid Tumor, Adult COMPLETED NCT06098651
No treatment given Drug Preclinical Overweight, Obesity ACTIVE_NOT_RECRUITING NCT06805539
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT05755360
Oral semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT05443568
Low Energy Diet Other Phase PHASE1 Obesity RECRUITING NCT07184086
CagriSema (Cagrilintide B + semaglutide I) Other Phase PHASE1 Obesity RECRUITING NCT07184086
Placebo (NNC0581-0001) Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05599945
NNC0581-0001 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05599945
Etavopivat Other Phase PHASE1 Healthy Volunteers Sickle Cell Disease, Thalassemia COMPLETED NCT06433661
Etavopivat Other Phase PHASE1 Liver Diseases COMPLETED NCT06336018
No treatment given Drug Preclinical Obesity COMPLETED NCT06288399
Semaglutide N Other Phase PHASE1 Healthy Volunteers Type 2 Diabetes COMPLETED NCT06642584
Semaglutide M Other Phase PHASE1 Healthy Volunteers Type 2 Diabetes COMPLETED NCT06642584
Semaglutide L Other Phase PHASE1 Healthy Volunteers Type 2 Diabetes COMPLETED NCT06642584
Semaglutide J Other Phase PHASE1 Healthy Volunteers Type 2 Diabetes COMPLETED NCT06642584
Semaglutide B Other Phase PHASE1 Healthy Volunteers Type 2 Diabetes COMPLETED NCT06642584
No treatment given Drug Preclinical Systemic Inflammation (hsCRP) COMPLETED NCT06655493
No treatment given Drug Preclinical Haemophilia ENROLLING_BY_INVITATION NCT07163260
Somatropin injection Other Preclinical Growth Hormone Deficiency COMPLETED NCT04020913
DCR-PDL1 Other Phase PHASE1 Solid Tumors, Adult RECRUITING NCT06504368
Mim8 Other Phase PHASE3 Haemophilia A With or Without Inhibitors COMPLETED NCT05306418
semaglutide 2.4 mg (placebo) Other Phase PHASE3 Obesity COMPLETED NCT05064735
semaglutide 2.4 mg Other Phase PHASE3 Obesity COMPLETED NCT05064735
Placebo (monlunabant) Other Phase PHASE1 Obesity COMPLETED NCT06542536
Monlunabant Other Phase PHASE1 Obesity COMPLETED NCT06542536
Placebo (NNC0487-0111) Other Phase PHASE2 Obesity COMPLETED NCT06064006
NNC0487-0111 Other Phase PHASE2 Obesity COMPLETED NCT06064006
NNC0174 0833 placebo Other Phase PHASE2 Non-alcoholic Steatohepatitis COMPLETED NCT05016882
NNC0174 0833 10 mg/mL Other Phase PHASE2 Non-alcoholic Steatohepatitis COMPLETED NCT05016882
Semaglutide placebo Other Phase PHASE2 Non-alcoholic Steatohepatitis COMPLETED NCT05016882
Semaglutide 3 mg/mL Other Phase PHASE2 Non-alcoholic Steatohepatitis COMPLETED NCT05016882
Placebo (NNC0194-0499) Other Phase PHASE2 Non-alcoholic Steatohepatitis COMPLETED NCT05016882
NNC0194 0499 50 mg/mL Other Phase PHASE2 Non-alcoholic Steatohepatitis COMPLETED NCT05016882
Community Co-designed Physical Activity and Diet Intervention Package Other Approved Quality of Life (QOL) ACTIVE_NOT_RECRUITING NCT07191925
Somapacitan Other Phase PHASE3 SGA ACTIVE_NOT_RECRUITING NCT05723835
No treatment given Drug Preclinical Obesity ENROLLING_BY_INVITATION NCT07154238
Sleep extension Other Approved Sleep Duration RECRUITING NCT06341179
Sleep extension Other Approved Sleep Duration RECRUITING NCT06341179
Insuline glargine U100 (titrated) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Insuline glargine U100 (reduced) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
oral glucose-lowering medications (commercially available) Drug Phase PHASE4 Diabetes Mellitus, Type 2 COMPLETED NCT05035082
semaglutide Other Phase PHASE4 Diabetes Mellitus, Type 2 COMPLETED NCT05035082
Community capacity building Other Approved Childhood Obesity COMPLETED NCT05940675
Sleep and screen media Other Approved Childhood Obesity COMPLETED NCT05940675
Physical Activity (FitFirst) Other Approved Childhood Obesity COMPLETED NCT05940675
Food and Nutrition Other Approved Childhood Obesity COMPLETED NCT05940675
PTM CILO/FIR Other Phase PHASE2 Nonalcoholic Steatohepatitis COMPLETED NCT04971785
PTM SEMA Other Phase PHASE2 Nonalcoholic Steatohepatitis COMPLETED NCT04971785
Cilofexor (CILO)/Firsocostat (FIR) Other Phase PHASE2 Nonalcoholic Steatohepatitis COMPLETED NCT04971785
Semaglutide (SEMA) Other Phase PHASE2 Nonalcoholic Steatohepatitis COMPLETED NCT04971785
Placebo (Semaglutide) Other Phase PHASE3 Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 COMPLETED NCT04916470
Semaglutide Other Phase PHASE3 Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 COMPLETED NCT04916470
Placebo Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06323161
Semaglutide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06323161
Cagrilintide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06323161
Hypercaloric High-Fat Diet Other Approved Metabolic Health NOT_YET_RECRUITING NCT07255807
Physical Inactivity Other Approved Metabolic Health NOT_YET_RECRUITING NCT07255807
Insulin Icodec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05823948
Semaglutide C Other Phase PHASE1 Healthy Participants COMPLETED NCT05784402
Semaglutide J Other Phase PHASE1 Healthy Participants COMPLETED NCT05784402
insulin aspart Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05013229
Insulin glargine Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05013229
IcoSema Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05013229
Insulin icodec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05352815
IcoSema Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05352815
Placebo (semaglutide) Other Phase PHASE3 Obesity COMPLETED NCT05035095
Oral semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05035095
Insulin aspart Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04880850
Insulin glargine Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04880850
Insulin icodec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04880850
insulin aspart Other Phase PHASE3 Diabetes Mellitus, Type 1 COMPLETED NCT04848480
insulin degludec Other Phase PHASE3 Diabetes Mellitus, Type 1 COMPLETED NCT04848480
insulin icodec Other Phase PHASE3 Diabetes Mellitus, Type 1 COMPLETED NCT04848480
Placebo Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT04775082
Liraglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT04775082
Novo Rapid Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT04698018
Faster Aspart Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT04698018
Insulin degludec Other Phase PHASE3 Diabetes Mellitus, Type 1 COMPLETED NCT04588259
Insulin aspart Other Phase PHASE3 Diabetes Mellitus, Type 1 COMPLETED NCT04588259
Faster aspart Other Phase PHASE3 Diabetes Mellitus, Type 1 COMPLETED NCT04588259
Insulin glargine Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04460885
Insulin icodec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04460885
Placebo Other Phase PHASE1 Heart Failure RECRUITING NCT07218627
NNC0537-1482 Other Phase PHASE1 Heart Failure RECRUITING NCT07218627
Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) Other Phase PHASE2 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06797869
CagriSema (Cagrilintide B and Semaglutide I) Other Phase PHASE2 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06797869
No treatment given Drug Preclinical Atherosclerotic Cardiovascular Disease (ASCVD) COMPLETED NCT06589791
Glucagon Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT06588504
Dasiglucagon Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT06588504
Placebo Other Phase PHASE1 Healthy Participants COMPLETED NCT06284798
NNC0650-0013 A Other Phase PHASE1 Healthy Participants COMPLETED NCT06284798
Oral Semaglutide Other Preclinical Type 2 Diabetes RECRUITING NCT06269120
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 NOT_YET_RECRUITING NCT05714683
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 NOT_YET_RECRUITING NCT05689372
Placebo (semaglutide) Other Phase PHASE3 Obesity COMPLETED NCT04788511
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT04788511
Oral Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04559815
Placebo Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07270731
NNC9733-0001 Other Phase PHASE1 Healthy Volunteer RECRUITING NCT07270731
NNC0365-3769 (Mim8) PPX Other Phase PHASE3 Haemophilia A COMPLETED NCT05878938
NNC0365-3769 (Mim8) Other Phase PHASE3 Haemophilia A COMPLETED NCT05053139
Oral semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04707469
Placebo Other Phase PHASE3 Overweight COMPLETED NCT04102189
Semaglutide Other Phase PHASE3 Overweight COMPLETED NCT04102189
Placebo (semaglutide) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT03914326
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT03914326
Semaglutide Other Preclinical Obesity ENROLLING_BY_INVITATION NCT07280221
Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT07011667
CagriSema (Cagrilintide B and Semaglutide I) Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT07011667
No treatment is given Drug Preclinical Idiopathic Short Stature TERMINATED NCT05894876
Cagrilintide Other Phase PHASE1 Hepatic Impairment COMPLETED NCT05564104
Placebo Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT05486065
Semaglutide Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT05486065
Semaglutide B Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05478252
Semaglutide J Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05478252
Cagrilintide and semaglutide Other Phase PHASE1 Obesity & Overweight COMPLETED NCT04940078
semaglutide Other Phase PHASE1 Obesity & Overweight COMPLETED NCT04940078
Cagrilintide Other Phase PHASE1 Obesity & Overweight COMPLETED NCT04940078
Insulin Icodec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04770532
Insulin degludec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04770532
Semaglutide Other Phase PHASE4 Obesity ACTIVE_NOT_RECRUITING NCT06571383
Community-based intervention packages Other Approved Obesity ENROLLING_BY_INVITATION NCT06855563
Placebo (Mim8) Other Phase PHASE2 Healthy Volunteers COMPLETED NCT04204408
NNC0365-3769 (Mim8) Other Phase PHASE2 Healthy Volunteers COMPLETED NCT04204408
Turoctocog alfa pegol (N8-GP) Other Preclinical Haemophilia A ENROLLING_BY_INVITATION NCT04574076
Nonacog beta pegol Other Preclinical Haemophilia B ENROLLING_BY_INVITATION NCT03745924
Placebo (cagrilintide) Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT04982575
Placebo (semaglutide) Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT04982575
Cagrilintide 2.4 mg Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT04982575
Semaglutide 2.4 mg Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT04982575
Norditropin® Other Phase PHASE2 Short Stature Children Born Small for Gestational Age (SGA) ACTIVE_NOT_RECRUITING NCT03878446
Somapacitan Other Phase PHASE2 Short Stature Children Born Small for Gestational Age (SGA) ACTIVE_NOT_RECRUITING NCT03878446
nonacog beta pegol Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT02141074
turoctocog alfa pegol Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT02137850
nonacog beta pegol Other Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT01467427
Group visits (control) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Food boxes (control) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Behavioral support (control) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Group visits (Ovo-lacto-vegetarian diet) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Food boxes (Ovo-lacto-vegetarian diet) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Behavioural support (Ovo-lacto-vegetarian diet) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Group visits PHD Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Food boxes PHD Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Behavioural support PHD Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Dietary advice (control) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Dietary advice (Ovo-lacto-vegetarian diet) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Dietary advice (PHD) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Group visits (control) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Food boxes (control) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Behavioral support (control) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Group visits (Ovo-lacto-vegetarian diet) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Food boxes (Ovo-lacto-vegetarian diet) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Behavioural support (Ovo-lacto-vegetarian diet) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Group visits PHD Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Food boxes PHD Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Behavioural support PHD Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Dietary advice (control) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Dietary advice (Ovo-lacto-vegetarian diet) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Dietary advice (PHD) Other Approved Cardiometabolic Diseases RECRUITING NCT07189676
Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05624580
NNC0582-0001 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05624580
DCR-PHXC Other Phase PHASE2 Primary Hyperoxaluria Type 1 RECRUITING NCT04580420
Etavopivat Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06581627
Placebo (NNC0487-0111 oral) Other Phase PHASE2 Type 2 Diabetes (T2D) COMPLETED NCT06542874
NNC0487-0111 oral Other Phase PHASE2 Type 2 Diabetes (T2D) COMPLETED NCT06542874
Placebo (NNC0487-0111 subcutanous) Other Phase PHASE2 Type 2 Diabetes (T2D) COMPLETED NCT06542874
NNC0487-0111 subcutanous Other Phase PHASE2 Type 2 Diabetes (T2D) COMPLETED NCT06542874
Decitabine-THU Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06291285
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT06507475
Ziltivekimab C Other Phase PHASE1 Healthy Participants COMPLETED NCT05721989
Ziltivekimab D Other Phase PHASE1 Healthy Participants COMPLETED NCT05721989
Ziltivekimab B Other Phase PHASE1 Healthy Participants COMPLETED NCT05721989
No treatment given Drug Preclinical Obesity and Cardiovascular Risk COMPLETED NCT05642533
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT05443191
Placebo Other Phase PHASE2 Sickle Cell Disease COMPLETED NCT05405114
HU - Hydroxyurea Other Phase PHASE2 Sickle Cell Disease COMPLETED NCT05405114
NDec - oral decitabine-tetrahydrouridine Other Phase PHASE2 Sickle Cell Disease COMPLETED NCT05405114
Concizumab Other Phase PHASE3 Haemophilia A and B With and Without Inhibitors ACTIVE_NOT_RECRUITING NCT05135559
Placebo (semaglutide 2.4 mg) Other Phase PHASE3 Obesity COMPLETED NCT04998136
Semaglutide 2.4 mg Other Phase PHASE3 Obesity COMPLETED NCT04998136
NNC0442-0344 A Other Phase PHASE1 Haemophilia A RECRUITING NCT07238816
Placebo Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT06567041
NNC0519-0130 Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT06567041
Trizepatide Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT06326047
Placebo Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT06326047
NNC0519-0130 Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT06326047
Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05521256
NNC0113-6856 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05521256
Placebo Other Phase PHASE1 Chronic Kidney Disease and Systemic Inflammation COMPLETED NCT05379829
Ziltivekimab Other Phase PHASE1 Chronic Kidney Disease and Systemic Inflammation COMPLETED NCT05379829
Placebo (NNC0519-0130) Other Phase PHASE1 Healthy Volunteers (Diabetes Mellitus, Type 2) COMPLETED NCT05363774
NNC0519-0130 Other Phase PHASE1 Healthy Volunteers (Diabetes Mellitus, Type 2) COMPLETED NCT05363774
Fast-acting insulin aspart Other Preclinical Diabetes Mellitus, Type 1 COMPLETED NCT05069545
Insulin degludec Other Preclinical Diabetes Mellitus, Type 1 COMPLETED NCT05069545
Xultophy® (insulin degludec/liraglutide) Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04952779
semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04469855
Ziltivekimab Other Phase PHASE2 Chronic Kidney Diseases COMPLETED NCT03926117
NNC0363-1063 Other Phase PHASE1 Diabetes Mellitus, Type 1 RECRUITING NCT07305805
Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT07023029
Moxifloxacin Other Phase PHASE1 Healthy Volunteers COMPLETED NCT07023029
Etavopivat Other Phase PHASE1 Healthy Volunteers COMPLETED NCT07023029
turoctocog alfa pegol (N8-GP) Other Phase PHASE3 Haemophilia A COMPLETED NCT05082116
Norditropin® Other Phase PHASE3 Growth Hormone Deficiency in Children COMPLETED NCT04970654
somapacitan Other Phase PHASE3 Growth Hormone Deficiency in Children COMPLETED NCT04970654
Norditropin® Other Phase PHASE3 Growth Hormone Deficiency in Children COMPLETED NCT03811535
Somapacitan Other Phase PHASE3 Growth Hormone Deficiency in Children COMPLETED NCT03811535
Semaglutide (administered by PDS290 pen-injector) Other Preclinical Monogenic Obesity RECRUITING NCT07302802
Placebo Other Phase PHASE1 Overweight COMPLETED NCT06267092
Cagrilintide and Semaglutide Other Phase PHASE1 Overweight COMPLETED NCT06267092
No treatment given Drug Phase PHASE1 Overweight COMPLETED NCT06267092
Placebo Other Phase PHASE1 Obesity COMPLETED NCT06207877
Semaglutide Other Phase PHASE1 Obesity COMPLETED NCT06207877
Cagrilintide Other Phase PHASE1 Obesity COMPLETED NCT06207877
Semaglutide 2.4 mg and placebo 1.0 mg Other Phase PHASE2 Obesity COMPLETED NCT04969939
Semaglutide 2.4 mg and NNC0165-1875 1.0 mg Other Phase PHASE2 Obesity COMPLETED NCT04969939
Semaglutide 2.4 mg and placebo 2.0 mg Other Phase PHASE2 Obesity COMPLETED NCT04969939
Semaglutide 2.4 mg and NNC0165-1875 2.0 mg Other Phase PHASE2 Obesity COMPLETED NCT04969939
Liraglutide Other Preclinical Obesity COMPLETED NCT06283641
Insulin degludec Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT06153537
Placebo Cagrilintide Other Phase PHASE3 Obesity or Overweight COMPLETED NCT05996848
Placebo Semaglutide Other Phase PHASE3 Obesity or Overweight COMPLETED NCT05996848
Semaglutide Other Phase PHASE3 Obesity or Overweight COMPLETED NCT05996848
Cagrilintide Other Phase PHASE3 Obesity or Overweight COMPLETED NCT05996848
Telemedicine behavioral weight program Other Phase PHASE2 Endometrial Hyperplasia WITHDRAWN NCT05829460
LNG-IUD (Progestin) Other Phase PHASE2 Endometrial Hyperplasia WITHDRAWN NCT05829460
Placebo Other Phase PHASE2 Endometrial Hyperplasia WITHDRAWN NCT05829460
Semaglutide Other Phase PHASE2 Endometrial Hyperplasia WITHDRAWN NCT05829460
Nonacog beta pegol Other Phase PHASE3 Haemophilia B COMPLETED NCT05365217
Placebo Other Phase PHASE3 Overweight COMPLETED NCT06041217
Semaglutide Other Phase PHASE3 Overweight COMPLETED NCT06041217
Liraglutide Other Phase PHASE4 Obesity COMPLETED NCT05579249
Naltrexone/Bupropion Other Phase PHASE4 Obesity COMPLETED NCT05579249
Phentermine/Topiramate Other Phase PHASE4 Obesity COMPLETED NCT05579249
Orlistat Other Phase PHASE4 Obesity COMPLETED NCT05579249
Semaglutide Other Phase PHASE4 Obesity COMPLETED NCT05579249
No Intervention Other Preclinical Pregnancy ENROLLING_BY_INVITATION NCT05503927
Conventional TURB Other Approved Non-muscle Invasive Bladder Cancer COMPLETED NCT05223491
En Bloc resection Other Approved Non-muscle Invasive Bladder Cancer COMPLETED NCT05223491
Norditropin® FlexPro® pen Other Phase PHASE2 Growth Hormone Disorder COMPLETED NCT02616562
somapacitan Other Phase PHASE2 Growth Hormone Disorder COMPLETED NCT02616562
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT06780449
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT06780449
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT06780449
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT06780449
Placebo Other Phase PHASE3 Intracerebral Hemorrhage ACTIVE_NOT_RECRUITING NCT03496883
Recombinant Activated Factor VII (rFVIIa) Other Phase PHASE3 Intracerebral Hemorrhage ACTIVE_NOT_RECRUITING NCT03496883
Placebo semaglutide Other Phase PHASE3 Type 2 Diabetes Mellitus COMPLETED NCT06065540
Placebo cagrilintide Other Phase PHASE3 Type 2 Diabetes Mellitus COMPLETED NCT06065540
Semaglutide Other Phase PHASE3 Type 2 Diabetes Mellitus COMPLETED NCT06065540
Cagrilintide Other Phase PHASE3 Type 2 Diabetes Mellitus COMPLETED NCT06065540
Semaglutide Placebo Other Phase PHASE3 Overweight COMPLETED NCT05890976
Semaglutide Other Phase PHASE3 Overweight COMPLETED NCT05890976
Placebo Semaglutide Other Phase PHASE3 Obesity or Overweight COMPLETED NCT05813925
Semaglutide Other Phase PHASE3 Obesity or Overweight COMPLETED NCT05813925
Cagrilintide Other Phase PHASE3 Obesity or Overweight COMPLETED NCT05813925
Semaglutide Other Phase PHASE1 Obesity RECRUITING NCT07225816
Oral Semaglutide Other Phase PHASE1 Obesity RECRUITING NCT07225816
Liraglutide Other Phase PHASE1 Obesity RECRUITING NCT07225816
Detemir Other Approved Diabetes ACTIVE_NOT_RECRUITING NCT01239550
Nicotinamide Riboside 1g (oral) Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Quercetin 1.250 mg (oral) Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Dasatinib 100 Mg Oral Tablet Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Nicotinamide Riboside 1g (oral) Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Quercetin 1.250 mg (oral) Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Dasatinib 100 Mg Oral Tablet Other Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Placebo semaglutide Other Phase PHASE3 Overweight COMPLETED NCT05394519
Placebo cagrilintide Other Phase PHASE3 Overweight COMPLETED NCT05394519
Semaglutide Other Phase PHASE3 Overweight COMPLETED NCT05394519
Cagrilintide Other Phase PHASE3 Overweight COMPLETED NCT05394519
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05040971
Semaglutide 2.4 mg Other Phase PHASE3 Obesity COMPLETED NCT05040971
Placebo (semaglutide) Other Phase PHASE3 Overweight COMPLETED NCT04251156
Semaglutide Other Phase PHASE3 Overweight COMPLETED NCT04251156
Glugagon Other Approved Metabolic Associated Fatty Liver Disease RECRUITING NCT07246421
Tirzepatide Other Phase PHASE3 Obesity COMPLETED NCT06131437
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT06131437
Cagrilintide Other Phase PHASE3 Obesity COMPLETED NCT06131437
Placebo (Semaglutide) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04865770
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04865770
Placebo Other Phase PHASE1 Fatty Liver Disease RECRUITING NCT07214870
NNC4005-001 Other Phase PHASE1 Fatty Liver Disease RECRUITING NCT07214870
No treatment given Drug Preclinical Atherosclerotic Cardiovascular Disease COMPLETED NCT07160829
Semaglutide Other Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT06478550
NNC0194-0499 Other Phase PHASE1 Hepatic Impairment COMPLETED NCT05917938
No treatment given Drug Preclinical Overweight COMPLETED NCT04972721
Beta-blocker treatment group Drug Phase PHASE4 Idiopathic Ventricular Fibrillation RECRUITING NCT07405229
Turoctocog alfa Other Preclinical Congenital Bleeding Disorder RECRUITING NCT06574984
Concizumab Other Preclinical Congenital Haemophilia AVAILABLE NCT04921956
Placebo A Other Phase PHASE1 Overweight COMPLETED NCT07121153
NNC0487-0111 A Other Phase PHASE1 Overweight COMPLETED NCT07121153
Placebo Other Phase PHASE3 Alzheimers Disease COMPLETED NCT05891496
Semaglutide Other Phase PHASE3 Alzheimers Disease COMPLETED NCT05891496
Placebo (NNC6989-0001 A) Other Phase PHASE1 Overweight RECRUITING NCT07437079
NNC6989-0001 A Other Phase PHASE1 Overweight RECRUITING NCT07437079
Placebo cagrilintide Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT06403761
Placebo semaglutide Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT06403761
Cagrilintide Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT06403761
Semaglutide Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT06403761
There is no intervention Other Preclinical Diabetic Nephropathies RECRUITING NCT02986984
Mineralocorticoid Receptor Antagonists(MRAs) Other Preclinical Diabetic Nephropathies RECRUITING NCT07444203
Glucagon-like peptide-1 receptor agonists (GLP 1 RA) Other Preclinical Diabetic Nephropathies RECRUITING NCT07444203
Renin-angiotensin-aldosterone system blockade Other Preclinical Diabetic Nephropathies RECRUITING NCT07444203
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) Other Preclinical Diabetic Nephropathies RECRUITING NCT07444203
CH-reduced diet with exercise Other Approved Type 2 Diabetes RECRUITING NCT07262788
CH-rich diet with exercise Other Approved Type 2 Diabetes RECRUITING NCT07262788
Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs Other Approved Type 2 Diabetes COMPLETED NCT06111508
Semaglutide Other Preclinical Obesity ENROLLING_BY_INVITATION NCT07055607
INV-347 Other Phase PHASE1 Obesity RECRUITING NCT07153172
D-β-hydroxybutyrate/D 1,3 butanediol monoester Other Approved Aging COMPLETED NCT05732909
Placebo Other Phase PHASE2 Diabetes Mellitus, Type 2 NOT_YET_RECRUITING NCT07415954
Semaglutide Other Phase PHASE2 Diabetes Mellitus, Type 2 NOT_YET_RECRUITING NCT07415954
NNC0662-0419 Other Phase PHASE2 Diabetes Mellitus, Type 2 NOT_YET_RECRUITING NCT07415954
Ziltivekimab Placebo Other Phase PHASE3 Myocardial Infarction RECRUITING NCT07301034
Ziltivekimab Other Phase PHASE3 Myocardial Infarction RECRUITING NCT07301034
Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT07029568
NNC0705-0001 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT07029568
Placebo Other Phase PHASE2 Heart Failure RECRUITING NCT06979375
CDR132L Other Phase PHASE2 Heart Failure RECRUITING NCT06979375
Placebo Other Phase PHASE2 Heart Failure RECRUITING NCT06979362
CDR132L Other Phase PHASE2 Heart Failure RECRUITING NCT06979362
Semaglutide Other Phase PHASE2 Chronic Kidney Disease RECRUITING NCT06717698
Placebo Other Phase PHASE2 Chronic Kidney Disease RECRUITING NCT06717698
NNC0519-0130 Other Phase PHASE2 Chronic Kidney Disease RECRUITING NCT06717698
Placebo Other Phase PHASE3 Heart Failure RECRUITING NCT05636176
Ziltivekimab Other Phase PHASE3 Heart Failure RECRUITING NCT05636176
Placebo (semaglutide) Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04596631
Oral semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04596631
Placebo (semaglutide) Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT03811561
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT03811561
No treatment given Drug Preclinical Metabolic Dysfunction-associated Steatohepatitis (MASH) COMPLETED NCT07201831
Paracetamol Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT06513104
Levonorgestrel + Ethinylestradiol Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT06513104
NNC0519-0130 Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT06513104
Semaglutide placebo (Group B) Other Phase PHASE2 Alcohol-related Liver Disease COMPLETED NCT06409130
Cagrilintide placebo Other Phase PHASE2 Alcohol-related Liver Disease COMPLETED NCT06409130
Cagrilintide Other Phase PHASE2 Alcohol-related Liver Disease COMPLETED NCT06409130
Cagrilintide + semaglutide Other Phase PHASE2 Alcohol-related Liver Disease COMPLETED NCT06409130
Semaglutide placebo (Group A) Other Phase PHASE2 Alcohol-related Liver Disease COMPLETED NCT06409130
NNC0194-0499 placebo Other Phase PHASE2 Alcohol-related Liver Disease COMPLETED NCT06409130
Semaglutide Other Phase PHASE2 Alcohol-related Liver Disease COMPLETED NCT06409130
NNC0194-0499 Other Phase PHASE2 Alcohol-related Liver Disease COMPLETED NCT06409130
Placebo Other Phase PHASE3 Cardiovascular Disease ACTIVE_NOT_RECRUITING NCT05669755
Semaglutide Other Phase PHASE3 Cardiovascular Disease ACTIVE_NOT_RECRUITING NCT05669755
Cagrilintide Other Phase PHASE3 Cardiovascular Disease ACTIVE_NOT_RECRUITING NCT05669755
Placebo (NNC0638-0355) Other Phase PHASE1 Obesity ACTIVE_NOT_RECRUITING NCT06577766
NNC0638-0355 Other Phase PHASE1 Obesity ACTIVE_NOT_RECRUITING NCT06577766
Placebo Other Phase PHASE3 Coronary Artery Disease RECRUITING NCT07276282
Ziltivekimab Other Phase PHASE3 Coronary Artery Disease RECRUITING NCT07276282
Etavopivat C Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06609226
Etavopivat B Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06609226
Etavopivat A Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06609226
Concizumab Other Phase PHASE3 Haemophilia A With Inhibitors ACTIVE_NOT_RECRUITING NCT04083781
Concizumab Other Phase PHASE3 Haemophilia A Without Inhibitors ACTIVE_NOT_RECRUITING NCT04082429
Placebo Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT06388187
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT06388187
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT06388187
Inactivity Other Approved Overweight RECRUITING NCT06240208
Placebo semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Placebo cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05567796
Oral semaglutide Other Phase PHASE3 Type 2 Diabetes ACTIVE_NOT_RECRUITING NCT07271251
Placebo Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT07004322
NNC0519-0130 Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT07004322
Placebo Other Phase PHASE1 Haemophilia A COMPLETED NCT06649630
NNC0442-0344 A Other Phase PHASE1 Haemophilia A COMPLETED NCT06649630
Placebo Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT06131372
Semaglutide Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT06131372
Cagrilintide Other Phase PHASE2 Chronic Kidney Disease COMPLETED NCT06131372
Placebo semaglutide Other Phase PHASE3 Overweight RECRUITING NCT07253285
Placebo cagrilintide Other Phase PHASE3 Overweight RECRUITING NCT07253285
Semaglutide Other Phase PHASE3 Overweight RECRUITING NCT07253285
Cagrilintide Other Phase PHASE3 Overweight RECRUITING NCT07253285
Placebo Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06323174
Semaglutide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06323174
Cagrilintide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06323174
Semaglutide Other Phase PHASE1 Diabetes Mellitus, Type 1 ACTIVE_NOT_RECRUITING NCT07087795
Placebo Other Phase PHASE1 Diabetes Mellitus, Type 1 ACTIVE_NOT_RECRUITING NCT07087795
NNC0194-0499 Other Phase PHASE1 Diabetes Mellitus, Type 1 ACTIVE_NOT_RECRUITING NCT07087795
NNC0519-0130 Other Phase PHASE1 Obesity COMPLETED NCT06718998
lifestyle change program Other Preclinical Obesity and Cardiovascular Risk ENROLLING_BY_INVITATION NCT07404150
Insulin icodec Other Preclinical Diabetes Mellitus, Type 1 RECRUITING NCT07160816
Basal insulin analogues Other Phase PHASE4 Diabetes Mellitus, Type 2 RECRUITING NCT07112339
Insulin icodec Other Phase PHASE4 Diabetes Mellitus, Type 2 RECRUITING NCT07112339
Insulin aspart Other Phase PHASE3 Diabetes Mellitus, Type 1 RECRUITING NCT07076199
Insulin glargine Other Phase PHASE3 Diabetes Mellitus, Type 1 RECRUITING NCT07076199
Insulin icodec Other Phase PHASE3 Diabetes Mellitus, Type 1 RECRUITING NCT07076199
Sitagliptin 100mg Other Phase PHASE4 Liver Transplant; Complications ENROLLING_BY_INVITATION NCT05195944
Semaglutide Treatment Drug Phase PHASE4 Liver Transplant; Complications ENROLLING_BY_INVITATION NCT05195944
Etavopivat Tablets Other Phase PHASE3 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT04624659
Placebo Tablets Other Phase PHASE3 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT04624659
Etavopivat Tablets High dose Other Phase PHASE3 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT04624659
Etavopivat Tablets Low dose Other Phase PHASE3 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT04624659
Etavopivat Tablets Other Phase PHASE3 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT04624659
Placebo Tablets Other Phase PHASE3 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT04624659
Etavopivat Tablets High dose Other Phase PHASE3 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT04624659
Etavopivat Tablets Low dose Other Phase PHASE3 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT04624659
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Obesity RECRUITING NCT07339423
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07339423
Insulin Aspart Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT07068295
NNC0471-0119 H Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT07068295
Placebo (NNC0581-0001) Other Phase PHASE1 Healthy Volunteers RECRUITING NCT06891365
NNC0581-0001 Other Phase PHASE1 Healthy Volunteers RECRUITING NCT06891365
NNC0519-0130 Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT06370819
Placebo Other Phase PHASE3 Heart Failure RECRUITING NCT06200207
Ziltivekimab Other Phase PHASE3 Heart Failure RECRUITING NCT06200207
Mim8 Other Phase PHASE3 Haemophilia A ACTIVE_NOT_RECRUITING NCT05685238
Placebo Other Phase PHASE2 Alpha 1-Antitrypsin Deficiency TERMINATED NCT04764448
Belcesiran Other Phase PHASE2 Alpha 1-Antitrypsin Deficiency TERMINATED NCT04764448
Placebo Other Phase PHASE2 Alpha 1-Antitrypsin Deficiency TERMINATED NCT04764448
Belcesiran Other Phase PHASE2 Alpha 1-Antitrypsin Deficiency TERMINATED NCT04764448
Placebo Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT07220642
Cagrilintide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT07220642
No treatment given Drug Preclinical Obesity COMPLETED NCT06843473
Tirzepatide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Cagrilintide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Etavopivat Other Phase PHASE2 Sickle Cell Disease COMPLETED NCT05725902
Standard of Care (SOC) Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 50 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 15 mL Other Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
DuraTouch® Other Preclinical Diabetes Mellitus, Type 1 COMPLETED NCT07052292
Insulin Icodec Other Preclinical Diabetes Mellitus, Type 1 RECRUITING NCT06807190
Insulin detemir Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT06685185
Insulin degludec Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT06685185
Placebo Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT06685185
NNC0363-1063 Other Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT06685185
Insulin glargine Other Phase PHASE3 Diabetes, Type 2 COMPLETED NCT06340854
Insulin icodec Other Phase PHASE3 Diabetes, Type 2 COMPLETED NCT06340854
Insulin glargine Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06269107
IcoSema Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06269107
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05813912
Insulin Icodec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05813912
Insulin icodec Other Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05790681
Somapacitan Other Preclinical Adult Growth Hormone Deficiency ENROLLING_BY_INVITATION NCT05718570
Placebo (semaglutide) Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT05144984
Placebo (NNC080-0389) Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT05144984
Semaglutide Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT05144984
NNC0480-0389 Other Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT05144984
Faster-acting insulin aspart Other Preclinical Diabetes Mellitus, Type 1 COMPLETED NCT03987802
Coramitug Other Phase PHASE1 Transthyretin Amyloid Cardiomyopathy RECRUITING NCT07448623
Somapacitan Other Preclinical Adult Growth Hormone Deficiency ACTIVE_NOT_RECRUITING NCT05230550
Placebo (Ziltivekimab C) Other Phase PHASE3 Cardiovascular Risk ACTIVE_NOT_RECRUITING NCT05021835
Placebo (Ziltivekimab B) Other Phase PHASE3 Cardiovascular Risk ACTIVE_NOT_RECRUITING NCT05021835
Ziltivekimab C Other Phase PHASE3 Cardiovascular Risk ACTIVE_NOT_RECRUITING NCT05021835
Ziltivekimab B Other Phase PHASE3 Cardiovascular Risk ACTIVE_NOT_RECRUITING NCT05021835
liraglutide 3.0 mg Other Preclinical Obesity COMPLETED NCT02773355
Placebo Other Phase PHASE3 Cardiovascular Risk RECRUITING NCT06118281
Ziltivekimab Other Phase PHASE3 Cardiovascular Risk RECRUITING NCT06118281
Tirzepatide Other Phase PHASE2 Obesity COMPLETED NCT06326060
Placebo Other Phase PHASE2 Obesity COMPLETED NCT06326060
NNC0519-0130 Other Phase PHASE2 Obesity COMPLETED NCT06326060
No treatment given Drug Preclinical Diabetes Mellitus, Type 2 RECRUITING NCT07532863
nedosiran Other Phase PHASE2 Primary Hyperoxaluria COMPLETED NCT05001269
Placebo Other Phase PHASE2 Overweight RECRUITING NCT07395687
UBT251 Other Phase PHASE2 Overweight RECRUITING NCT07395687
Biological/Vaccine: Placebo Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Recombinant Factor VIIa Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Semaglutide Other Preclinical Obesity ACTIVE_NOT_RECRUITING NCT06283667
Placebo Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05646706
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05646706
Placebo Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
NNC0487-0111 Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
Acetaminophen Other Phase PHASE1 Overweight RECRUITING NCT07525791
Oral contraceptive Other Phase PHASE1 Overweight RECRUITING NCT07525791
NNC0662-0419 Other Phase PHASE1 Overweight RECRUITING NCT07525791
NNC0442-0344 A Other Phase PHASE1 Haemophilia A RECRUITING NCT07220564
High carbohydrate liquid test meal Other Approved Obesity RECRUITING NCT06752967
High protein liquid test meal Other Approved Obesity RECRUITING NCT06752967
Placebo Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Etavopivat Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Etavopivat Other Phase PHASE2 Sickle Cell Disease RECRUITING NCT06198712
Norditropin® Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Somapacitan Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Refixia® Other Preclinical Haemophilia B COMPLETED NCT03875547
Insulin Icodec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05823948
Placebo Cagrilintide Other Phase PHASE1 Overweight NOT_YET_RECRUITING NCT07557953
Cagrilintide Other Phase PHASE1 Overweight NOT_YET_RECRUITING NCT07557953
Placebo (semaglutide) Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT03811561
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT03811561
No intervention (observational study) Other Preclinical Diabetes Mellitus COMPLETED NCT07560059
Insulin Icodec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05823948
Placebo Cagrilintide Other Phase PHASE1 Overweight NOT_YET_RECRUITING NCT07557953
Cagrilintide Other Phase PHASE1 Overweight NOT_YET_RECRUITING NCT07557953
Placebo (semaglutide) Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT03811561
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT03811561
No intervention (observational study) Other Preclinical Diabetes Mellitus COMPLETED NCT07560059
Placebo (NNC6019-0001) Other Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
NNC6019-0001 Other Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
Placebo (semaglutide) Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT03811561
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT03811561
Placebo Cagrilintide Other Phase PHASE1 Overweight NOT_YET_RECRUITING NCT07557953
Cagrilintide Other Phase PHASE1 Overweight NOT_YET_RECRUITING NCT07557953
No intervention (observational study) Other Preclinical Diabetes Mellitus COMPLETED NCT07560059
Insulin Icodec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05823948
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Diabetes Mellitus RECRUITING NCT07533175
NNC0487-0111 Other Phase PHASE3 Diabetes Mellitus RECRUITING NCT07533175
Placebo (matched to NNC0487-0111) Other Phase PHASE1 Obesity RECRUITING NCT07508020
NNC0487-0111 Other Phase PHASE1 Obesity RECRUITING NCT07508020
Placebo Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
NNC0662-0419 Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
Semaglutide Other Preclinical Obesity TERMINATED NCT07081178
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
No intervention (observational study) Other Preclinical Diabetes Mellitus COMPLETED NCT07560059
Placebo Cagrilintide Other Phase PHASE1 Overweight NOT_YET_RECRUITING NCT07557953
Cagrilintide Other Phase PHASE1 Overweight NOT_YET_RECRUITING NCT07557953
Placebo (semaglutide) Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT03811561
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT03811561
Placebo Cagrilintide Other Phase PHASE1 Overweight NOT_YET_RECRUITING NCT07557953
Cagrilintide Other Phase PHASE1 Overweight NOT_YET_RECRUITING NCT07557953
No intervention (observational study) Other Preclinical Diabetes Mellitus COMPLETED NCT07560059
Insulin Icodec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05823948
Placebo (semaglutide) Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT03811561
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT03811561
Placebo Cagrilintide Other Phase PHASE1 Overweight NOT_YET_RECRUITING NCT07557953
Cagrilintide Other Phase PHASE1 Overweight NOT_YET_RECRUITING NCT07557953
No intervention (observational study) Other Preclinical Diabetes Mellitus COMPLETED NCT07560059
Insulin Icodec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05823948
Physical activity monitoring and recommendations Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Complex lifestyle intervention Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Somapacitan Other Preclinical Growth Hormone Deficiency in Children ENROLLING_BY_INVITATION NCT06109935
Somapacitan Other Preclinical Growth Hormone Deficiency in Children ENROLLING_BY_INVITATION NCT06109935
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Placebo (semaglutide) Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT03811561
Semaglutide Other Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT03811561
Physical activity monitoring and recommendations Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Complex lifestyle intervention Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Placebo Cagrilintide Other Phase PHASE1 Overweight NOT_YET_RECRUITING NCT07557953
Cagrilintide Other Phase PHASE1 Overweight NOT_YET_RECRUITING NCT07557953
No intervention (observational study) Other Preclinical Diabetes Mellitus COMPLETED NCT07560059
Insulin Icodec Other Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05823948
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05649137
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05649137
Physical activity monitoring and recommendations Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Complex lifestyle intervention Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Somapacitan Other Preclinical Growth Hormone Deficiency in Children ENROLLING_BY_INVITATION NCT06109935
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Physical activity monitoring and recommendations Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Complex lifestyle intervention Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Somapacitan Other Preclinical Growth Hormone Deficiency in Children ENROLLING_BY_INVITATION NCT06109935
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Physical activity monitoring and recommendations Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Complex lifestyle intervention Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Somapacitan Other Preclinical Growth Hormone Deficiency in Children ENROLLING_BY_INVITATION NCT06109935
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Physical activity monitoring and recommendations Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Complex lifestyle intervention Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Somapacitan Other Preclinical Growth Hormone Deficiency in Children ENROLLING_BY_INVITATION NCT06109935
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Physical activity monitoring and recommendations Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Complex lifestyle intervention Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Somapacitan Other Preclinical Growth Hormone Deficiency in Children ENROLLING_BY_INVITATION NCT06109935
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Physical activity monitoring and recommendations Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Complex lifestyle intervention Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Somapacitan Other Preclinical Growth Hormone Deficiency in Children ENROLLING_BY_INVITATION NCT06109935
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Physical activity monitoring and recommendations Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Complex lifestyle intervention Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Somapacitan Other Preclinical Growth Hormone Deficiency in Children ENROLLING_BY_INVITATION NCT06109935
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Physical activity monitoring and recommendations Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Complex lifestyle intervention Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Somapacitan Other Preclinical Growth Hormone Deficiency in Children ENROLLING_BY_INVITATION NCT06109935
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Physical activity monitoring and recommendations Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Complex lifestyle intervention Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Somapacitan Other Preclinical Growth Hormone Deficiency in Children ENROLLING_BY_INVITATION NCT06109935
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Physical activity monitoring and recommendations Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Complex lifestyle intervention Other Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Somapacitan Other Preclinical Growth Hormone Deficiency in Children ENROLLING_BY_INVITATION NCT06109935
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Placebo Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
NNC0662-0419 Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05649137
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05649137
Placebo (matched to NNC0487-0111) Other Phase PHASE1 Obesity RECRUITING NCT07508020
NNC0487-0111 Other Phase PHASE1 Obesity RECRUITING NCT07508020
Placebo (NNC6019-0001) Other Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
NNC6019-0001 Other Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Semaglutide Other Preclinical Obesity TERMINATED NCT07081178
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Diabetes Mellitus RECRUITING NCT07533175
NNC0487-0111 Other Phase PHASE3 Diabetes Mellitus RECRUITING NCT07533175
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Placebo Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
NNC0662-0419 Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
Placebo (matched to NNC0487-0111) Other Phase PHASE1 Obesity RECRUITING NCT07508020
NNC0487-0111 Other Phase PHASE1 Obesity RECRUITING NCT07508020
Semaglutide Other Preclinical Obesity TERMINATED NCT07081178
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05649137
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05649137
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Diabetes Mellitus RECRUITING NCT07533175
NNC0487-0111 Other Phase PHASE3 Diabetes Mellitus RECRUITING NCT07533175
Placebo (NNC6019-0001) Other Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
NNC6019-0001 Other Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Placebo Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
NNC0662-0419 Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
Placebo (matched to NNC0487-0111) Other Phase PHASE1 Obesity RECRUITING NCT07508020
NNC0487-0111 Other Phase PHASE1 Obesity RECRUITING NCT07508020
Semaglutide Other Preclinical Obesity TERMINATED NCT07081178
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05649137
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05649137
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Diabetes Mellitus RECRUITING NCT07533175
NNC0487-0111 Other Phase PHASE3 Diabetes Mellitus RECRUITING NCT07533175
Placebo (NNC6019-0001) Other Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
NNC6019-0001 Other Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Placebo Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
NNC0662-0419 Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
Placebo (matched to NNC0487-0111) Other Phase PHASE1 Obesity RECRUITING NCT07508020
NNC0487-0111 Other Phase PHASE1 Obesity RECRUITING NCT07508020
Semaglutide Other Preclinical Obesity TERMINATED NCT07081178
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05649137
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05649137
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Diabetes Mellitus RECRUITING NCT07533175
NNC0487-0111 Other Phase PHASE3 Diabetes Mellitus RECRUITING NCT07533175
Placebo (NNC6019-0001) Other Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
NNC6019-0001 Other Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Placebo Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
NNC0662-0419 Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
Placebo (matched to NNC0487-0111) Other Phase PHASE1 Obesity RECRUITING NCT07508020
NNC0487-0111 Other Phase PHASE1 Obesity RECRUITING NCT07508020
Semaglutide Other Preclinical Obesity TERMINATED NCT07081178
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05649137
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05649137
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Diabetes Mellitus RECRUITING NCT07533175
NNC0487-0111 Other Phase PHASE3 Diabetes Mellitus RECRUITING NCT07533175
Placebo (NNC6019-0001) Other Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
NNC6019-0001 Other Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Placebo Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
NNC0662-0419 Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
Placebo (matched to NNC0487-0111) Other Phase PHASE1 Obesity RECRUITING NCT07508020
NNC0487-0111 Other Phase PHASE1 Obesity RECRUITING NCT07508020
Semaglutide Other Preclinical Obesity TERMINATED NCT07081178
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05649137
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05649137
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Diabetes Mellitus RECRUITING NCT07533175
NNC0487-0111 Other Phase PHASE3 Diabetes Mellitus RECRUITING NCT07533175
Placebo (NNC6019-0001) Other Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
NNC6019-0001 Other Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
Placebo (matched to NNC0487-0111 ) Other Phase PHASE3 Obesity RECRUITING NCT07481630
NNC0487-0111 Other Phase PHASE3 Obesity RECRUITING NCT07481630
Placebo Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
NNC0662-0419 Other Phase PHASE2 Overweight ACTIVE_NOT_RECRUITING NCT07184632
Placebo (matched to NNC0487-0111) Other Phase PHASE1 Obesity RECRUITING NCT07508020
NNC0487-0111 Other Phase PHASE1 Obesity RECRUITING NCT07508020
Semaglutide Other Preclinical Obesity TERMINATED NCT07081178
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05649137
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05649137
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Diabetes Mellitus RECRUITING NCT07533175
NNC0487-0111 Other Phase PHASE3 Diabetes Mellitus RECRUITING NCT07533175
Placebo (NNC6019-0001) Other Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
NNC6019-0001 Other Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
Placebo Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Etavopivat Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Refixia® Other Preclinical Haemophilia B COMPLETED NCT03875547
Etavopivat Other Phase PHASE2 Sickle Cell Disease RECRUITING NCT06198712
NNC0442-0344 A Other Phase PHASE1 Haemophilia A RECRUITING NCT07220564
Acetaminophen Other Phase PHASE1 Overweight RECRUITING NCT07525791
Oral contraceptive Other Phase PHASE1 Overweight RECRUITING NCT07525791
NNC0662-0419 Other Phase PHASE1 Overweight RECRUITING NCT07525791
Norditropin® Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Somapacitan Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Placebo Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
NNC0487-0111 Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
High carbohydrate liquid test meal Other Approved Obesity RECRUITING NCT06752967
High protein liquid test meal Other Approved Obesity RECRUITING NCT06752967
Placebo Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Etavopivat Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Refixia® Other Preclinical Haemophilia B COMPLETED NCT03875547
Etavopivat Other Phase PHASE2 Sickle Cell Disease RECRUITING NCT06198712
NNC0442-0344 A Other Phase PHASE1 Haemophilia A RECRUITING NCT07220564
Acetaminophen Other Phase PHASE1 Overweight RECRUITING NCT07525791
Oral contraceptive Other Phase PHASE1 Overweight RECRUITING NCT07525791
NNC0662-0419 Other Phase PHASE1 Overweight RECRUITING NCT07525791
Norditropin® Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Somapacitan Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Placebo Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
NNC0487-0111 Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
High carbohydrate liquid test meal Other Approved Obesity RECRUITING NCT06752967
High protein liquid test meal Other Approved Obesity RECRUITING NCT06752967
Placebo Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Etavopivat Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Refixia® Other Preclinical Haemophilia B COMPLETED NCT03875547
Etavopivat Other Phase PHASE2 Sickle Cell Disease RECRUITING NCT06198712
NNC0442-0344 A Other Phase PHASE1 Haemophilia A RECRUITING NCT07220564
Acetaminophen Other Phase PHASE1 Overweight RECRUITING NCT07525791
Oral contraceptive Other Phase PHASE1 Overweight RECRUITING NCT07525791
NNC0662-0419 Other Phase PHASE1 Overweight RECRUITING NCT07525791
Norditropin® Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Somapacitan Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Placebo Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
NNC0487-0111 Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
High carbohydrate liquid test meal Other Approved Obesity RECRUITING NCT06752967
High protein liquid test meal Other Approved Obesity RECRUITING NCT06752967
Placebo Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Etavopivat Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Refixia® Other Preclinical Haemophilia B COMPLETED NCT03875547
Etavopivat Other Phase PHASE2 Sickle Cell Disease RECRUITING NCT06198712
NNC0442-0344 A Other Phase PHASE1 Haemophilia A RECRUITING NCT07220564
Acetaminophen Other Phase PHASE1 Overweight RECRUITING NCT07525791
Oral contraceptive Other Phase PHASE1 Overweight RECRUITING NCT07525791
NNC0662-0419 Other Phase PHASE1 Overweight RECRUITING NCT07525791
Norditropin® Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Somapacitan Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Placebo Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
NNC0487-0111 Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
High carbohydrate liquid test meal Other Approved Obesity RECRUITING NCT06752967
High protein liquid test meal Other Approved Obesity RECRUITING NCT06752967
Placebo Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Etavopivat Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Refixia® Other Preclinical Haemophilia B COMPLETED NCT03875547
Etavopivat Other Phase PHASE2 Sickle Cell Disease RECRUITING NCT06198712
NNC0442-0344 A Other Phase PHASE1 Haemophilia A RECRUITING NCT07220564
Acetaminophen Other Phase PHASE1 Overweight RECRUITING NCT07525791
Oral contraceptive Other Phase PHASE1 Overweight RECRUITING NCT07525791
NNC0662-0419 Other Phase PHASE1 Overweight RECRUITING NCT07525791
Norditropin® Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Somapacitan Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Placebo Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
NNC0487-0111 Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
High carbohydrate liquid test meal Other Approved Obesity RECRUITING NCT06752967
High protein liquid test meal Other Approved Obesity RECRUITING NCT06752967
Placebo Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Etavopivat Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Refixia® Other Preclinical Haemophilia B COMPLETED NCT03875547
Etavopivat Other Phase PHASE2 Sickle Cell Disease RECRUITING NCT06198712
NNC0442-0344 A Other Phase PHASE1 Haemophilia A RECRUITING NCT07220564
Acetaminophen Other Phase PHASE1 Overweight RECRUITING NCT07525791
Oral contraceptive Other Phase PHASE1 Overweight RECRUITING NCT07525791
NNC0662-0419 Other Phase PHASE1 Overweight RECRUITING NCT07525791
Norditropin® Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Somapacitan Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Placebo Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
NNC0487-0111 Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
High carbohydrate liquid test meal Other Approved Obesity RECRUITING NCT06752967
High protein liquid test meal Other Approved Obesity RECRUITING NCT06752967
Placebo Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Etavopivat Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Refixia® Other Preclinical Haemophilia B COMPLETED NCT03875547
Etavopivat Other Phase PHASE2 Sickle Cell Disease RECRUITING NCT06198712
NNC0442-0344 A Other Phase PHASE1 Haemophilia A RECRUITING NCT07220564
Acetaminophen Other Phase PHASE1 Overweight RECRUITING NCT07525791
Oral contraceptive Other Phase PHASE1 Overweight RECRUITING NCT07525791
NNC0662-0419 Other Phase PHASE1 Overweight RECRUITING NCT07525791
Norditropin® Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Somapacitan Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Placebo Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
NNC0487-0111 Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
High carbohydrate liquid test meal Other Approved Obesity RECRUITING NCT06752967
High protein liquid test meal Other Approved Obesity RECRUITING NCT06752967
Placebo Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Etavopivat Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Refixia® Other Preclinical Haemophilia B COMPLETED NCT03875547
Etavopivat Other Phase PHASE2 Sickle Cell Disease RECRUITING NCT06198712
NNC0442-0344 A Other Phase PHASE1 Haemophilia A RECRUITING NCT07220564
Acetaminophen Other Phase PHASE1 Overweight RECRUITING NCT07525791
Oral contraceptive Other Phase PHASE1 Overweight RECRUITING NCT07525791
NNC0662-0419 Other Phase PHASE1 Overweight RECRUITING NCT07525791
Norditropin® Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Somapacitan Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Placebo Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
NNC0487-0111 Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
High carbohydrate liquid test meal Other Approved Obesity RECRUITING NCT06752967
High protein liquid test meal Other Approved Obesity RECRUITING NCT06752967
Placebo Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Etavopivat Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Refixia® Other Preclinical Haemophilia B COMPLETED NCT03875547
Etavopivat Other Phase PHASE2 Sickle Cell Disease RECRUITING NCT06198712
NNC0442-0344 A Other Phase PHASE1 Haemophilia A RECRUITING NCT07220564
Acetaminophen Other Phase PHASE1 Overweight RECRUITING NCT07525791
Oral contraceptive Other Phase PHASE1 Overweight RECRUITING NCT07525791
NNC0662-0419 Other Phase PHASE1 Overweight RECRUITING NCT07525791
Norditropin® Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Somapacitan Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Placebo Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
NNC0487-0111 Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
High carbohydrate liquid test meal Other Approved Obesity RECRUITING NCT06752967
High protein liquid test meal Other Approved Obesity RECRUITING NCT06752967
Placebo Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Etavopivat Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Refixia® Other Preclinical Haemophilia B COMPLETED NCT03875547
Etavopivat Other Phase PHASE2 Sickle Cell Disease RECRUITING NCT06198712
NNC0442-0344 A Other Phase PHASE1 Haemophilia A RECRUITING NCT07220564
Acetaminophen Other Phase PHASE1 Overweight RECRUITING NCT07525791
Oral contraceptive Other Phase PHASE1 Overweight RECRUITING NCT07525791
NNC0662-0419 Other Phase PHASE1 Overweight RECRUITING NCT07525791
Norditropin® Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Somapacitan Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Placebo Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
NNC0487-0111 Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
High carbohydrate liquid test meal Other Approved Obesity RECRUITING NCT06752967
High protein liquid test meal Other Approved Obesity RECRUITING NCT06752967
Placebo Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Etavopivat Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Refixia® Other Preclinical Haemophilia B COMPLETED NCT03875547
Etavopivat Other Phase PHASE2 Sickle Cell Disease RECRUITING NCT06198712
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05646706
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05646706
NNC0442-0344 A Other Phase PHASE1 Haemophilia A RECRUITING NCT07220564
Acetaminophen Other Phase PHASE1 Overweight RECRUITING NCT07525791
Oral contraceptive Other Phase PHASE1 Overweight RECRUITING NCT07525791
NNC0662-0419 Other Phase PHASE1 Overweight RECRUITING NCT07525791
Norditropin® Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Somapacitan Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Placebo Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
NNC0487-0111 Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
High carbohydrate liquid test meal Other Approved Obesity RECRUITING NCT06752967
High protein liquid test meal Other Approved Obesity RECRUITING NCT06752967
Placebo Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Placebo Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Etavopivat Other Phase PHASE3 Sickle Cell Disease RECRUITING NCT06612268
Refixia® Other Preclinical Haemophilia B COMPLETED NCT03875547
Etavopivat Other Phase PHASE2 Sickle Cell Disease RECRUITING NCT06198712
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05646706
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05646706
NNC0442-0344 A Other Phase PHASE1 Haemophilia A RECRUITING NCT07220564
Acetaminophen Other Phase PHASE1 Overweight RECRUITING NCT07525791
Oral contraceptive Other Phase PHASE1 Overweight RECRUITING NCT07525791
NNC0662-0419 Other Phase PHASE1 Overweight RECRUITING NCT07525791
Norditropin® Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Somapacitan Other Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Placebo Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
NNC0487-0111 Other Phase PHASE1 Diabetes Mellitus RECRUITING NCT07535307
High carbohydrate liquid test meal Other Approved Obesity RECRUITING NCT06752967
High protein liquid test meal Other Approved Obesity RECRUITING NCT06752967
Placebo Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05646706
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05646706
Placebo Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05646706
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05646706
Placebo Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05646706
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05646706
Placebo Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05646706
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05646706
Placebo Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05646706
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05646706
Placebo Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05646706
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05646706
Placebo Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05646706
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05646706
Placebo Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Placebo Other Phase PHASE3 Obesity COMPLETED NCT05646706
Semaglutide Other Phase PHASE3 Obesity COMPLETED NCT05646706
Tirzepatide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Semaglutide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Cagrilintide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Semaglutide Other Preclinical Obesity ACTIVE_NOT_RECRUITING NCT06283667
Placebo Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Biological/Vaccine: Placebo Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Recombinant Factor VIIa Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Tirzepatide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Semaglutide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Cagrilintide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Semaglutide Other Preclinical Obesity ACTIVE_NOT_RECRUITING NCT06283667
Placebo Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Semaglutide Other Phase PHASE3 Obesity ACTIVE_NOT_RECRUITING NCT05726227
Biological/Vaccine: Placebo Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Recombinant Factor VIIa Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Tirzepatide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Semaglutide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Cagrilintide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Biological/Vaccine: Placebo Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Recombinant Factor VIIa Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Semaglutide Other Preclinical Obesity ACTIVE_NOT_RECRUITING NCT06283667
Tirzepatide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Semaglutide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Cagrilintide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Biological/Vaccine: Placebo Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Recombinant Factor VIIa Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Semaglutide Other Preclinical Obesity ACTIVE_NOT_RECRUITING NCT06283667
Tirzepatide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Semaglutide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Cagrilintide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Biological/Vaccine: Placebo Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Recombinant Factor VIIa Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Semaglutide Other Preclinical Obesity ACTIVE_NOT_RECRUITING NCT06283667
Tirzepatide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Semaglutide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Cagrilintide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Biological/Vaccine: Placebo Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Recombinant Factor VIIa Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Semaglutide Other Preclinical Obesity ACTIVE_NOT_RECRUITING NCT06283667
Placebo (matched to Cagrilintide) Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Cagrilintide Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Tirzepatide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Semaglutide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Cagrilintide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Placebo Other Phase PHASE2 Overweight RECRUITING NCT07395687
UBT251 Other Phase PHASE2 Overweight RECRUITING NCT07395687
Biological/Vaccine: Placebo Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Recombinant Factor VIIa Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Semaglutide Other Preclinical Obesity ACTIVE_NOT_RECRUITING NCT06283667
Placebo (matched to Cagrilintide) Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Cagrilintide Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Tirzepatide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Semaglutide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Cagrilintide Other Phase PHASE3 Type 2 Diabetes COMPLETED NCT06221969
Placebo Other Phase PHASE2 Overweight RECRUITING NCT07395687
UBT251 Other Phase PHASE2 Overweight RECRUITING NCT07395687
Biological/Vaccine: Placebo Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Recombinant Factor VIIa Other Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Semaglutide Other Preclinical Obesity ACTIVE_NOT_RECRUITING NCT06283667
Placebo (matched to Cagrilintide) Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Cagrilintide Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Placebo Other Phase PHASE2 Overweight RECRUITING NCT07395687
UBT251 Other Phase PHASE2 Overweight RECRUITING NCT07395687
Placebo (matched to Cagrilintide) Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Cagrilintide Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Placebo Other Phase PHASE2 Overweight RECRUITING NCT07395687
UBT251 Other Phase PHASE2 Overweight RECRUITING NCT07395687
Placebo (matched to Cagrilintide) Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Cagrilintide Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Placebo Other Phase PHASE2 Overweight RECRUITING NCT07395687
UBT251 Other Phase PHASE2 Overweight RECRUITING NCT07395687
Placebo (matched to Cagrilintide) Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Cagrilintide Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Placebo Other Phase PHASE2 Overweight RECRUITING NCT07395687
UBT251 Other Phase PHASE2 Overweight RECRUITING NCT07395687
Placebo (matched to Cagrilintide) Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Cagrilintide Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Placebo Other Phase PHASE2 Overweight RECRUITING NCT07395687
UBT251 Other Phase PHASE2 Overweight RECRUITING NCT07395687
Placebo (matched to Cagrilintide) Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Cagrilintide Other Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
Placebo Other Phase PHASE2 Overweight RECRUITING NCT07395687
UBT251 Other Phase PHASE2 Overweight RECRUITING NCT07395687
Placebo Other Phase PHASE1 Diabetes Mellitus NOT_YET_RECRUITING NCT07535307
NNC0487-0111 Other Phase PHASE1 Diabetes Mellitus NOT_YET_RECRUITING NCT07535307
Placebo Other Phase PHASE2 Overweight RECRUITING NCT07395687
UBT251 Other Phase PHASE2 Overweight RECRUITING NCT07395687
No treatment given Drug Preclinical Diabetes Mellitus, Type 2 RECRUITING NCT07532863
nedosiran Other Phase PHASE2 Primary Hyperoxaluria COMPLETED NCT05001269
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Diabetes Mellitus NOT_YET_RECRUITING NCT07533175
NNC0487-0111 Other Phase PHASE3 Diabetes Mellitus NOT_YET_RECRUITING NCT07533175
Placebo Other Phase PHASE3 Non-alcoholic Steatohepatitis ACTIVE_NOT_RECRUITING NCT04822181
Semaglutide Other Phase PHASE3 Non-alcoholic Steatohepatitis ACTIVE_NOT_RECRUITING NCT04822181
No treatment given Drug Preclinical Diabetes Mellitus, Type 2 RECRUITING NCT07532863
nedosiran Other Phase PHASE2 Primary Hyperoxaluria COMPLETED NCT05001269
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Diabetes Mellitus NOT_YET_RECRUITING NCT07533175
NNC0487-0111 Other Phase PHASE3 Diabetes Mellitus NOT_YET_RECRUITING NCT07533175
No treatment given Drug Preclinical Diabetes Mellitus, Type 2 RECRUITING NCT07532863
nedosiran Other Phase PHASE2 Primary Hyperoxaluria COMPLETED NCT05001269
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Diabetes Mellitus NOT_YET_RECRUITING NCT07533175
NNC0487-0111 Other Phase PHASE3 Diabetes Mellitus NOT_YET_RECRUITING NCT07533175
No treatment given Drug Preclinical Diabetes Mellitus, Type 2 RECRUITING NCT07532863
nedosiran Other Phase PHASE2 Primary Hyperoxaluria COMPLETED NCT05001269
Placebo (matched to NNC0487-0111) Other Phase PHASE3 Diabetes Mellitus NOT_YET_RECRUITING NCT07533175
NNC0487-0111 Other Phase PHASE3 Diabetes Mellitus NOT_YET_RECRUITING NCT07533175
Placebo (matched to NNC0487-0111 ) DRUG Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07481630
Radiologic Surveillance (MRI and Transvaginal Ultrasound) PROCEDURE Preclinical Endometrial Cancer NOT_YET_RECRUITING NCT07462663
Endometrial Biopsy With or Without Hysteroscopy PROCEDURE Preclinical Endometrial Cancer NOT_YET_RECRUITING NCT07462663
Structured Exercise and Prehabilitation Program BEHAVIORAL Preclinical Endometrial Cancer NOT_YET_RECRUITING NCT07462663
Dietetic-Nutritional intervention BEHAVIORAL Preclinical Endometrial Cancer NOT_YET_RECRUITING NCT07462663
Oral Progestins DRUG Preclinical Endometrial Cancer NOT_YET_RECRUITING NCT07462663
Levonorgestrel IUD (Lng-IUD) DEVICE Preclinical Endometrial Cancer NOT_YET_RECRUITING NCT07462663
Coramitug DRUG Phase PHASE1 Transthyretin Amyloid Cardiomyopathy NOT_YET_RECRUITING NCT07448623
Mineralocorticoid Receptor Antagonists(MRAs) DRUG Preclinical Diabetic Nephropathies RECRUITING NCT07444203
Glucagon-like peptide-1 receptor agonists (GLP 1 RA) DRUG Preclinical Diabetic Nephropathies RECRUITING NCT07444203
Renin-angiotensin-aldosterone system blockade DRUG Preclinical Diabetic Nephropathies RECRUITING NCT07444203
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) DRUG Preclinical Diabetic Nephropathies RECRUITING NCT07444203
Placebo (NNC6989-0001 A) DRUG Phase PHASE1 Overweight RECRUITING NCT07437079
NNC6989-0001 A DRUG Phase PHASE1 Overweight RECRUITING NCT07437079
SEMAFOLLOW questionnaire OTHER Preclinical Obesity & Overweight NOT_YET_RECRUITING NCT07423481
Placebo GIP DRUG Phase PHASE1 Overweight NOT_YET_RECRUITING NCT07411560
Glucose-dependent Insulinotropic Polypeptide (GIP) DRUG Phase PHASE1 Overweight NOT_YET_RECRUITING NCT07411560
Beta-blocker treatment group DRUG Phase PHASE4 Idiopathic Ventricular Fibrillation RECRUITING NCT07405229
lifestyle change program OTHER Preclinical Obesity and Cardiovascular Risk ENROLLING_BY_INVITATION NCT07404150
Placebo (matched to semaglutide) DRUG Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07400107
UBT251 DRUG Phase PHASE2 Overweight RECRUITING NCT07395687
Standard of Care (SOC) DRUG Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 50 mL DRUG Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Amicidin-β topical solution - 15 mL DRUG Phase PHASE1 Surgical Wound Infection RECRUITING NCT07379684
Cagrisema DRUG Phase PHASE3 Overweight NOT_YET_RECRUITING NCT07357766
Placebo CagriSema DRUG Phase PHASE3 Overweight NOT_YET_RECRUITING NCT07357766
CagriSema DRUG Phase PHASE2 Diabetes Mellitus, Type 2 NOT_YET_RECRUITING NCT07357740
Placebo (matched to NNC0487-0111) DRUG Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07509307
Ziltivekimab Placebo DRUG Phase PHASE3 Myocardial Infarction RECRUITING NCT07301034
NNC9733-0001 DRUG Phase PHASE1 Healthy Volunteer RECRUITING NCT07270731
CH-reduced diet with exercise OTHER Approved Type 2 Diabetes RECRUITING NCT07262788
CH-rich diet with exercise OTHER Approved Type 2 Diabetes RECRUITING NCT07262788
Hypercaloric High-Fat Diet BEHAVIORAL Approved Metabolic Health NOT_YET_RECRUITING NCT07255807
Physical Inactivity BEHAVIORAL Approved Metabolic Health NOT_YET_RECRUITING NCT07255807
Glugagon OTHER Approved Metabolic Associated Fatty Liver Disease RECRUITING NCT07246421
Biological/Vaccine: Placebo BIOLOGICAL Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Recombinant Factor VIIa BIOLOGICAL Phase PHASE3 Intracerebral Hemorrhage RECRUITING NCT07227246
Placebo (matched to Cagrilintide) DRUG Phase PHASE3 Overweight ACTIVE_NOT_RECRUITING NCT07220759
NNC4005-001 DRUG Phase PHASE1 Fatty Liver Disease RECRUITING NCT07214870
Community Co-designed Physical Activity and Diet Intervention Package BEHAVIORAL Approved Quality of Life (QOL) ACTIVE_NOT_RECRUITING NCT07191925
Group visits (control) BEHAVIORAL Approved Cardiometabolic Diseases RECRUITING NCT07189676
Food boxes (control) BEHAVIORAL Approved Cardiometabolic Diseases RECRUITING NCT07189676
Behavioral support (control) BEHAVIORAL Approved Cardiometabolic Diseases RECRUITING NCT07189676
Group visits (Ovo-lacto-vegetarian diet) BEHAVIORAL Approved Cardiometabolic Diseases RECRUITING NCT07189676
Food boxes (Ovo-lacto-vegetarian diet) BEHAVIORAL Approved Cardiometabolic Diseases RECRUITING NCT07189676
Behavioural support (Ovo-lacto-vegetarian diet) BEHAVIORAL Approved Cardiometabolic Diseases RECRUITING NCT07189676
Group visits PHD BEHAVIORAL Approved Cardiometabolic Diseases RECRUITING NCT07189676
Food boxes PHD BEHAVIORAL Approved Cardiometabolic Diseases RECRUITING NCT07189676
Behavioural support PHD BEHAVIORAL Approved Cardiometabolic Diseases RECRUITING NCT07189676
Dietary advice (control) BEHAVIORAL Approved Cardiometabolic Diseases RECRUITING NCT07189676
Dietary advice (Ovo-lacto-vegetarian diet) BEHAVIORAL Approved Cardiometabolic Diseases RECRUITING NCT07189676
Dietary advice (PHD) BEHAVIORAL Approved Cardiometabolic Diseases RECRUITING NCT07189676
Low Energy Diet BEHAVIORAL Phase PHASE1 Obesity RECRUITING NCT07184086
CagriSema (Cagrilintide B + semaglutide I) DRUG Phase PHASE1 Obesity RECRUITING NCT07184086
Eptacog alfa (NovoSeven) DRUG Phase PHASE4 Severe Postpartum Haemorrhage RECRUITING NCT07157423
INV-347 DRUG Phase PHASE1 Obesity RECRUITING NCT07153172
Placebo A DRUG Phase PHASE1 Overweight COMPLETED NCT07121153
Basal insulin analogues DRUG Phase PHASE4 Diabetes Mellitus, Type 2 RECRUITING NCT07112339
Multi-level, Multi-component Intervention Package BEHAVIORAL Approved Quality of Life (QOL) NOT_YET_RECRUITING NCT07061665
DuraTouch® DEVICE Preclinical Diabetes Mellitus, Type 1 ACTIVE_NOT_RECRUITING NCT07052292
Debio 1453P DRUG Phase PHASE1 Healthy Participants RECRUITING NCT07035769
NNC0705-0001 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT07029568
CDR132L DRUG Phase PHASE2 Heart Failure RECRUITING NCT06979375
NNC4004-0002 DRUG Phase PHASE1 Healthy Volunteers RECRUITING NCT06859073
B-COMPASS implementation BEHAVIORAL Approved Cardiovascular Diseases RECRUITING NCT06856902
Community-based intervention packages BEHAVIORAL Approved Obesity ENROLLING_BY_INVITATION NCT06855563
Midazolam DRUG Phase PHASE1 Healthy Volunteers Sickle Cell Disease, Thalassemia COMPLETED NCT06813924
Pitavastatin DRUG Phase PHASE1 Healthy Volunteers Sickle Cell Disease, Thalassemia COMPLETED NCT06813924
Digoxin DRUG Phase PHASE1 Healthy Volunteers Sickle Cell Disease, Thalassemia COMPLETED NCT06813924
NNC0471-0119 H DRUG Phase PHASE1 Diabetes Mellitus, Type 2 RECRUITING NCT07068295
Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) DRUG Phase PHASE3 Diabetes Mellitus, Type 2 NOT_YET_RECRUITING NCT07282613
CagriSema (Cagrilintide B and Semaglutide I) DRUG Phase PHASE3 Diabetes Mellitus, Type 2 NOT_YET_RECRUITING NCT07282613
Football Fitness Concept OTHER Phase PHASE2 Postmenopausal Women ACTIVE_NOT_RECRUITING NCT06789900
Everolimus (Afinitor®) DRUG Phase PHASE2 Postmenopausal Women ACTIVE_NOT_RECRUITING NCT06789900
No tretament given OTHER Preclinical Type 2 Diabetes Mellitus (T2D) and Chronic Kidney Disease (CKD) COMPLETED NCT06769646
High carbohydrate liquid test meal OTHER Approved Obesity RECRUITING NCT06752967
High protein liquid test meal OTHER Approved Obesity RECRUITING NCT06752967
Motivational enhancement therapy OTHER Approved Alcoholic Hepatitis (AH) RECRUITING NCT06740318
Placebo (NNC0662-0419) OTHER Phase PHASE1 Overweight COMPLETED NCT06737536
NNC0662-0419 DRUG Phase PHASE2 Diabetes Mellitus, Type 2 NOT_YET_RECRUITING NCT07415954
Placebo A (NNC0174 1213 A) DRUG Phase PHASE1 Obesity RECRUITING NCT06719011
Cagrilintide B DRUG Phase PHASE1 Obesity RECRUITING NCT06719011
NNC0174-1213 A DRUG Phase PHASE1 Obesity RECRUITING NCT06719011
CagriSema A DRUG Phase PHASE1 Obesity COMPLETED NCT06716307
CagriSema (cagrilintide B and semaglutide I) DRUG Phase PHASE1 Obesity COMPLETED NCT06716307
NNC0363-1063 DRUG Phase PHASE1 Diabetes Mellitus, Type 1 RECRUITING NCT07305805
NNC0442-0344 A DRUG Phase PHASE1 Haemophilia A RECRUITING NCT07238816
Semaglutide N DRUG Phase PHASE1 Healthy Volunteers Type 2 Diabetes COMPLETED NCT06642584
Semaglutide M DRUG Phase PHASE1 Healthy Volunteers Type 2 Diabetes COMPLETED NCT06642584
Semaglutide L DRUG Phase PHASE1 Healthy Volunteers Type 2 Diabetes COMPLETED NCT06642584
NNC0519-0130 C DRUG Phase PHASE1 Obesity COMPLETED NCT06642571
NNC0519-0130 B DRUG Phase PHASE1 Obesity COMPLETED NCT06642571
NNC0537-1482 DRUG Phase PHASE1 Heart Failure RECRUITING NCT07218627
Etavopivat C DRUG Phase PHASE3 Sickle Cell Disease RECRUITING NCT06609226
Etavopivat B DRUG Phase PHASE3 Sickle Cell Disease RECRUITING NCT06609226
Etavopivat A DRUG Phase PHASE3 Sickle Cell Disease RECRUITING NCT06609226
Placebo (NNC0638-0355) DRUG Phase PHASE1 Obesity ACTIVE_NOT_RECRUITING NCT06577766
NNC0638-0355 DRUG Phase PHASE1 Obesity ACTIVE_NOT_RECRUITING NCT06577766
Placebo (NNC0487-0111 oral) DRUG Phase PHASE2 Type 2 Diabetes (T2D) COMPLETED NCT06542874
NNC0487-0111 oral DRUG Phase PHASE2 Type 2 Diabetes (T2D) COMPLETED NCT06542874
Placebo (NNC0487-0111 subcutanous) DRUG Phase PHASE2 Type 2 Diabetes (T2D) COMPLETED NCT06542874
NNC0487-0111 subcutanous DRUG Phase PHASE2 Type 2 Diabetes (T2D) COMPLETED NCT06542874
Placebo (monlunabant) DRUG Phase PHASE1 Obesity COMPLETED NCT06542536
Monlunabant DRUG Phase PHASE1 Obesity COMPLETED NCT06542536
Paracetamol DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT06513104
Levonorgestrel + Ethinylestradiol DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT06513104
DCR-PDL1 DRUG Phase PHASE1 Solid Tumors, Adult RECRUITING NCT06504368
NNC0487-0111 (formulation C) DRUG Phase PHASE1 Obesity COMPLETED NCT06478563
NNC0487-0111 (formulation D) DRUG Phase PHASE1 Obesity COMPLETED NCT06478563
Acetaminophen - 500 mg/15 ml DRUG Phase PHASE1 Obesity COMPLETED NCT06461039
Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC) DRUG Phase PHASE1 Obesity COMPLETED NCT06461039
NNC0487-0111 C DRUG Phase PHASE1 Obesity COMPLETED NCT06461039
Live music in the intensive care unit OTHER Approved Stress NOT_YET_RECRUITING NCT06442644
Semaglutide placebo (Group B) DRUG Phase PHASE2 Alcohol-related Liver Disease COMPLETED NCT06409130
Cagrilintide placebo DRUG Phase PHASE2 Alcohol-related Liver Disease COMPLETED NCT06409130
Cagrilintide + semaglutide DRUG Phase PHASE2 Alcohol-related Liver Disease COMPLETED NCT06409130
Semaglutide placebo (Group A) DRUG Phase PHASE2 Alcohol-related Liver Disease COMPLETED NCT06409130
NNC0194-0499 placebo DRUG Phase PHASE2 Alcohol-related Liver Disease COMPLETED NCT06409130
Sleep extension BEHAVIORAL Approved Sleep Duration RECRUITING NCT06341179
Placebo (NNC6022-0001) DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT06336005
NNC6022-0001 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT06336005
Trizepatide DRUG Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT06326047
VIA Family 2.0 OTHER Approved Child RECRUITING NCT06312410
Decitabine-THU DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT06291285
Warfarin DRUG Phase PHASE1 Obesity COMPLETED NCT06289504
Atorvastatin DRUG Phase PHASE1 Obesity COMPLETED NCT06289504
NNC0650-0013 A DRUG Phase PHASE1 Healthy Participants COMPLETED NCT06284798
Cagrilintide and Semaglutide DRUG Phase PHASE1 Overweight COMPLETED NCT06267092
Inactivity BEHAVIORAL Approved Overweight RECRUITING NCT06240208
GLP-1 receptor agonist DRUG Preclinical Type 2 Diabetes COMPLETED NCT06236672
Control group OTHER Approved Postoperative Pain, Acute RECRUITING NCT06222151
Intervention 2: Mobilization the first 4 postoperative weeks OTHER Approved Postoperative Pain, Acute RECRUITING NCT06222151
Intervention 1: Mobilization during hospitalization OTHER Approved Postoperative Pain, Acute RECRUITING NCT06222151
ethinylestradiol/levonorgestrel DRUG Phase PHASE1 Healthy Volunteers (Non-alcoholic Steatohepatitis) COMPLETED NCT06188026
Intelligent telemonitoring DEVICE Approved Type 2 Diabetes Treated With Insulin RECRUITING NCT06185296
FIT FIRST BEHAVIORAL Approved Primary Prevention ENROLLING_BY_INVITATION NCT06180772
Sooma Oy (Sham), Helsinki, Finland DEVICE Approved Diabetic Neuropathy, Painful RECRUITING NCT06152887
Sooma Oy (tDCS), Helsinki, Finland DEVICE Approved Diabetic Neuropathy, Painful RECRUITING NCT06152887
Infusion of either NST or placebo at different blood glucose levels OTHER Approved Type 1 Diabetes COMPLETED NCT06143267
Infusion of GIP[1-42], GIP[1-30] or placebo OTHER Approved Type1diabetes COMPLETED NCT06137586
Placebo (NNC0560-0004) DRUG Phase PHASE1 Healthy Volunteers - Liver Diseases COMPLETED NCT06133270
NNC0560-0004 DRUG Phase PHASE1 Healthy Volunteers - Liver Diseases COMPLETED NCT06133270
Tirzepatide DRUG Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Physical activity monitoring and recommendations BEHAVIORAL Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Complex lifestyle intervention BEHAVIORAL Approved Lifestyle, Healthy ACTIVE_NOT_RECRUITING NCT06122441
Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs DEVICE Approved Type 2 Diabetes COMPLETED NCT06111508
DCR-STAT3 DRUG Phase PHASE1 Solid Tumor, Adult COMPLETED NCT06098651
Placebo (NNC0487-0111) DRUG Phase PHASE1 Overweight COMPLETED NCT06820476
NNC0487-0111 DRUG Phase PHASE3 Obesity NOT_YET_RECRUITING NCT07509307
Education-First BEHAVIORAL Phase PHASE4 Cardiovascular Diseases COMPLETED NCT06046560
SGLT2 inhibitor, GLP-1 RA DRUG Phase PHASE4 Cardiovascular Diseases COMPLETED NCT06046560
Dasatinib 100 Mg Oral Tablet DRUG Phase PHASE2 Osteopenia, Osteoporosis ACTIVE_NOT_RECRUITING NCT06018467
Placebo Cagrilintide DRUG Phase PHASE3 Obesity or Overweight COMPLETED NCT05996848
Nedosiran DRUG Preclinical Primary Hyperoxaluria Type 1 (PH1) NO_LONGER_AVAILABLE NCT05993416
NNC0491-6075 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT05979428
Amino acid bolus infusion OTHER Approved Healthy COMPLETED NCT05954923
Facilitated referral to a cardiometabolic team-based center OTHER Approved Type 2 Diabetes UNKNOWN NCT05948969
Decision support OTHER Approved Type 2 Diabetes UNKNOWN NCT05948969
Community capacity building BEHAVIORAL Approved Childhood Obesity COMPLETED NCT05940675
Sleep and screen media BEHAVIORAL Approved Childhood Obesity COMPLETED NCT05940675
Physical Activity (FitFirst) BEHAVIORAL Approved Childhood Obesity COMPLETED NCT05940675
Food and Nutrition BEHAVIORAL Approved Childhood Obesity COMPLETED NCT05940675
No treatment is given OTHER Preclinical Overweight COMPLETED NCT06260696
Semaglutide Placebo DRUG Phase PHASE3 Overweight COMPLETED NCT05890976
NNC0365-3769 (Mim8) PPX DRUG Phase PHASE3 Haemophilia A COMPLETED NCT05878938
Nutritional Psycho-Behavioral Reeducation Program BEHAVIORAL Preclinical Overweight and Obesity NOT_YET_RECRUITING NCT05857319
Telemedicine behavioral weight program BEHAVIORAL Phase PHASE2 Endometrial Hyperplasia WITHDRAWN NCT05829460
LNG-IUD (Progestin) DRUG Phase PHASE2 Endometrial Hyperplasia WITHDRAWN NCT05829460
Placebo Semaglutide DRUG Phase PHASE3 Obesity or Overweight COMPLETED NCT05996848
Moxifloxacin Placebo DRUG Phase PHASE1 Obesity COMPLETED NCT05804162
Cagrilintide Placebo DRUG Phase PHASE1 Obesity COMPLETED NCT05804162
Semaglutide C DRUG Phase PHASE1 Healthy Participants COMPLETED NCT05784402
Semaglutide Auto-Injector DRUG Phase PHASE4 Diabetes Mellitus, Type 2 RECRUITING NCT05780905
Control OTHER Approved Overweight and Obesity ACTIVE_NOT_RECRUITING NCT05768958
NNC0194-0499/Semaglutide A (40/0.33mg/mL) DRUG Phase PHASE1 Non-alcoholic Steatohepatitis COMPLETED NCT05766709
NNC0194-0499/Semaglutide A (40/3.20 mg/mL) DRUG Phase PHASE1 Non-alcoholic Steatohepatitis COMPLETED NCT05766709
NC0194-0499 DRUG Phase PHASE1 Non-alcoholic Fatty Liver Disease COMPLETED NCT05742919
Etavopivat DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT07023029
Ziltivekimab D DRUG Phase PHASE1 Healthy Participants COMPLETED NCT05721989
Semaglutide B, 0.68 mg/mL DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05689099
Vira mobile app intervention + coaching BEHAVIORAL Approved Mental Health Disorder COMPLETED NCT05638516
Vira mobile app intervention BEHAVIORAL Approved Mental Health Disorder COMPLETED NCT05638516
NNC0582-0001 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT05624580
Esperoct DRUG Preclinical Haemophilia A RECRUITING NCT05621746
CT-guided radiotherapy RADIATION Preclinical Prostate Cancer COMPLETED NCT05615909
Online MR-guided radiotherapy RADIATION Preclinical Prostate Cancer COMPLETED NCT05615909
Placebo (NNC0581-0001) DRUG Phase PHASE1 Healthy Volunteers RECRUITING NCT06891365
NNC0581-0001 DRUG Phase PHASE1 Healthy Volunteers RECRUITING NCT06891365
Naltrexone/Bupropion DRUG Phase PHASE4 Obesity COMPLETED NCT05579249
Phentermine/Topiramate DRUG Phase PHASE4 Obesity COMPLETED NCT05579249
Orlistat DRUG Phase PHASE4 Obesity COMPLETED NCT05579249
Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY] DRUG Phase PHASE4 Obesity COMPLETED NCT05548647
Behavioral Treatment BEHAVIORAL Phase PHASE4 Obesity COMPLETED NCT05548647
NNC0113-6856 DRUG Phase PHASE1 Healthy Participants COMPLETED NCT06069895
Insuline glargine U100 (titrated) DRUG Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
Insuline glargine U100 (reduced) DRUG Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05514535
No Intervention OTHER Preclinical Pregnancy ENROLLING_BY_INVITATION NCT05872022
NNC0480 0389 DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05498610
Adhera® Caring digital intervention for Type 1 Diabetes BEHAVIORAL Approved Diabetes Mellitus, Type 1 COMPLETED NCT05483803
School-based extracurricular intervention focusing on screen media use and time spent with friends BEHAVIORAL Approved Screen Media Use COMPLETED NCT05480085
Semaglutide B DRUG Phase PHASE1 Healthy Volunteers Type 2 Diabetes COMPLETED NCT06642584
Semaglutide J DRUG Phase PHASE1 Healthy Volunteers Type 2 Diabetes COMPLETED NCT06642584
Empagliflozin DRUG Phase PHASE3 Diabetes Mellitus, Type 2 WITHDRAWN NCT06083675
Placebo (NNC6019-0001) DRUG Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
NNC6019-0001 DRUG Phase PHASE3 Transthyretin Amyloid Cardiomyopathy (ATTR CM) RECRUITING NCT07207811
Placebo oral tablet DRUG Phase PHASE4 Diabetes Mellitus, Type 2 RECRUITING NCT05441267
Semaglutide Oral Tablet DRUG Phase PHASE4 Diabetes Mellitus, Type 2 RECRUITING NCT05441267
Semaglutide/dapagliflozin DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT05429593
Dapagliflozin DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT05429593
no treatment given OTHER Preclinical Obesity COMPLETED NCT05428501
Semaglutide Pen Injector DRUG Phase PHASE2 Diabetes type1 RECRUITING NCT06411210
HU - Hydroxyurea DRUG Phase PHASE2 Sickle Cell Disease COMPLETED NCT05405114
NDec - oral decitabine-tetrahydrouridine DRUG Phase PHASE2 Sickle Cell Disease COMPLETED NCT05405114
Placebo semaglutide DRUG Phase PHASE3 Overweight RECRUITING NCT07253285
Placebo cagrilintide DRUG Phase PHASE3 Overweight RECRUITING NCT07253285
Dasiglucagon DRUG Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT06588504
Placebo A (NNC0487-0111 A) OTHER Phase PHASE1 Obesity COMPLETED NCT05369390
Placebo B (NNC0487-0111 B) OTHER Phase PHASE1 Obesity COMPLETED NCT05369390
NNC0487-0111 B DRUG Phase PHASE1 Obesity COMPLETED NCT05369390
NNC0487-0111 A DRUG Phase PHASE1 Overweight COMPLETED NCT07121153
Placebo (NNC0519-0130) DRUG Phase PHASE1 Healthy Volunteers (Diabetes Mellitus, Type 2) COMPLETED NCT05363774
NNC0519-0130 DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT06370819
NaCl 0.9% DRUG Phase PHASE2 Acute Myocardial Infarction ACTIVE_NOT_RECRUITING NCT05350592
Dobutamine DRUG Phase PHASE2 Acute Myocardial Infarction ACTIVE_NOT_RECRUITING NCT05350592
Tocilizumab DRUG Phase PHASE2 Acute Myocardial Infarction ACTIVE_NOT_RECRUITING NCT05350592
Physical activity OTHER Approved Intellectual Disability UNKNOWN NCT05336487
NNC0385-0434 F DRUG Phase PHASE1 Healthy Volunteers; High Cholesterol COMPLETED NCT05333107
NNC0385-0434 G DRUG Phase PHASE1 Healthy Volunteers; High Cholesterol COMPLETED NCT05333107
DV3395 C1 DEVICE Phase PHASE1 Healthy Volunteers, Medical Device COMPLETED NCT05314283
Mim8 DRUG Phase PHASE3 Haemophilia A ACTIVE_NOT_RECRUITING NCT05685238
Standard heart failure medical therapy DRUG Phase PHASE4 Advanced Heart Failure RECRUITING NCT05284955
CardioMEMS HF System DEVICE Phase PHASE4 Advanced Heart Failure RECRUITING NCT05284955
Preventive treatment with oral hydration OTHER Approved Contrast-induced Nephropathy RECRUITING NCT05283512
Preventive treatment with IV-hydration OTHER Approved Contrast-induced Nephropathy RECRUITING NCT05283512
NNC0471-0119 D DRUG Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT05262595
NNC0471-0119 B DRUG Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT05262595
NNC0471-0119 A DRUG Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT05262595
Semaglutide 1 mg DRUG Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05259033
NNC0174 0833 DRUG Phase PHASE1 Overweight and Obesity COMPLETED NCT05254158
Non-Vagifem® LDVE, Estradiol DRUG Preclinical Postmenopausal Vaginal Atrophy COMPLETED NCT05243823
Vagifem® DRUG Preclinical Postmenopausal Vaginal Atrophy COMPLETED NCT05243823
Placebo ( Semaglutide D) DRUG Phase PHASE1 Obesity COMPLETED NCT05236517
Placebo (Semaglutide C) DRUG Phase PHASE1 Obesity COMPLETED NCT05236517
Semaglutide C Dose 5 (50 mg) DRUG Phase PHASE1 Obesity COMPLETED NCT05236517
Semaglutide C Dose 4 DRUG Phase PHASE1 Obesity COMPLETED NCT05236517
Semaglutide D, 1.0 mg/mL DRUG Phase PHASE1 Healthy Volunteers (Diabetes Mellitus, Type 2) COMPLETED NCT05232708
Semaglutide B, 1.34 mg/mL DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05689099
Semaglutide Dose 6 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT05227196
Semaglutide Dose 5 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT05227196
Semaglutide Dose 4 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT05227196
Semaglutide D Dose 3 DRUG Phase PHASE1 Obesity COMPLETED NCT05236517
Semaglutide D Dose 2 DRUG Phase PHASE1 Obesity COMPLETED NCT05236517
Semaglutide D Dose 1 DRUG Phase PHASE1 Obesity COMPLETED NCT05236517
Conventional TURB PROCEDURE Approved Non-muscle Invasive Bladder Cancer COMPLETED NCT05223491
En Bloc resection PROCEDURE Approved Non-muscle Invasive Bladder Cancer COMPLETED NCT05223491
Biopsy OTHER Preclinical Diabetes UNKNOWN NCT05209061
Sitagliptin 100mg DRUG Phase PHASE4 Liver Transplant; Complications ENROLLING_BY_INVITATION NCT05195944
Semaglutide Treatment DRUG Phase PHASE4 Liver Transplant; Complications ENROLLING_BY_INVITATION NCT05195944
Heparin DRUG Phase EARLY_PHASE1 Healthy Volunteers COMPLETED NCT05178550
NNC0480-0389 30 mg/mL DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05153564
NNC0480-0389 10 mg/mL DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05153564
Semaglutide 3.0 mg/mL DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05153564
Placebo (NNC080-0389) DRUG Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT05144984
placebo (semaglutide) DRUG Phase PHASE3 Overweight and Obesity COMPLETED NCT05132088
semaglutide 50 mg DRUG Phase PHASE3 Overweight and Obesity COMPLETED NCT05132088
NNC0385-0434 E DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT05129891
NNC0385-0434 D DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT05129891
NNC0385-0434 C DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT05129891
NNC0385-0434 B DRUG Phase PHASE1 Healthy Volunteers; High Cholesterol COMPLETED NCT05333107
Semaglutide I DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT05129891
Semaglutide H DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT05129891
Semaglutide G DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT05129891
Semaglutide D DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT05129891
Mim8 B, placebo DRUG Phase PHASE1 Healthy Volunteers - Haemophilia A COMPLETED NCT05127473
Mim8 B, 100 mg/mL DRUG Phase PHASE1 Healthy Volunteers - Haemophilia A COMPLETED NCT05127473
Mim8 B, 10 mg/mL DRUG Phase PHASE1 Healthy Volunteers - Haemophilia A COMPLETED NCT05127473
Semaglutide 2.4mg DRUG Phase PHASE3 Obesity COMPLETED NCT05087342
turoctocog alfa pegol (N8-GP) DRUG Phase PHASE3 Haemophilia A COMPLETED NCT05082116
semaglutide 2.4 mg (placebo) DRUG Phase PHASE3 Obesity COMPLETED NCT05064735
semaglutide 2.4 mg DRUG Phase PHASE3 Obesity COMPLETED NCT05064735
Primed tracer infusion BIOLOGICAL Approved Chronic Kidney Diseases COMPLETED NCT05056584
Glucagon infusion BIOLOGICAL Approved Chronic Kidney Diseases COMPLETED NCT05056584
NNC0480-0389 A 10 mg/mL DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05046873
Semaglutide 1.34 mg/mL DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05153564
semaglutide 1.34 mg/mL (placebo) DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05046873
Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05046873
oral glucose-lowering medications (commercially available) DRUG Phase PHASE4 Diabetes Mellitus, Type 2 COMPLETED NCT05035082
Placebo (Ziltivekimab C) DRUG Phase PHASE3 Cardiovascular Risk ACTIVE_NOT_RECRUITING NCT05021835
Placebo (Ziltivekimab B) DRUG Phase PHASE3 Cardiovascular Risk ACTIVE_NOT_RECRUITING NCT05021835
Ziltivekimab C DRUG Phase PHASE1 Healthy Participants COMPLETED NCT05721989
Ziltivekimab B DRUG Phase PHASE1 Healthy Participants COMPLETED NCT05721989
Placebo for DCR-AUD DRUG Phase PHASE1 Alcohol Use Disorder (AUD) COMPLETED NCT05021640
DCR-AUD DRUG Phase PHASE1 Alcohol Use Disorder COMPLETED NCT05845398
NNC0174 0833 placebo DRUG Phase PHASE2 Non-alcoholic Steatohepatitis COMPLETED NCT05016882
NNC0174 0833 10 mg/mL DRUG Phase PHASE2 Non-alcoholic Steatohepatitis COMPLETED NCT05016882
Semaglutide placebo DRUG Phase PHASE2 Non-alcoholic Steatohepatitis COMPLETED NCT05016882
Semaglutide 3 mg/mL DRUG Phase PHASE2 Non-alcoholic Steatohepatitis COMPLETED NCT05016882
Placebo (NNC0194-0499) DRUG Phase PHASE2 Non-alcoholic Steatohepatitis COMPLETED NCT05016882
NNC0194 0499 50 mg/mL DRUG Phase PHASE2 Non-alcoholic Steatohepatitis COMPLETED NCT05016882
IcoSema DRUG Phase PHASE3 Type 2 Diabetes COMPLETED NCT06269107
nedosiran DRUG Phase PHASE2 Primary Hyperoxaluria COMPLETED NCT05001269
Placebo (semaglutide 2.4 mg) DRUG Phase PHASE3 Obesity COMPLETED NCT04998136
Evolocumab 140 mg/mL, Repatha® DRUG Phase PHASE2 Atherosclerotic Cardiovascular Disease COMPLETED NCT04992065
Placebo II A (for NNC0385-0434 A 100 mg) OTHER Phase PHASE2 Atherosclerotic Cardiovascular Disease COMPLETED NCT04992065
Placebo I A (for NNC0385-0434 A 40 mg) OTHER Phase PHASE2 Atherosclerotic Cardiovascular Disease COMPLETED NCT04992065
NNC0385-0434 A 100 mg DRUG Phase PHASE1 Chronic Kidney Disease TERMINATED NCT05094934
Placebo I A (for NNC0385-0434 A 15 mg) OTHER Phase PHASE2 Atherosclerotic Cardiovascular Disease COMPLETED NCT04992065
NNC0385-0434 A 40 mg DRUG Phase PHASE2 Atherosclerotic Cardiovascular Disease COMPLETED NCT04992065
NNC0385-0434 A 15 mg DRUG Phase PHASE2 Atherosclerotic Cardiovascular Disease COMPLETED NCT04992065
Placebo (cagrilintide) DRUG Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT04982575
Cagrilintide 2.4 mg DRUG Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT04982575
Telemonitoring DEVICE Approved Type 2 Diabetes Treated With Insulin RECRUITING NCT06185296
PTM CILO/FIR DRUG Phase PHASE2 Nonalcoholic Steatohepatitis COMPLETED NCT04971785
PTM SEMA DRUG Phase PHASE2 Nonalcoholic Steatohepatitis COMPLETED NCT04971785
Cilofexor (CILO)/Firsocostat (FIR) DRUG Phase PHASE2 Nonalcoholic Steatohepatitis COMPLETED NCT04971785
Semaglutide (SEMA) DRUG Phase PHASE2 Nonalcoholic Steatohepatitis COMPLETED NCT04971785
Semaglutide 2.4 mg and placebo 1.0 mg DRUG Phase PHASE2 Obesity COMPLETED NCT04969939
Semaglutide 2.4 mg and NNC0165-1875 1.0 mg DRUG Phase PHASE2 Obesity COMPLETED NCT04969939
Semaglutide 2.4 mg and placebo 2.0 mg DRUG Phase PHASE2 Obesity COMPLETED NCT04969939
Semaglutide 2.4 mg and NNC0165-1875 2.0 mg DRUG Phase PHASE2 Obesity COMPLETED NCT04969939
Xultophy® (insulin degludec/liraglutide) DRUG Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04952779
Aerobic exercise training BEHAVIORAL Approved Diabetes Mellitus, Type 2 UNKNOWN NCT04945551
Cagrilintide and semaglutide DRUG Phase PHASE1 Obesity & Overweight COMPLETED NCT04940078
Cagrilintide DRUG Phase PHASE3 Diabetes Mellitus, Type 2 ACTIVE_NOT_RECRUITING NCT06534411
Semaglutide Pill DRUG Phase PHASE4 Diabetes Mellitus, Type 2 TERMINATED NCT04938388
Kidney Biopsy PROCEDURE Preclinical Chronic Kidney Diseases RECRUITING NCT04916132
Lee Symptom Scala BEHAVIORAL Approved GVHD, Chronic COMPLETED NCT04884204
Placebo semaglutide pen injector DRUG Phase PHASE4 Pre Diabetes RECRUITING NCT04873050
Semaglutide Pen Injector [Ozempic] DRUG Phase PHASE2 Intestinal Mucositis NOT_YET_RECRUITING NCT06449625
Glucagon-like peptide-1 (GLP-1) DRUG Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04809311
Basal insulin DRUG Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04809311
Oral antidiabetetic drugs DRUG Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04809311
Placebo insulin degludec DRUG Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04795531
Placebo insulin icodec DRUG Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04795531
Semagludtide DRUG Phase PHASE3 Early Alzheimer's Disease ACTIVE_NOT_RECRUITING NCT04777396
Belcesiran DRUG Phase PHASE2 Alpha 1-Antitrypsin Deficiency TERMINATED NCT04764448
Placebo Pen Injector DRUG Phase PHASE2 Pouchitis TERMINATED NCT04763564
Liraglutide Pen Injector DRUG Phase PHASE2 Pouchitis TERMINATED NCT04763564
Insulin Glargine 300U/mL DRUG Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04760626
Insulin Glargine 100U/mL DRUG Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04760626
HM-PRO OTHER Approved Hematologic Malignancy COMPLETED NCT04757545
Placebo (NNC0194-0499 ) DRUG Phase PHASE1 Non-alcoholic Steatohepatitis COMPLETED NCT04722653
Together on Diabetes BEHAVIORAL Approved Type 2 Diabetes Mellitus COMPLETED NCT04722289
BPD-DS as a revisional procedure PROCEDURE Approved Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures UNKNOWN NCT04712409
SADI-S as a revisional procedure PROCEDURE Approved Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures UNKNOWN NCT04712409
Biliopancreatic diversion with duodenal switch PROCEDURE Approved Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures UNKNOWN NCT04712409
Single anastomosis duodeno-ileal bypass PROCEDURE Approved Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures UNKNOWN NCT04712409
Novo Rapid DRUG Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT04698018
Faster Aspart DRUG Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT04698018
NNC0113-6891 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04676906
NNC0113-6860 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04676906
NNC0113-6861 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04676906
Standard face-to-face patient education OTHER Approved Rheumatoid Arthritis COMPLETED NCT04669340
E-learning patient education OTHER Approved Rheumatoid Arthritis COMPLETED NCT04669340
Insulin degludec and liraglutide (IDegLira) DRUG Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04666987
Ryzodeg® DRUG Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT05221580
NNC0471-0119 DRUG Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT04655690
CCK OTHER Approved Gallbladder COMPLETED NCT04651868
GLP-2 OTHER Approved Gallbladder COMPLETED NCT04651868
Placebo matching empagliflozin and placebo pen injector matching semaglutide DRUG Phase PHASE4 Type 2 Diabetes ACTIVE_NOT_RECRUITING NCT04639414
Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide DRUG Phase PHASE4 Type 2 Diabetes ACTIVE_NOT_RECRUITING NCT04639414
Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector DRUG Phase PHASE4 Type 2 Diabetes ACTIVE_NOT_RECRUITING NCT04639414
Placebo (ziltivekimab) DRUG Phase PHASE2 Chronic Kidney Disease COMPLETED NCT04626505
Semaglutide (1 Mg Dose) DRUG Phase PHASE4 Diabetes Mellitus, Type 2 TERMINATED NCT04624672
Etavopivat Tablets DRUG Phase PHASE3 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT04624659
Placebo Tablets DRUG Phase PHASE3 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT04624659
Etavopivat Tablets High dose DRUG Phase PHASE3 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT04624659
Etavopivat Tablets Low dose DRUG Phase PHASE3 Sickle Cell Disease ACTIVE_NOT_RECRUITING NCT04624659
Insulin Icodec DRUG Preclinical Diabetes Mellitus, Type 1 RECRUITING NCT06807190
FT-7051 DRUG Phase PHASE1 Metastatic Castration-resistant Prostate Cancer TERMINATED NCT04575766
Placebo (NNC0268-0965) DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04575181
Turoctocog alfa pegol (N8-GP) DRUG Preclinical Haemophilia A ENROLLING_BY_INVITATION NCT04574076
Rybelsus® DRUG Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT04572165
Active Comparator DRUG Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT04572165
Ozempic® DRUG Preclinical Diabetes Mellitus, Type 2 ENROLLING_BY_INVITATION NCT04572165
Placebo (NNC0363-0845) DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04569994
NNC0363-0845 DRUG Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT05134987
Oral Semaglutide DRUG Phase PHASE1 Obesity RECRUITING NCT07225816
Trial product 12 OTHER Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 10 OTHER Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 9 OTHER Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 8 OTHER Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 7 OTHER Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 6 OTHER Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 5 OTHER Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 4 OTHER Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 3 OTHER Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 2 OTHER Phase PHASE1 Obesity COMPLETED NCT04482725
Trial product 1 OTHER Phase PHASE1 Obesity COMPLETED NCT04482725
Eptacog alfa (activated) DRUG Preclinical Severe Postpartum Haemorrhage COMPLETED NCT04444856
NO intervention - observational study OTHER Preclinical Diabetes Mellitus, Type 1 COMPLETED NCT04304963
NNC0361-0041 DRUG Phase PHASE1 Type I Diabetes COMPLETED NCT04279613
Placebo (NNC0472-0147) DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04262661
NNC0472-0147 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04262661
Placebo (NNC0480-0389) DRUG Phase PHASE1 Healthy Volunteers Type 2 Diabetes COMPLETED NCT04878406
NNC0480-0389 DRUG Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT05144984
Semaglutide (administered by PDS290 pen-injector) DRUG Preclinical Monogenic Obesity RECRUITING NCT07302802
Semaglutide (administered by DV3396 pen-injector) DRUG Phase PHASE1 Overweight COMPLETED NCT04238962
Promestriene Vaginal DRUG Phase PHASE3 Vulvovaginal Atrophy COMPLETED NCT04232813
Estradiol 10 MCG Vaginal Tablet [VAGIFEM] DRUG Phase PHASE3 Vulvovaginal Atrophy COMPLETED NCT04232813
Placebo infusion (saline) OTHER Approved Fibroblast Growth Factor 21 COMPLETED NCT04232033
Fibroblast growth factor 21 infusion OTHER Approved Fibroblast Growth Factor 21 COMPLETED NCT04232033
Placebo (Mim8) DRUG Phase PHASE2 Healthy Volunteers COMPLETED NCT04204408
NNC0365-3769 (Mim8) DRUG Phase PHASE1 Haemophilia A COMPLETED NCT05681845
Long BPL RYGB PROCEDURE Approved Obesity UNKNOWN NCT04196348
Short BPL RYGB PROCEDURE Approved Obesity UNKNOWN NCT04196348
Forxiga DRUG Phase PHASE4 Nephropathy COMPLETED NCT04193566
belcesiran DRUG Phase PHASE1 Alpha 1-Antitrypsin Deficiency COMPLETED NCT04174118
Growth Hormone BIOLOGICAL Phase PHASE2 TBI (Traumatic Brain Injury) RECRUITING NCT04121780
Estradiol Vaginal Insert DRUG Phase PHASE4 HIV Infection COMPLETED NCT04079218
Acetaminophen DRUG Phase PHASE1 Overweight COMPLETED NCT04074174
Oral contraceptive (OC) tablets DRUG Phase PHASE1 Overweight COMPLETED NCT04074174
Placebo (liraglutide) DRUG Phase PHASE3 Overweight COMPLETED NCT04074161
Empagliflozin 25 MG DRUG Phase PHASE4 Type 2 Diabetes With Renal Manifestations UNKNOWN NCT04061200
Placebo, 1,34 mg/mL OTHER Phase PHASE4 Type 2 Diabetes With Renal Manifestations UNKNOWN NCT04061200
Cocktail of 5 already approved drugs DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04059367
Placebo (NNC0385-0434) DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04058834
NNC0385-0434 DRUG Phase PHASE1 Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk COMPLETED NCT05091073
Somatropin injection DRUG Preclinical Growth Hormone Deficiency COMPLETED NCT04020913
Placebo (sitagliptin) DRUG Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04017832
Placebo (oral semaglutide) DRUG Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04017832
Oral semaglutide DRUG Phase PHASE3 Type 2 Diabetes ACTIVE_NOT_RECRUITING NCT07271251
Cross-over study OTHER Approved Diabetes Mellitus, Type 2 COMPLETED NCT05375656
Placebo (NNC0247-0829) DRUG Phase PHASE1 Overweight COMPLETED NCT04010786
NNC0247-0829 DRUG Phase PHASE1 Overweight COMPLETED NCT04010786
Semaglutide (administered by PDS290 pen) DRUG Phase PHASE2 Healthy Volunteers Diabetes Mellitus, Type 2 COMPLETED NCT04143945
Semaglutide (administered by DV3396 pen) DRUG Phase PHASE2 Healthy Volunteers Diabetes Mellitus, Type 2 COMPLETED NCT04143945
Cilofexor DRUG Phase PHASE2 Nonalcoholic Steatohepatitis COMPLETED NCT03987074
Firsocostat DRUG Phase PHASE2 Nonalcoholic Steatohepatitis COMPLETED NCT03987074
Norditropin® FlexPro® DRUG Preclinical Growth Hormone Deficiency in Children ENROLLING_BY_INVITATION NCT03972345
NNC0268-0965 DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04575181
Ziltivekimab DRUG Phase PHASE3 Heart Failure RECRUITING NCT06200207
Fiasp® DRUG Preclinical Diabetes Mellitus, Type 1 COMPLETED NCT03895515
Refixia® DRUG Preclinical Haemophilia B COMPLETED NCT03875547
Clinical and demographic data OTHER Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Blood samples BIOLOGICAL Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Dual Energy X-ray Absorptiometry (DEXA) scan RADIATION Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Continuous glucose monitoring (CGM) for four days. DEVICE Preclinical Non-Alcoholic Fatty Liver Disease TERMINATED NCT03866421
Lifestyle Therapy BEHAVIORAL Phase PHASE3 Type 2 Diabetes Mellitus COMPLETED NCT03862716
Placebo (Liraglutide 3.0 mg) DRUG Phase PHASE2 Overweight COMPLETED NCT03856047
Sterile Normal Saline (0.9% NaCl) DRUG Phase PHASE1 Primary Hyperoxaluria Type 3 COMPLETED NCT04555486
iLet™ DEVICE Phase PHASE2 Diabetes Mellitus, Type 1 COMPLETED NCT03816761
Norditropin® DRUG Phase PHASE3 SGA, Turner Syndrome, Noonan Syndrome, ISS ACTIVE_NOT_RECRUITING NCT05330325
Medication for chronic weight management (Rx) DRUG Phase PHASE4 Obesity COMPLETED NCT03799198
Weight Management Program (WMP) OTHER Phase PHASE4 Obesity COMPLETED NCT03799198
Saxenda® DRUG Preclinical Obesity or Overweight COMPLETED NCT05153590
NNC0148-0287 DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03789578
NNC0148-0287sema DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03789578
Placebo for DCR-HBVS DRUG Phase PHASE1 Hepatitis B, Chronic COMPLETED NCT03772249
DCR-HBVS DRUG Phase PHASE1 Hepatitis B, Chronic COMPLETED NCT03772249
insulin icodec DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05435677
Placebo (insulin glargine) DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT04575181
Dipeptidyl peptidase-4 inhibitors DRUG Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT03751657
Placebo (insulin 287) DRUG Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT03751657
Insulin Degludec/Insulin Aspart DRUG Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT04892069
Insulin Degludec (U-100) DRUG Phase PHASE3 Diabetes Mellitus COMPLETED NCT03737240
IDegLira DRUG Preclinical Diabetes Mellitus, Type 2 WITHDRAWN NCT06113341
IGlar U100 DRUG Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT03723772
Faster aspart 100 U/mL DRUG Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT03723759
Faster Aspart 200 U/mL DRUG Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT03723759
Smoking Cessation Counseling BEHAVIORAL Phase PHASE2 Smoking Cessation COMPLETED NCT03712098
Placebo (NNC0165-1875) DRUG Phase PHASE1 Obesity and Overweight COMPLETED NCT03707990
NNC0165-1875 DRUG Phase PHASE1 Obesity and Overweight COMPLETED NCT03707990
Placebo (Semaglutide) DRUG Phase PHASE3 Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 COMPLETED NCT04916470
Nonacog beta pegol DRUG Phase PHASE3 Haemophilia B COMPLETED NCT05365217
Insulin glargine U100 DRUG Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT03922750
N-acetylcysteine DRUG Phase PHASE1 Drug-Induced Acute Liver Injury COMPLETED NCT03679442
LANTUS® SOLOSTAR® INSULIN PEN DEVICE Phase PHASE4 Diabetes Mellitus, Type 1 COMPLETED NCT03668808
TRESIBA® FLEXTOUCH® DEVICE Phase PHASE4 Diabetes Mellitus, Type 1 COMPLETED NCT03668808
Placebo (NNC9204-1706) DRUG Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT03661879
NNC9204-1706 DRUG Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT03661879
Semaglutide D 7 mg DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03638778
Semaglutide D 3 mg DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03638778
Semaglutide C 7 mg DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03638778
Semaglutide C 3 mg DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03638778
Semaglutide B 7 mg DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03638778
Semaglutide B 3 mg DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03638778
Semaglutide 7 mg DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03638778
Semaglutide 3 mg DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03638778
Placebo (NNC0113-2023) DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03617081
NNC0113-2023 DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03617081
PDS290 pen-injector DEVICE Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03611322
DV3372 DEVICE Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03611322
Semaglutide, 1.0 mg DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03611322
Semaglutide, 0.5 mg DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03611322
Semaglutide, 0.25 mg DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03611322
Placebo (NNC0174-0833) DRUG Phase PHASE2 Overweight COMPLETED NCT03856047
NovoPen®4 DEVICE Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03598621
PDS290 DEVICE Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03598621
DV3372, 1.0 mg/mL DEVICE Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03598621
DV3372, 0.5 mg/mL DEVICE Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03598621
Semaglutide, 2.0 mg/mL DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03598621
Semaglutide, 1.34 mg/mL DRUG Phase PHASE4 Type 2 Diabetes With Renal Manifestations UNKNOWN NCT04061200
Semaglutide, 1.0 mg/mL DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03598621
Semaglutide, 0.5 mg/mL DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT03598621
Standard of care OTHER Preclinical Post Partum Hemorrhage COMPLETED NCT04723979
Insulin aspart (standard of care insulin) + closed loop device DEVICE Approved Diabetes Mellitus, Type 1 COMPLETED NCT03579615
FIASP + closed loop device DEVICE Approved Diabetes Mellitus, Type 1 COMPLETED NCT03579615
Placebo (NNC0165-1562) DRUG Phase PHASE1 Metabolism and Nutrition Disorders COMPLETED NCT03574584
Indocyanine Green (ICG) DRUG Approved Secondary Lymphedema UNKNOWN NCT03572998
Placebo II (Semaglutide) DRUG Phase PHASE3 Obesity COMPLETED NCT03552757
Placebo I (Semaglutide) DRUG Phase PHASE3 Obesity COMPLETED NCT03552757
Semaglutide 2.4 mg DRUG Phase PHASE3 Obesity COMPLETED NCT05040971
Turoctocog alfa pegol DRUG Preclinical Haemophilia A ENROLLING_BY_INVITATION NCT04682145
Metformin Hydrochloride DRUG Phase PHASE4 Heart Failure COMPLETED NCT03514108
Hydralazine Isosorbide Dinitrate DRUG Phase PHASE4 Heart Failure COMPLETED NCT03514108
Recombinant Activated Factor VII (rFVIIa) BIOLOGICAL Phase PHASE3 Intracerebral Hemorrhage ACTIVE_NOT_RECRUITING NCT03496883
Placebo Liraglutide Pen Injector DRUG Phase PHASE3 Pre Diabetes COMPLETED NCT03480022
Liraglutide Pen Injector [Saxenda] DRUG Phase PHASE3 Pre Diabetes COMPLETED NCT03480022
Ciclosporin DRUG Phase PHASE1 Diabetes COMPLETED NCT03466567
Probenecid DRUG Phase PHASE1 Diabetes COMPLETED NCT03466567
Fast-acting insulin aspart DRUG Preclinical Diabetes Mellitus, Type 1 COMPLETED NCT05069545
NNC9204-1513 DRUG Phase PHASE1 Diabetes COMPLETED NCT03444467
Needs assesment tool integrated in nursing consultation. OTHER Approved Head and Neck Neoplasms COMPLETED NCT03443258
Somatropin DRUG Preclinical Genetic Disorder COMPLETED NCT03435627
Insulin degludec /insulin aspart DRUG Preclinical Diabetes COMPLETED NCT03416855
Insulin aspart (NovoRapid®) DRUG Phase PHASE1 Diabetes COMPLETED NCT03407599
Faster aspart DRUG Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT05262595
DCR-PHXC DRUG Phase PHASE2 Primary Hyperoxaluria Type 1 RECRUITING NCT04580420
BIAsp 30 DRUG Preclinical Diabetes Mellitus, Type 2 WITHDRAWN NCT03862690
Starter Kit Algorithm DEVICE Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT03365180
Insulin Degludec U100 DRUG Phase PHASE4 Type2 Diabetes TERMINATED NCT03349840
Aspart DRUG Phase PHASE4 Type1 Diabetes Mellitus COMPLETED NCT04409587
Degludec DRUG Phase PHASE4 Type 2 Diabetes COMPLETED NCT03336528
PLACEBO DRUG Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT03308721
NNC9204-1177 A 1.0 mg/mL DRUG Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT03308721
Placebo (semaglutide 1.0 mg) DRUG Phase PHASE1 Diabetes COMPLETED NCT03288740
Placebo (semaglutide 0.5 mg) DRUG Phase PHASE1 Diabetes COMPLETED NCT03288740
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml DRUG Phase PHASE3 Binge-Eating Disorder TERMINATED NCT03279731
matching liraglutide-placebo pre-filled pens DRUG Phase PHASE4 Type2 Diabetes COMPLETED NCT03260881
Liraglutide Pen Injector [Victoza] DRUG Phase PHASE3 Type 2 Diabetes WITHDRAWN NCT04057261
Insulin Degludec 100 UNT/ML [Tresiba] DRUG Phase PHASE4 Type 2 Diabetes Mellitus UNKNOWN NCT03244241
Cornerstones4Care Powered by Glooko App DEVICE Approved Diabetes Mellitus, Type 2 UNKNOWN NCT03222284
Turoctocog alfa DRUG Preclinical Congenital Bleeding Disorder RECRUITING NCT06574984
Eptacog alfa DRUG Preclinical Post Partum Hemorrhage COMPLETED NCT04723979
Somapacitan DRUG Preclinical Growth Hormone Deficiency ENROLLING_BY_INVITATION NCT06709040
Placebo (semaglutide) DRUG Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT05144984
Placebo (canagliflozin) DRUG Phase PHASE3 Diabetes COMPLETED NCT03136484
Canagliflozin DRUG Phase PHASE3 Diabetes COMPLETED NCT03136484
RYGB PROCEDURE Phase PHASE3 Obesity COMPLETED NCT03115424
NNC9204-1706 A DRUG Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT03095807
Continuous Glucose Monitor (CGM) alone OTHER Approved Type1 Diabetes Mellitus COMPLETED NCT03093636
Continuous Glucose Monitor (CGM)+Decision Support System (DSS) DEVICE Approved Type1 Diabetes Mellitus COMPLETED NCT03093636
ALPROLIX® DRUG Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT03075670
N9-GP DRUG Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT03075670
Norditropin DRUG Preclinical Noonan Syndrome ENROLLING_BY_INVITATION NCT05308927
Semaglutide placebo 1.0 mg DRUG Phase PHASE3 Diabetes COMPLETED NCT03061214
Semaglutide placebo 0.5 mg DRUG Phase PHASE3 Diabetes COMPLETED NCT03061214
Sitagliptin placebo DRUG Phase PHASE3 Diabetes COMPLETED NCT03061214
Semaglutide 1.0 mg DRUG Phase PHASE3 Obesity COMPLETED NCT03552757
Semaglutide 0.5 mg DRUG Phase PHASE1 Diabetes COMPLETED NCT03288740
Specialist Obesity Management Services OTHER Phase PHASE4 Obesity COMPLETED NCT03036800
Saxenda DRUG Phase PHASE3 Obesity COMPLETED NCT03115424
Cardiac CT RADIATION Approved Diabetes UNKNOWN NCT03022344
NNC0194-0499 DRUG Phase PHASE1 Diabetes Mellitus, Type 1 ACTIVE_NOT_RECRUITING NCT07087795
Rosuvastatin DRUG Phase PHASE1 Healthy Volunteers Sickle Cell Disease, Thalassemia COMPLETED NCT06813924
Furosemide DRUG Phase PHASE1 Diabetes COMPLETED NCT03010475
There is no intervention OTHER Preclinical Diabetic Nephropathies RECRUITING NCT02986984
Normal physical activity BEHAVIORAL Approved Type 2 Diabetes Mellitus COMPLETED NCT02982408
no treatment OTHER Preclinical Quality of Life COMPLETED NCT02965144
CMS Intensive Behavior Therapy BEHAVIORAL Phase PHASE3 Metabolism and Nutrition Disorder COMPLETED NCT02963935
Liraglutide 3.0 mg DRUG Phase PHASE2 Overweight COMPLETED NCT03856047
NNC9204-1177 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04059367
Levothyroxine DRUG Phase PHASE1 Diabetes COMPLETED NCT02920385
Semaglutide DRUG Preclinical Obesity ENROLLING_BY_INVITATION NCT07081178
Neutral drinking-water OTHER Approved Healthy Participants COMPLETED NCT02917616
Alkaline drinking-water OTHER Approved Healthy Participants COMPLETED NCT02917616
Insulin degludec DRUG Phase PHASE1 Diabetes Mellitus, Type 1 RECRUITING NCT06685185
Insulin degludec/liraglutide DRUG Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT03823339
Moxifloxacin DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT07023029
Extension Study CMS-recommended lifestyle counseling BEHAVIORAL Phase PHASE4 Obesity COMPLETED NCT02911818
Phentermine 15 MG DRUG Phase PHASE4 Obesity COMPLETED NCT02911818
Placebo Oral Tablet DRUG Phase PHASE4 Heart Failure COMPLETED NCT03514108
Portion-Controlled Diet OTHER Phase PHASE4 Obesity COMPLETED NCT02911818
Liraglutide 3.0mg DRUG Phase PHASE4 Obesity COMPLETED NCT02911818
CMS-recommended lifestyle counseling BEHAVIORAL Phase PHASE4 Obesity COMPLETED NCT02911818
Insulin degludec/insulin aspart DRUG Phase PHASE3 Diabetes COMPLETED NCT02906917
Liraglutide 3 mg placebo DRUG Phase PHASE4 Osteoarthritis COMPLETED NCT02905864
Liraglutide 3 mg (Saxenda) DRUG Phase PHASE4 Osteoarthritis COMPLETED NCT02905864
COR-001 DRUG Phase PHASE1 Anemia COMPLETED NCT02868229
empagliflozin DRUG Phase PHASE3 Diabetes COMPLETED NCT02863328
Microgynon® DRUG Phase PHASE1 Diabetes Mellitus, Type 2 COMPLETED NCT05153564
SNAC DRUG Phase PHASE1 Diabetes COMPLETED NCT03010475
DCR-PH1 DRUG Phase PHASE1 Primary Hyperoxaluria Type 1 TERMINATED NCT02795325
liraglutide 3.0 mg DRUG Preclinical Obesity COMPLETED NCT02773355
thiazolidinediones DRUG Phase PHASE4 Diabetes COMPLETED NCT02730377
SGLT-2 inhibitors DRUG Phase PHASE4 Diabetes COMPLETED NCT02730377
meglitinides DRUG Phase PHASE4 Diabetes COMPLETED NCT02730377
DPP-4 inhibitors DRUG Phase PHASE4 Diabetes COMPLETED NCT02730377
alpha-glucosidase inhibitors DRUG Phase PHASE4 Diabetes COMPLETED NCT02730377
Dulaglutide DRUG Phase PHASE4 Healthy Volunteers COMPLETED NCT04189848
DV3316 pen-injector DEVICE Phase PHASE1 Diabetes COMPLETED NCT02627287
standard antenatal care OTHER Phase PHASE4 Diabetes COMPLETED NCT02617693
lifestyle intervention BEHAVIORAL Phase PHASE4 Diabetes COMPLETED NCT02617693
Control Group OTHER Approved Type 1 Diabetes TERMINATED NCT02617160
MD-Logic Pump Advisor DEVICE Approved Type 1 Diabetes TERMINATED NCT02617160
NNC0143-0406 DRUG Phase PHASE1 Diabetes COMPLETED NCT02938572
3D-Transit after Malone appendicostomy DEVICE Approved Diabetic Autonomic Neuropathy TERMINATED NCT02573519
3D-Transit during treatment with Pyridostigmine DRUG Approved Diabetic Autonomic Neuropathy TERMINATED NCT02573519
3D-Transit DEVICE Approved Diabetic Autonomic Neuropathy TERMINATED NCT02573519
11C Donepezil PET/CT scan RADIATION Approved Diabetic Autonomic Neuropathy TERMINATED NCT02573519
NNC0165-1562 DRUG Phase PHASE1 Metabolism and Nutrition Disorders COMPLETED NCT03574584
Subcutaneous insertions of needles DEVICE Approved Diabetes Mellitus, Type 2 COMPLETED NCT02531776
Omron Walking Style pro. 20 DEVICE Approved Colorectal Cancer COMPLETED NCT02522520
Pedometer + hospital based intervention BEHAVIORAL Approved Colorectal Cancer COMPLETED NCT02522520
Pedometer intervention BEHAVIORAL Approved Colorectal Cancer COMPLETED NCT02522520
Meal Test OTHER Preclinical Bone Remodeling COMPLETED NCT02518737
Concizumab DRUG Preclinical Haemophilia A, Haemophilia B ENROLLING_BY_INVITATION NCT06831734
Outdoor weather OTHER Preclinical Nonshivering Thermogenisis COMPLETED NCT02486419
None, observational study OTHER Preclinical Diabetes Mellitus, Type 2 COMPLETED NCT02486237
Insulin 320 DRUG Phase PHASE1 Diabetes COMPLETED NCT02479022
Regular Human Insulin DRUG Phase PHASE2 Type 2 Diabetes Mellitus COMPLETED NCT02415556
Mixed Meal Tolerance Test with paracetamol DRUG Phase PHASE2 Type 1 Diabetes Mellitus COMPLETED NCT02408705
Sugar Pill DRUG Phase PHASE4 Insulin Resistance COMPLETED NCT02403284
Physical activity intervention BEHAVIORAL Approved Type 2 Diabetes COMPLETED NCT02371239
Pancreatic clamp OTHER Approved Non-alcoholic Fatty Liver Disease COMPLETED NCT02337660
Liver biopsy PROCEDURE Approved Non-alcoholic Fatty Liver Disease COMPLETED NCT02337660
NNC0174-0833 DRUG Phase PHASE1 Overweight COMPLETED NCT04209049
Liraglutide or Placebo DRUG Phase PHASE4 Diabetes Mellitus, Non-Insulin-Dependent COMPLETED NCT02299388
Omeprazole DRUG Phase PHASE1 Diabetes COMPLETED NCT02249871
Insulin 338 DRUG Phase PHASE1 Healthy COMPLETED NCT02220296
Sitagliptin DRUG Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04017832
survey BEHAVIORAL Preclinical Diabetes COMPLETED NCT01950650
Other: 4. Usual care BEHAVIORAL Approved Lung Cancer TERMINATED NCT01893580
Experimental: 3. Experimental BEHAVIORAL Approved Lung Cancer TERMINATED NCT01893580
Experimental: 2. Experimental BEHAVIORAL Approved Lung Cancer TERMINATED NCT01893580
Experimental: 1. Experimental BEHAVIORAL Approved Lung Cancer TERMINATED NCT01893580
other injectable antidiabetic treatment regimens DRUG Preclinical Diabetes Mellitus COMPLETED NCT01892319
Insulin (glargine) DRUG Phase PHASE3 Type 2 Diabetes COMPLETED NCT01794143
GLP-1 receptor agonist (liraglutide) DRUG Phase PHASE3 Type 2 Diabetes COMPLETED NCT01794143
DPP-4 inhibitor (sitagliptin) DRUG Phase PHASE3 Type 2 Diabetes COMPLETED NCT01794143
Sulfonylurea (glimepiride) DRUG Phase PHASE3 Type 2 Diabetes COMPLETED NCT01794143
insulin degludec/insulin aspart 15 DRUG Phase PHASE1 Diabetes COMPLETED NCT01773798
Soccer training BEHAVIORAL Approved Prostatic Neoplasms COMPLETED NCT01711892
Blast Traumatic Brain Injury OTHER Preclinical Traumatic Brain Injury UNKNOWN NCT01666964
Personal instruction BEHAVIORAL Approved Musculoskeletal Disorders COMPLETED NCT01543893
Video instruction BEHAVIORAL Approved Musculoskeletal Disorders COMPLETED NCT01543893
digoxin DRUG Phase PHASE1 Diabetes COMPLETED NCT02249910
griseofulvin DRUG Phase PHASE1 Diabetes COMPLETED NCT01518166
atorvastatin DRUG Phase PHASE1 Diabetes COMPLETED NCT02243098
oestrogen DRUG Phase PHASE4 Genetic Disorder COMPLETED NCT01518062
liraglutide [3H] DRUG Phase PHASE1 Diabetes COMPLETED NCT01517568
paracetamol DRUG Phase PHASE1 Diabetes COMPLETED NCT01517555
NordiFlex PenMate™ DEVICE Preclinical Growth Hormone Disorder COMPLETED NCT01500486
NNC 0123-0000-0338 DRUG Phase PHASE1 Diabetes COMPLETED NCT01334034
Insulin Asparte DRUG Phase PHASE3 Cystic Fibrosis COMPLETED NCT00072904
NNC9204-0530 DRUG Phase PHASE1 Metabolism and Nutrition Disorder COMPLETED NCT02870231
DPP-4 inhibitor DRUG Phase PHASE3 Diabetes COMPLETED NCT02207374
NNC0090-2746 DRUG Phase PHASE2 Diabetes COMPLETED NCT02205528
Metformin DRUG Phase PHASE1 Healthy Volunteers Sickle Cell Disease, Thalassemia COMPLETED NCT06813924
Insulin icodec DRUG Preclinical Diabetes Mellitus, Type 1 RECRUITING NCT07160816
Liraglutide treatment DRUG Approved Diabetes Mellitus, Type 1 COMPLETED NCT02138045
Placebo treatment DRUG Approved Diabetes Mellitus, Type 1 COMPLETED NCT02138045
Diet/exercise BEHAVIORAL Phase PHASE3 Diabetes TERMINATED NCT02131272
Insulin NPH DRUG Phase PHASE3 Diabetes TERMINATED NCT02131272
DCR-MYC DRUG Phase PHASE1 Hepatocellular Carcinoma TERMINATED NCT02314052
Adalimumab DRUG Phase PHASE2 Inflammation WITHDRAWN NCT02097264
Synthetic mesh DEVICE Approved Abdominal Donor-site COMPLETED NCT02076724
Biological mesh DEVICE Approved Abdominal Donor-site COMPLETED NCT02076724
lisinopril DRUG Phase PHASE1 Diabetes COMPLETED NCT02070510
lixisenatide DRUG Phase PHASE4 Diabetes COMPLETED NCT01973231
Genotropin Pen® DRUG Phase PHASE1 Growth Disorder COMPLETED NCT01943084
Norditropin® FlexPro® pen DRUG Phase PHASE2 Growth Hormone Disorder COMPLETED NCT02616562
Glargine + OADs DRUG Phase PHASE4 Type 2 Diabetes COMPLETED NCT01919489
Liraglutide + OADs DRUG Phase PHASE4 Type 2 Diabetes COMPLETED NCT01919489
insulin degludec/insulin aspart 55 DRUG Phase PHASE1 Diabetes COMPLETED NCT01868568
insulin degludec/insulin aspart 45 DRUG Phase PHASE1 Diabetes COMPLETED NCT01868568
insulin degludec/insulin aspart 50 DRUG Phase PHASE1 Diabetes COMPLETED NCT01865331
insulin degludec/insulin aspart 40 DRUG Phase PHASE1 Diabetes COMPLETED NCT01868568
insulin degludec/insulin aspart 30 DRUG Phase PHASE1 Diabetes COMPLETED NCT01868568
basal insulin DRUG Preclinical Type 2 Diabetes COMPLETED NCT06236672
Insulin Degludec DRUG Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT04760626
Basal-bolus detemir-aspart insulin regimen DRUG Phase PHASE4 Diabetes Mellitus COMPLETED NCT01828970
insulin 287 DRUG Phase PHASE1 Diabetes COMPLETED NCT01809184
Early intervention BEHAVIORAL Approved Health Behavior COMPLETED NCT01799447
insulin 338 (GIPET I) DRUG Phase PHASE2 Diabetes COMPLETED NCT02470039
Atenolol DRUG Approved Healthy UNKNOWN NCT01795235
Glucagon DRUG Phase PHASE1 Diabetes Mellitus, Type 1 COMPLETED NCT06588504
Placebos DRUG Phase PHASE3 Obesity COMPLETED NCT03115424
glucose clamp OTHER Phase PHASE1 Diabetes COMPLETED NCT01789593
Plasma-derived FVII conc. (pdFVII PFL) DRUG Preclinical Congenital Bleeding Disorder COMPLETED NCT01779921
Plasma-derived FVII conc. (pdFVII Baxter) DRUG Preclinical Congenital Bleeding Disorder COMPLETED NCT01779921
Prothrombin Complex conc. (PCC) DRUG Preclinical Congenital Bleeding Disorder COMPLETED NCT01779921
Plasma-derived FVII (LFB) DRUG Preclinical Congenital Bleeding Disorder COMPLETED NCT01779921
Fresh frozen plasma (Source unspecified) DRUG Preclinical Congenital Bleeding Disorder COMPLETED NCT01779921
Liraglutide - Placebo DRUG Phase PHASE4 Diabetes Mellitus Type 2 COMPLETED NCT02660047
sodium chloride 0.9% w/v DRUG Phase PHASE1 Diabetes COMPLETED NCT01730014
148-0287-A-4.2mM-cartridge DRUG Phase PHASE1 Diabetes COMPLETED NCT01730014
17-beta estradiol DRUG Phase PHASE3 Genetic Disorder COMPLETED NCT01710696
NNC0113-0987 DRUG Phase PHASE1 Diabetes COMPLETED NCT02094521
sodium chloride 0.9% solution DRUG Phase PHASE1 Diabetes COMPLETED NCT01680328
19 injections OTHER Phase PHASE1 Diabetes COMPLETED NCT01680328
Placebo-liraglutide DRUG Phase PHASE4 Type 2 Diabetes Mellitus COMPLETED NCT01664676
biphasic human insulin 50 DRUG Phase PHASE4 Diabetes COMPLETED NCT01892020
NNC0109-0012 DRUG Phase PHASE2 Inflammation WITHDRAWN NCT02097264
placebo injection DRUG Phase PHASE3 Type 2 Diabetes TERMINATED NCT01628445
SOMATROPINE* : Norditropine® simplexx® DRUG Phase PHASE2 Anorexia Nervosa COMPLETED NCT01626833
NNC0215-0384 DRUG Phase PHASE1 Inflammation COMPLETED NCT01955603
Glimepiride DRUG Phase PHASE2 Maturity-onset Diabetes of the Young COMPLETED NCT01610934
NNC 0148-0000-0362 DRUG Phase PHASE1 Diabetes COMPLETED NCT01597713
2 mg estradiol / 1 mg norethisterone acetate (NETA) DRUG Phase PHASE1 Menopause COMPLETED NCT01596010
NNC0114-0006 DRUG Phase PHASE2 Diabetes COMPLETED NCT02443155
standard therapy DRUG Phase PHASE2 Acquired Bleeding Disorder TERMINATED NCT01564563
clopidogrel DRUG Phase PHASE1 Haemostasis COMPLETED NCT01603342
warfarin DRUG Phase PHASE1 Diabetes COMPLETED NCT02070510
factor VIII DRUG Phase PHASE4 Congenital Bleeding Disorder COMPLETED NCT01561391
factor IX OTHER Phase PHASE4 Congenital Bleeding Disorder COMPLETED NCT01561391
MEDI5117 Placebo BIOLOGICAL Phase PHASE1 Rheumatoid Arthritis TERMINATED NCT01559103
MEDI5117 BIOLOGICAL Phase PHASE1 Rheumatoid Arthritis TERMINATED NCT01559103
Health counseling and exercise BEHAVIORAL Phase EARLY_PHASE1 Acute Leukemia COMPLETED NCT01557686
NNC172-2021 DRUG Phase PHASE1 Congenital Bleeding Disorder TERMINATED NCT01631942
observational study OTHER Preclinical Hemorrhage COMPLETED NCT01532661
electrocardiogram (ECG) PROCEDURE Phase PHASE1 Diabetes COMPLETED NCT01516255
moxifloxacin DRUG Phase PHASE1 Diabetes COMPLETED NCT02064348
placebo (somapacitan) DRUG Phase PHASE1 Growth Hormone Disorder COMPLETED NCT01514500
somapacitan DRUG Phase PHASE3 Growth Hormone Deficiency in Children COMPLETED NCT04970654
oral anti-diabetic drug DRUG Phase PHASE3 Diabetes COMPLETED NCT01512108
levonorgestrel / ethinylestradiol DRUG Phase PHASE1 Diabetes COMPLETED NCT01508858
Saline DRUG Approved Healthy UNKNOWN NCT01795235
Marketed low dose hormone replacement therapy DRUG Preclinical Menopause COMPLETED NCT01487304
human soluble insulin DRUG Phase PHASE1 Diabetes COMPLETED NCT02162407
1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA) DRUG Phase PHASE4 Menopause COMPLETED NCT01705249
liraglutide-depot DRUG Phase PHASE1 Diabetes COMPLETED NCT01473953
gastric bypass PROCEDURE Preclinical Obesity COMPLETED NCT01463449
Open-loop control OTHER Approved Type 1 Diabetes COMPLETED NCT01444443
Closed-loop control DEVICE Approved Type 1 Diabetes COMPLETED NCT01444443
oral placebo DRUG Phase PHASE2 Diabetes COMPLETED NCT01923181
I.v. NNC 0113-0987 DRUG Phase PHASE1 Diabetes COMPLETED NCT01405261
oral NNC 0113-0987 DRUG Phase PHASE1 Diabetes COMPLETED NCT01405261
Exercise based multimodal intervention OTHER Approved Acute Leukemia COMPLETED NCT01404520
Remote ischemic conditioning OTHER Approved Kidney Transplantation UNKNOWN NCT01395719
IVGTT OTHER Approved Hypoglycaemia COMPLETED NCT01347801
OGTT OTHER Approved Hypoglycaemia COMPLETED NCT01347801
TNF-alfa DRUG Approved Hypoglycaemia COMPLETED NCT01347801
Placebo (Saline) DRUG Approved Hypoglycaemia COMPLETED NCT01347801
GLP-1 DRUG Approved Hypoglycaemia COMPLETED NCT01347801
Isotone NaCl BIOLOGICAL Approved Kidney Functional COMPLETED NCT01333163
Human GLP-1 (7-36) amide BIOLOGICAL Approved Kidney Functional COMPLETED NCT01333163
Microgyn® DRUG Phase PHASE1 Diabetes COMPLETED NCT01324505
counseling and behavioral therapy for weight loss BEHAVIORAL Approved Obesity COMPLETED NCT01312090
Whole body cryotherapy BIOLOGICAL Approved Obesity COMPLETED NCT01312090
neutral protamine insulin DRUG Approved Type 2 Diabetes Mellitus UNKNOWN NCT01310452
NNC109-0012 DRUG Phase PHASE2 Inflammation COMPLETED NCT01282255
NNC 0128-0000-2021 DRUG Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01272206
NNC 0128-0000-2011 DRUG Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01288391
Exercise OTHER Approved Overweight and Obesity ACTIVE_NOT_RECRUITING NCT05768958
Education OTHER Approved Type 1 Diabetes COMPLETED NCT01223547
Victoza® DRUG Phase PHASE4 Diabetes Mellitus, Type 2 COMPLETED NCT01208012
NN1218 DRUG Phase PHASE1 Diabetes COMPLETED NCT01121289
Faster-acting insulin aspart DRUG Preclinical Diabetes Mellitus, Type 1 COMPLETED NCT03987802
NN9924 (i.v.) DRUG Phase PHASE1 Diabetes COMPLETED NCT01037582
NN9924 (s.c.) DRUG Phase PHASE1 Diabetes COMPLETED NCT01037582
NN9924 (oral) DRUG Phase PHASE1 Diabetes COMPLETED NCT01037582
NN1952 DRUG Phase PHASE1 Diabetes COMPLETED NCT01028404
insulin degludec/liraglutide DRUG Phase PHASE1 Diabetes COMPLETED NCT03292185
PDAphone DEVICE Approved TYPE 2 DIABETES COMPLETED NCT00937703
IVS DEVICE Approved TYPE 2 DIABETES COMPLETED NCT00937703
Novofine needle DEVICE Phase PHASE4 Diabetes Mellitus COMPLETED NCT00894270
Placebo injection PROCEDURE Phase PHASE4 Diabetes Mellitus COMPLETED NCT00894270
Sterile air injection PROCEDURE Phase PHASE4 Diabetes Mellitus COMPLETED NCT00894270
Chronic care multidisciplinary intervention of childhood obesity OTHER Preclinical Childhood Obesity COMPLETED NCT00823277
insulin aspart protamine/insulin aspart 70/30 mix DRUG Phase PHASE4 Type 2 Diabetes Mellitus COMPLETED NCT00821795
NPH/Regular 70/30 mix DRUG Phase PHASE4 Type 2 Diabetes Mellitus COMPLETED NCT00821795
biphasic insulin aspart 70 DRUG Phase PHASE1 Diabetes COMPLETED NCT01620333
placebo+placebo DRUG Phase PHASE3 Type 2 Diabetes COMPLETED NCT00699426
nexium DRUG Phase PHASE3 Type 2 Diabetes COMPLETED NCT00699426
short-acting Insulin (Actrapid) DRUG Phase PHASE3 Cystic Fibrosis COMPLETED NCT00662714
Repaglinide DRUG Phase PHASE3 Cystic Fibrosis COMPLETED NCT00662714
NovoPen® 3 DEVICE Preclinical Diabetes COMPLETED NCT01454024
NovoPen™ 4 DEVICE Phase PHASE3 Diabetes COMPLETED NCT00569998
rehabilitation OTHER Phase PHASE2 Quality of Life COMPLETED NCT00569478
somatotropin DRUG Phase PHASE2 Muscular Atrophy, Spinal COMPLETED NCT00533221
NPH insulin DRUG Phase PHASE3 Diabetes Mellitus, Type 1 COMPLETED NCT03220425
detemir DRUG Approved Type 2 Diabetes COMPLETED NCT00457093
glargine DRUG Approved Type 2 Diabetes COMPLETED NCT00457093
Subjects without diabetes will have their blood glucose levels monitored while in the hospital BEHAVIORAL Approved Type 2 Diabetes TERMINATED NCT00456105
Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team BEHAVIORAL Approved Type 2 Diabetes TERMINATED NCT00456105
Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician BEHAVIORAL Approved Type 2 Diabetes TERMINATED NCT00456105
Rosiglitazone DRUG Phase PHASE4 Type 1 Diabetes COMPLETED NCT00372086
dual-action insulin analog DRUG Approved Diabetes Mellitus, Type 2 UNKNOWN NCT00348231
Hormone replacement therapy DRUG Phase PHASE4 Osteoporosis COMPLETED NCT00252408
Actrapid® (Insulin) DRUG Phase PHASE3 Severe Sepsis COMPLETED NCT00135473
Sterofundin® (Ringer lactate solution) DRUG Phase PHASE3 Severe Sepsis COMPLETED NCT00135473
10% Hemohes® (10% Hydroxyethyl starch) DRUG Phase PHASE3 Severe Sepsis COMPLETED NCT00135473
administration of autologous stored platelets OTHER Phase PHASE2 Bleeding COMPLETED NCT01248351
autologous stored platelets BIOLOGICAL Phase PHASE2 Bleeding COMPLETED NCT01248351
Norditropin NordiFlex® DRUG Phase PHASE1 Growth Hormone Disorder COMPLETED NCT01706783
Liraglutide-placebo OTHER Phase PHASE2 Nonalcoholic Steatohepatitis COMPLETED NCT01237119
Liraglutide DRUG Phase PHASE1 Obesity RECRUITING NCT07225816
Metformin XR plus liraglutide DRUG Phase PHASE3 Gestational Diabetes Mellitus COMPLETED NCT01234649
Metformin XR plus placebo DRUG Phase PHASE3 Gestational Diabetes Mellitus COMPLETED NCT01234649
liraglutide plus insulin detemir DRUG Approved Type 2 Diabetes COMPLETED NCT01232946
NNC 0172-0000-2021 DRUG Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT01228669
NNC0114-0000-0005 DRUG Phase PHASE1 Inflammation COMPLETED NCT01208506
turoctocog alfa pegol DRUG Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT02994407
NovoPen Echo® DEVICE Preclinical Diabetes COMPLETED NCT01180530
Epidemiological intervention OTHER Preclinical Diabetes Mellitus COMPLETED NCT01117831
Aspart flexible dose DRUG Phase PHASE4 Diabetes COMPLETED NCT01101867
Aspart fixed dose DRUG Phase PHASE4 Diabetes COMPLETED NCT01101867
Norditropin SimpleXx (growth hormone) DRUG Phase PHASE2 Growth Hormone Deficiency COMPLETED NCT01090778
Placebo DRUG Phase PHASE3 Non-alcoholic Steatohepatitis ACTIVE_NOT_RECRUITING NCT04822181
Hydrocortisone DRUG Phase PHASE4 Partial Corticotrope Insufficiency TERMINATED NCT01089075
NN9925 (i.v.) DRUG Phase PHASE1 Diabetes COMPLETED NCT01087645
NN9925 (oral) DRUG Phase PHASE1 Diabetes COMPLETED NCT01087645
recombinant factor XIII DRUG Preclinical Congenital Bleeding Disorder COMPLETED NCT02670213
DexCom CGM DEVICE Phase PHASE4 Diabetes Type 2 COMPLETED NCT01076842
SenseWear Pro3® armband DEVICE Phase PHASE4 Diabetes Type 2 COMPLETED NCT01076842
Insulin-Levemir and Exenatide-Bayetta DRUG Phase PHASE4 Diabetes Type 2 COMPLETED NCT01076842
Exenatide-Bayetta DRUG Phase PHASE4 Diabetes Type 2 COMPLETED NCT01076842
Insulin-Levemir DRUG Phase PHASE4 Diabetes Type 2 COMPLETED NCT01076842
'2-0453 DRUG Phase PHASE1 Metabolism and Nutrition Disorder TERMINATED NCT01044108
NNC 0070-0002-0453 DRUG Phase PHASE1 Metabolism and Nutrition Disorder TERMINATED NCT01044108
Norditropin® SimpleXx® DRUG Phase PHASE1 Growth Hormone Disorder COMPLETED NCT01034202
gliclazide DRUG Phase PHASE4 Diabetes COMPLETED NCT01022762
NNC 0151-0000-0000 DRUG Phase PHASE1 Inflammation COMPLETED NCT02151409
Insulin detemir and pre-meal insulin aspart. DRUG Phase PHASE4 Type 2 Diabetes COMPLETED NCT00998335
Long-acting bedtime insulin detemir (Levemir) DRUG Phase PHASE4 Type 2 Diabetes COMPLETED NCT00998335
nonacog beta pegol DRUG Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT02141074
activated recombinant human factor VII, long acting DRUG Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT00951873
Insulin (Aspart Insulin [Novolog], Regular Insulin) DRUG Approved Diabetic Ketoacidosis COMPLETED NCT00920725
Erythropoietin DRUG Phase PHASE2 Mood Disorders COMPLETED NCT00916552
gastric bypass surgery and testing PROCEDURE Preclinical Gastric Bypass COMPLETED NCT00915980
Levemir (Detemir) and Novolog (Aspart) Insulin DRUG Phase PHASE4 Type 2 Diabetes WITHDRAWN NCT00906529
Euglycaemic hyperinsulinaemic clamp OTHER Phase PHASE1 Diabetes COMPLETED NCT00897169
Oral Glucose Tolerance Test (OGTT) OTHER Phase PHASE1 Diabetes COMPLETED NCT00897169
Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin DRUG Phase PHASE3 Diabetes Mellitus, Type 1 COMPLETED NCT00888732
NovoFine® needle 8 mm DEVICE Phase PHASE4 Diabetes COMPLETED NCT01024218
NovoFine® needle 12 mm DEVICE Phase PHASE3 Diabetes COMPLETED NCT00871416
Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch DRUG Phase PHASE1 Turner's Syndrome TERMINATED NCT00870220
Detemir or Glargine DRUG Phase PHASE4 Type 2 Diabetes COMPLETED NCT00862875
Nurse case management OTHER Approved Colonic Neoplasms COMPLETED NCT00845247
turoctocog alfa DRUG Phase PHASE4 Congenital Bleeding Disorder COMPLETED NCT03449342
Advate® DRUG Phase PHASE1 Congenital Bleeding Disorder COMPLETED NCT00837356
insulin glulisine DRUG Phase PHASE1 Diabetes COMPLETED NCT00824668
anti-IL-20 DRUG Phase PHASE1 Inflammation TERMINATED NCT01261767
insulin analogue DRUG Preclinical Diabetes COMPLETED NCT00806936
NovoPen® 4 DEVICE Preclinical Diabetes COMPLETED NCT00806858
No treatment given OTHER Preclinical Obesity COMPLETED NCT06843473
biphasic human insulin 30 DRUG Phase PHASE1 Diabetes COMPLETED NCT01707160
sulphonylurea DRUG Phase PHASE4 Diabetes COMPLETED NCT02730377
Tablet treatment DRUG Approved Latent Autoimmune Diabetes in Adults LADA UNKNOWN NCT00776607
NovoMix 30 DRUG Approved Latent Autoimmune Diabetes in Adults LADA UNKNOWN NCT00776607
FlexTouch® DEVICE Phase PHASE3 Diabetes COMPLETED NCT00773279
human regular insulin and NPH insulin (Actrapid, Protaphne) DRUG Phase PHASE4 Type 2 Diabetes Mellitus UNKNOWN NCT00747409
insulin aspart and detemir (NovoRapid, Levemir) DRUG Phase PHASE4 Type 2 Diabetes Mellitus UNKNOWN NCT00747409
NNC 0070-0002-0349 DRUG Phase PHASE1 Metabolism and Nutrition Disorder WITHDRAWN NCT00728455
Detemir DRUG Approved Diabetes ACTIVE_NOT_RECRUITING NCT01239550
NNC126-0083 DRUG Phase PHASE1 Growth Hormone Disorder COMPLETED NCT01034202
insulin DRUG Phase PHASE4 Diabetes COMPLETED NCT01720303
automated telephone intervention vs. usual care BEHAVIORAL Approved Type 2 Diabetes COMPLETED NCT00700908
sitagliptin DRUG Phase PHASE3 Diabetes COMPLETED NCT02849080
semaglutide DRUG Preclinical Endometrial Cancer NOT_YET_RECRUITING NCT07462663
NNC 0070-0002-0182 DRUG Phase PHASE1 Metabolism and Nutrition Disorder TERMINATED NCT00665665
Usual care as prescribed by the ED physicians. DRUG Phase PHASE4 Diabetes WITHDRAWN NCT00663624
aspart insulin DRUG Phase PHASE4 Diabetes WITHDRAWN NCT00663624
EX1000 DRUG Phase PHASE2 Diabetes COMPLETED NCT00698802
Insulin aspart DRUG Phase PHASE3 Diabetes Mellitus, Type 1 RECRUITING NCT07076199
insulin aspart + insulin aspart protamin DRUG Phase PHASE4 Type 2 Diabetes COMPLETED NCT00657943
insulin detemir [rDNA origin] injection DRUG Phase PHASE2 Cystic Fibrosis Related Diabetes TERMINATED NCT00639626
biphasic insulin aspart 50 DRUG Phase PHASE4 Diabetes COMPLETED NCT01892020
biphasic insulin aspart 30 DRUG Phase PHASE4 Diabetes COMPLETED NCT02582242
Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate OTHER Preclinical Obesity TERMINATED NCT00625040
sunitinib DRUG Phase PHASE2 Cancer COMPLETED NCT00617253
insulin degludec/insulin aspart DRUG Phase PHASE1 Healthy COMPLETED NCT02844790
insulin degludec DRUG Phase PHASE3 Diabetes Mellitus, Type 1 COMPLETED NCT04848480
saline DRUG Phase PHASE4 Diabetes Mellitus COMPLETED NCT00607737
NPH insulin + regular insulin DRUG Phase PHASE4 Type 2 Diabetes COMPLETED NCT00590226
Detemir + aspart insulin before meals DRUG Phase PHASE4 Type 2 Diabetes COMPLETED NCT00590226
Ultra-Fine needle 12.7 mm DEVICE Phase PHASE4 Diabetes COMPLETED NCT00572052
glicazide DRUG Phase PHASE4 Diabetes COMPLETED NCT00568984
Glucobay® DRUG Phase PHASE4 Diabetes COMPLETED NCT00568074
Glurenorm® DRUG Phase PHASE4 Diabetes COMPLETED NCT00568074
Insulatard DRUG Phase PHASE4 Type 2 Diabetes Mellitus COMPLETED NCT00788840
Insulin glargine DRUG Phase PHASE3 Diabetes Mellitus, Type 1 RECRUITING NCT07076199
NPH DRUG Approved Type 1 Diabetes TERMINATED NCT00564018
Glargine DRUG Phase PHASE4 Type 2 Diabetes COMPLETED NCT03336528
Insulin detemir DRUG Phase PHASE1 Diabetes Mellitus, Type 1 RECRUITING NCT06685185
estradiol, 25 mcg DRUG Preclinical Menopause COMPLETED NCT01507454
caelyx (pegylated liposomal doxorubicin) DRUG Phase PHASE2 Cancer COMPLETED NCT00523380
paroxetine DRUG Phase PHASE4 Premenstrual Dysphoric Disorder COMPLETED NCT00516113
human regular insulin DRUG Phase PHASE1 Diabetes Mellitus COMPLETED NCT00513643
Insulin Aspart DRUG Phase PHASE1 Diabetes Mellitus, Type 2 RECRUITING NCT07068295
Insulin Glargine DRUG Phase PHASE2 Diabetes Mellitus, Type 2 COMPLETED NCT03951805
repaglinide DRUG Phase PHASE4 Diabetes COMPLETED NCT01720303
vatreptacog alfa (activated) DRUG Phase PHASE3 Congenital Bleeding Disorder COMPLETED NCT01392547
biphasic human insulin DRUG Preclinical Diabetes COMPLETED NCT01492153
GlucoNorm DRUG Phase PHASE2 Type 2 Diabetes COMPLETED NCT00451620
glyburide DRUG Phase PHASE4 Diabetes COMPLETED NCT01698931
Insulin Lispro versus Insulin Aspart DRUG Approved Type 1 Diabetes Mellitus TERMINATED NCT00428207
Insulin Aspart versus Insulin Lispro DRUG Approved Type 1 Diabetes Mellitus TERMINATED NCT00428207
orlistat DRUG Phase PHASE2 Metabolism and Nutrition Disorder COMPLETED NCT00422058
UNITED Planned Care BEHAVIORAL Approved Diabetes Mellitus COMPLETED NCT00421850
isophane human insulin DRUG Phase PHASE1 Diabetes COMPLETED NCT01865279
soluble human insulin DRUG Preclinical Diabetes COMPLETED NCT00715780
NNC 55-0414 DRUG Phase PHASE1 Diabetes COMPLETED NCT00400283
rosiglitazone and metformin combination tablet DRUG Phase PHASE3 Diabetes COMPLETED NCT00399711
repaglinide and metformin combination tablet DRUG Phase PHASE1 Diabetes COMPLETED NCT01490658
sulfonylurea DRUG Phase PHASE3 Diabetes COMPLETED NCT00395746
NIDCAP BEHAVIORAL Phase EARLY_PHASE1 Infant Growth COMPLETED NCT00388141
Metformin on top of intensive insulin therapy DRUG Phase PHASE3 Type 2 Diabetes Mellitus COMPLETED NCT00375388
Norditropin SimpleXx DRUG Approved Prader-Willi Syndrome COMPLETED NCT00372125
human insulin /insulin isophane DRUG Phase PHASE4 Type 1 Diabetes COMPLETED NCT00346996
insulin levemir / aspart DRUG Phase PHASE4 Type 1 Diabetes COMPLETED NCT00346996
NovoFine® needle 4 mm DEVICE Phase PHASE2 Diabetes COMPLETED NCT00343343
NovoFine® needle 6 mm DEVICE Phase PHASE3 Diabetes COMPLETED NCT00872560
recombinant interleukin-21 DRUG Phase PHASE2 Cancer COMPLETED NCT00617253
inhaled human insulin DRUG Phase PHASE3 Diabetes COMPLETED NCT00725036
rosiglitazone DRUG Phase PHASE3 Diabetes TERMINATED NCT00427154
exenatide DRUG Phase PHASE3 Diabetes COMPLETED NCT01885208
glimepiride DRUG Phase PHASE1 Diabetes COMPLETED NCT01511692
NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70 DRUG Approved Type 1 Diabetes COMPLETED NCT00283218
Insulin infusion with a goal DRUG Phase PHASE3 Cardiac Surgical Procedures COMPLETED NCT00282698
Novolin R (human recombinant Insulin) DRUG Approved Sepsis COMPLETED NCT00282594
Order Set, Education, Feedback BEHAVIORAL Approved Diabetes Mellitus COMPLETED NCT00271700
glibenclamide DRUG Phase PHASE3 Diabetes COMPLETED NCT00393718
Growth hormone DRUG Preclinical Growth Hormone Deficiency COMPLETED NCT03225755
0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) DRUG Phase PHASE1 Menopause COMPLETED NCT01477632
0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) DRUG Phase PHASE1 Menopause COMPLETED NCT01477632
placebo DRUG Phase PHASE3 Diabetes COMPLETED NCT03021187
Measles vaccine BIOLOGICAL Phase PHASE4 Measles COMPLETED NCT00168571
liraglutide DRUG Phase PHASE1 Diabetes COMPLETED NCT03292185
estradiol DRUG Phase PHASE4 Turner Syndrome COMPLETED NCT00134745
vial and syringe DEVICE Phase PHASE1 Diabetes COMPLETED NCT00127296
FlexPen® DEVICE Phase PHASE1 Diabetes COMPLETED NCT02627287
autocover needle DEVICE Phase PHASE4 Diabetes COMPLETED NCT01024218
safety glide DEVICE Phase PHASE4 Diabetes COMPLETED NCT00121355
pump DEVICE Phase PHASE1 Diabetes COMPLETED NCT00184613
intensive insulin therapy to maintain normoglycemia DRUG Phase PHASE2 Critical Illness COMPLETED NCT00115479
estradiol, 10 mcg DRUG Phase PHASE1 Menopause COMPLETED NCT01486979
Feiba VH DRUG Preclinical Congenital Bleeding Disorder COMPLETED NCT00710619
activated recombinant human factor VII DRUG Phase PHASE1 Congenital Bleeding Disorder WITHDRAWN NCT02084810
somatropin DRUG Phase PHASE3 Adult Growth Hormone Deficiency COMPLETED NCT02382939
eptacog alfa (activated) DRUG Phase PHASE1 Congenital Bleeding Disorder WITHDRAWN NCT02084810
dietary regimen BEHAVIORAL Phase PHASE4 Diabetes COMPLETED NCT00101751
metformin DRUG Phase PHASE1 Diabetes COMPLETED NCT02249910
pioglitazone DRUG Phase PHASE3 Diabetes COMPLETED NCT00598793
biphasic insulin aspart DRUG Phase PHASE3 Diabetes COMPLETED NCT02762578
insulin glargine DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04262661
insulin detemir DRUG Phase PHASE1 Diabetes COMPLETED NCT02162407
insulin lispro DRUG Phase PHASE3 Diabetes COMPLETED NCT00097071
insulin human DRUG Preclinical Diabetes TERMINATED NCT02382757
insulin aspart DRUG Phase PHASE3 Diabetes Mellitus, Type 2 COMPLETED NCT05013229
insulin NPH DRUG Phase PHASE3 Diabetes COMPLETED NCT01707134
human insulin DRUG Phase PHASE4 Diabetes COMPLETED NCT01467141
catridecacog DRUG Phase PHASE1 Acquired Bleeding Disorder COMPLETED NCT02239146
Total products: 4464